US20220119886A1 - Means for diagnosing, predicting or monitoring pneumocystis pneumonia - Google Patents
Means for diagnosing, predicting or monitoring pneumocystis pneumonia Download PDFInfo
- Publication number
- US20220119886A1 US20220119886A1 US17/552,130 US202117552130A US2022119886A1 US 20220119886 A1 US20220119886 A1 US 20220119886A1 US 202117552130 A US202117552130 A US 202117552130A US 2022119886 A1 US2022119886 A1 US 2022119886A1
- Authority
- US
- United States
- Prior art keywords
- seq
- jirovecii
- gene
- sequence
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000317 pneumocystosis Diseases 0.000 title claims abstract description 215
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 title claims abstract description 209
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 title claims abstract description 209
- 238000012544 monitoring process Methods 0.000 title abstract description 5
- 241000142787 Pneumocystis jirovecii Species 0.000 claims abstract description 342
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 253
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 210
- 108020005196 Mitochondrial DNA Proteins 0.000 claims abstract description 198
- 238000011002 quantification Methods 0.000 claims abstract description 86
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 39
- 101150001086 COB gene Proteins 0.000 claims abstract description 36
- 101150053771 MT-CYB gene Proteins 0.000 claims abstract description 36
- 101150006264 ctb-1 gene Proteins 0.000 claims abstract description 36
- 101150088166 mt:Cyt-b gene Proteins 0.000 claims abstract description 36
- 108020004418 ribosomal RNA Proteins 0.000 claims abstract description 19
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 18
- 101800002927 Small subunit Proteins 0.000 claims abstract description 6
- 239000000523 sample Substances 0.000 claims description 310
- 239000002299 complementary DNA Substances 0.000 claims description 146
- 230000000295 complement effect Effects 0.000 claims description 137
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 66
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 59
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 28
- 102100034343 Integrase Human genes 0.000 claims description 24
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 10
- 238000001514 detection method Methods 0.000 abstract description 34
- 239000002773 nucleotide Substances 0.000 description 190
- 125000003729 nucleotide group Chemical group 0.000 description 190
- 108020004414 DNA Proteins 0.000 description 87
- 238000009396 hybridization Methods 0.000 description 76
- 108091093088 Amplicon Proteins 0.000 description 41
- 238000000034 method Methods 0.000 description 30
- 238000011529 RT qPCR Methods 0.000 description 29
- 239000012634 fragment Substances 0.000 description 28
- 108090000704 Tubulin Proteins 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 102000004243 Tubulin Human genes 0.000 description 18
- 208000036815 beta tubulin Diseases 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 238000002123 RNA extraction Methods 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 14
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 14
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 14
- 238000010839 reverse transcription Methods 0.000 description 14
- 238000010240 RT-PCR analysis Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000012408 PCR amplification Methods 0.000 description 12
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 12
- 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 10
- 101000604411 Homo sapiens NADH-ubiquinone oxidoreductase chain 1 Proteins 0.000 description 10
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 10
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 206010061598 Immunodeficiency Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000013060 biological fluid Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 7
- 101150093272 ATP9 gene Proteins 0.000 description 7
- 101100324954 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) oli gene Proteins 0.000 description 7
- 101150096101 OLI1 gene Proteins 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 229940047766 co-trimoxazole Drugs 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 6
- 241000233870 Pneumocystis Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000013165 exonuclease Human genes 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 4
- 101000891654 Homo sapiens TATA-box-binding protein Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 238000002944 PCR assay Methods 0.000 description 4
- 108020004518 RNA Probes Proteins 0.000 description 4
- 239000003391 RNA probe Substances 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 241000239226 Scorpiones Species 0.000 description 4
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 4
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 229960000860 dapsone Drugs 0.000 description 4
- 102000045334 human TBP Human genes 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 4
- 229960000611 pyrimethamine Drugs 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710084021 Large envelope protein Proteins 0.000 description 3
- 229940123317 Sulfonamide antibiotic Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100031242 Deoxyhypusine synthase Human genes 0.000 description 2
- 108010049047 Echinocandins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- 101000844963 Homo sapiens Deoxyhypusine synthase Proteins 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000013381 RNA quantification Methods 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003409 anti-rejection Effects 0.000 description 2
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 2
- 229960005179 primaquine Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 101150018198 COX1 gene Proteins 0.000 description 1
- -1 CYTB Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 210000002383 alveolar type I cell Anatomy 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004993 binary fission Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- YJHDFAAFYNRKQE-YHPRVSEPSA-L disodium;5-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[(e)-2-[4-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(N=C(NC=5C=CC=CC=5)N=4)N(CCO)CCO)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(N(CCO)CCO)=NC=1NC1=CC=CC=C1 YJHDFAAFYNRKQE-YHPRVSEPSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 101150036739 nad11 gene Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Definitions
- the application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP).
- the means of the application involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecil mitochondrial genes.
- the means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- PneumoCystis Pneumonia is an opportunistic infection due to the ascomycetous fungus Pneumocystis jirovecii .
- This pathogen is specific for humans whereas related species exists for other terrestrial mammals, and growing evidence suggest that P. jirovecii could be considered as a commensal of human respiratory tract. It lives and thrives at the surface of the alveolar cells (type I pneumocytes) and can be found typically as two main forms: (i) the trophic form that undergo asexual multiplication by binary fission and (ii) ascus (cyst) containing eight ascospores that is the result of the sexual mode of replication.
- Pneumocystis carinii The complete life cycle of Pneumocystis carinii has been studied in rats. Experiments in animals suggest that Pneumocystis is transmissible from host to host with immunocompetent individuals as the most important reservoir and asci as the potential agent of transmission. Epidemiological and experimental data suggests that P. jirovecii is also a transmissible organism in humans. HIV-infected individuals with low CD4 counts are at risk of developing PCP.
- PCP Despite highly effective prophylaxis with cotrimoxazole (association of a Dihydrofolate reductase inhibitor (trimethoprim) and of a sulfonamide antibiotic (sulfamethoxazole)) and highly active anti-retroviral treatments, PCP remains one of the most prevalent infections in patients with AIDS. PCP also occurs in non-HIV immunocompromised patients, including patients with hematological or solid malignancies, transplant recipients, and those receiving immunosuppressive treatments for autoimmune or inflammatory diseases.
- PCP In non-HIV immunocompromised patients, PCP is typically more acute and severe than in HIV patients. PCP diagnosis is also harder since the average fungal charge is lower in non-HIV patients than in HIV patients.
- PCP carries a mortality rate of 35 to 55% in non-HIV immunocompromised patients, compared to 10 to 20% in HIV-infected patients.
- Diagnosis of PCP usually relies on microscopic demonstration of P. jirovecii in respiratory specimens using various staining methods that includes conventional staining (Calcofluor White. Toluidine Blue O, Gomori methamine, Giemsa staining) and anti- P. jirovecii immunofluorescence assays (IFA) (direct or indirect IFA). It is known for a long time that immunofluorescence is more sensitive than conventional staining. Alternatively, in the 1990's, two methods have been developed: beta-D-glucan (BDG) detection and PCR.
- BDG beta-D-glucan
- DNA detection aimed also at increasing sensitivity of P. jirovecii detection to avoid invasive procedure such as BronchoAlveolar Lavage (BAL) in patients suspected of PCP with the ambition to use induced sputa (IS) and/or upper respiratory specimens (URS, nasopharyngeal aspirate, oral washes or nasal swab) as diagnostic specimens.
- BAL BronchoAlveolar Lavage
- IS induced sputa
- URS upper respiratory specimens
- sPCR and nested end point (nPCR) formats used initially for DNA detection were progressively replaced by the quantitative real-time PCR (qPCR) format, where the PCR products is detected and quantified during amplification without opening of the reaction tube.
- qPCR quantitative real-time PCR
- the main advantages of this format are preventing false positives due to environmental contamination with previously amplified products, and to provide rapid quantitative results.
- Subgroup analysis regarding the PCR format was performed in the meta-analyses and showed higher sensitivity and specificity in qPCR assays compared to the global analysis.
- recommendations for diagnostic PCR already exist, highlighting the necessity to use real-time PCR format.
- the difference in performance reported for different PCR assays could be explained by the different DNA targets used for amplification and the primer designs. Indeed, most of the authors have developed their own primers, although generally designed to amplify a multicopy gene, which increase the sensitivity compared to a single copy gene.
- the P. jirovecii mitochondrial Large Sub-Unit ribosomal RNA (rRNA) gene (mtLSU) is the most commonly used.
- the multicopy Major Surface Antigen (MSG) gene was also targeted in various reports.
- ribosomal DNA 18S ribosomal DNA (rDNA), 5S rDNA, Internal transcribed spacer (ITS), DHPS, KEX, HSP70, Beta-TUBulin (BTUB) and CDC2.
- ribosomal RNA genes cluster is unique in Pneumocystis.
- PCR revealed the possibility to detect Pneumocystis DNA in pulmonary specimens from immunocompromised individuals without clinical signs or symptoms of PCP. This phenomenon was called P. jirovecii colonization or carriage. For this reason, PCR is not completely accepted as a diagnostic criterion for PCP, although the sensitivity of PCR assays is higher than microscopy and PCR was cost-effective in non-invasive specimens.
- Real-time quantitative PCR refers to real-time PCR that is able to quantify the amount of DNA in the extract using calibration curves based on reference DNA (plasmid), expressed as copy/volume unit. However, quantitative results can be expressed with other units. Alternatively, some authors use the crude qPCR results (as quantification cycle, Cq, Ct, or Cp), or some others translate it into a number of microorganisms based on counts (for example trophic form equivalent). No international standard qPCR assay and no threshold are currently consensual. Large international studies, or at least prospective studies, are highly needed to allow technical validation of this tool. Thereafter, the use of qPCR for clinical interpretation of qPCR results would be possible and validated.
- the application provides means, which are notably useful for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP).
- PCP Pneumocystis pneumonia
- the means of the application notably enable to discriminate a PCP patient from a P. jirovecii carrier, who does not have or does not develop PCP, including when the patient is HIV-negative.
- the PCP status of HIV-negative human patients is especially difficult to determine, because the P. jirovecii charge of these patients is lower than that of HIV-positive human patients.
- the means of the application may thereby avoid that said P. jirovecii carriers receive an unnecessary PCP treatment.
- the means of the application involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes.
- the means of the application involve more particularly determining the ratio of the RNA transcripts of one of said two different P. jirovecii mitochondrial genes (hereinafter the first P. jirovecii mitochondrial gene) to the RNA transcripts of the other of said two different P. jirovecii mitochondrial genes (hereinafter the second P. jirovecii mitochondrial gene).
- Each of the two different P. jirovecii mitochondrial genes are independently selected from the group consisting of
- At least one of said two different P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene or the mtSSU gene.
- At least one of said two different P. jirovecii mitochondrial genes is the mtLSU gene.
- the first P. jirovecii mitochondrial gene of said ratio is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene.
- the second P. jirovecii mitochondrial gene of said ratio is the mtSSU gene or the mtLSU gene (while still being different from the first P. jirovecii mitochondrial gene of said ratio), more particularly the mtLSU gene.
- the first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein
- the second P. jirovecil mitochondrial gene is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecil ribosomal RNA, such as the mtLSU gene or the mtSSU gene [ratio Cytb/(mtLSU or mtSSU), more particularly ratio Cytb/mtLSU].
- the first P. jirovecii mitochondrial gene is the mtSSU gene
- the second P. jirovecii mitochondrial gene is the mtLSU gene [ratio mtSSU/mtLSU].
- the means of the application comprises methods, products (e.g., primers and/or probes), association(s) or combination(s) of at least two of these products, as well as kit(s) and composition(s) comprising at least one of said products.
- products e.g., primers and/or probes
- association(s) or combination(s) of at least two of these products as well as kit(s) and composition(s) comprising at least one of said products.
- the means of the application also comprises solid supports such as microarray, nanoarray, chip, onto which at least one of said product is attached, as well as nucleic acid library(ies) which are suitable for the quantification of a P. jirovecii transcriptome, computer program product(s), computer device(s) and kit(s) for use in the treatment and/or prevention and/or palliation of PCP in a human patient.
- solid supports such as microarray, nanoarray, chip, onto which at least one of said product is attached, as well as nucleic acid library(ies) which are suitable for the quantification of a P. jirovecii transcriptome, computer program product(s), computer device(s) and kit(s) for use in the treatment and/or prevention and/or palliation of PCP in a human patient.
- FIG. 1 Comparison of mLSU quantification thresholds obtained with DNA (Cq mtLSU DNA PCR) or RNA amplification (Cq mtLSU RNA PCR) in BALF of patients.
- the mean loss of Cq is 3.58 (95% CI: 2.68-4.47), corresponding approximately to about a 10 fold higher expression for RNA.
- FIG. 3A Plot of the mtLSU RNA quantification cycle (Cq) for each mtLSU positive samples in the different categories of samples.
- the range of threshold that allows the higher likelihood ratio is depicted as a dotted line]30.49 to 31.78[. Cleared dots are from patients classified in a category but for which the ratio is in favor of the other group of patient.
- FIG. 3B Plots of the values of the CYTB/mtLSU ratio for each category of patients in samples in which both CYTB and mtLSU RNAs were amplified.
- PCP samples harbored mostly a CYTB/mtLSU ⁇ 1.27, whereas non-PCP samples (carriers) or patients treated for a minimum of 15 days (PCP Rx) harbored mostly a CYTB/mtLSU ratio >1.66.
- Sixteen samples had CYTB unamplified so that the ratio was no calculated.
- Those samples were from patients without PCP.
- the range of threshold that allows the higher likelihood ratio is depicted as a dotted line]1.27 to 1.66[. Cleared dots are from patients classified in a category but for which the ratio is in favor of the other group of patients.
- FIG. 4 ROC curve analysis for the BTUB, HSP70 and CYTB to mtLSU ratios. The higher likelihood ration was obtained with the CYTB/mtLSU ratio.
- FIG. 5 mtLSU and mtSSU quantification in BAL fluid samples by PCR.
- FIG. 6 analysis of the ROC curves obtained with the PCR (cycle) quantification of mtSSU and of mtLSU (in BAL fluid samples), and obtained with the mtSSU/mtLSU ratio.
- the maximal Likehood Ratio (LR) of the mtSSU/mtLSU ratio is at 10 (for an optimal ratio of 2.7) [whereas the maximal LR of each of mtLSU and mtSSU quantification alone is at 6].
- a ratio of 3.1-3.3 would however allow to reach a sensitivity of 100%, and may appear preferable for accurate PCP detection.
- FIG. 7 distribution of the mtSSU/mtLSU ratio in the BAL fluid samples of PCP patients and of P. jirovecii carrier (but non-PCP) patients. The ratio of 2.7 is showed in dashed line.
- FIGS. 8A and 8B distribution of the mtSSU ( FIG. 8A on the left) and mtLSU ( FIG. 8B on the right) quantification cycles in the BAL fluid samples of PCP patients and of P. jirovecii carrier (but non-PCP) patients.
- the application provides means, which involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes.
- RNA transcripts of the application are those of ( P. jirovecii ) mitochondrial genes.
- the means of the application involve more particularly determining the ratio of the RNA transcripts of one of said two different P. jirovecii mitochondrial genes (hereinafter the first P. jirovecii mitochondrial gene) to the RNA transcripts of the other of said two different P. jirovecil mitochondrial genes (hereinafter the second P. jirovecii mitochondrial gene).
- Each of the two different P. jirovecii mitochondrial genes are independently selected from the group consisting of
- At least one of said two different P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene or the mtLSU gene.
- At least one of said two different P. jirovecil mitochondrial genes is the mtLSU gene.
- the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein (SEQ ID NO: 3).
- the second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene (SEQ ID NO: 1) or the mtSSU gene (SEQ ID NO: 2), more particularly the mtLSU gene.
- the first of said two P. jirovecii mitochondrial genes is the mtSSU gene.
- the second of said two P. jirovecii mitochondrial genes is the mtLSU gene, or the P. jirovecii gene, the sequence of which codes for the Cytb protein, more particularly the mtLSU gene.
- the first of said two P. jirovecii mitochondrial genes is the mtLSU gene.
- the second of said two P. jirovecii mitochondrial genes is the mtSSU gene, or the P. jirovecii gene, the sequence of which codes for the Cytb protein, more particularly the mtSSU gene.
- the means of the invention are sufficiently reliable to determine the PCP status of a human patient, who is HIV-negative, more particularly a HIV-negative and immunocompromised human patient.
- the PCP status of HIV-negative human patients is especially difficult to determine, because the P. jirovecii charge of these patients is lower than that of HIV-positive human patients.
- RNA transcripts of said two different P. jirovecii mitochondrial genes may be achieved by any means that the skilled person may found appropriate. Nevertheless, the application provides Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) means, which RT-PCR means can be implemented in real-time.
- RT-PCR Reverse-Transcriptase Polymerase Chain Reaction
- the application relates to an in vitro method for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly an in vitro method for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, wherein said method comprises
- said step iii. can be the step of comparing the ratio of ii. to a threshold (numerical) value, wherein, when the value of the ratio of ii. is equal to or lower than (more particularly lower than) said threshold value, said human patient is diagnosed or predicted to be at high risk of having or developing PCP,
- said step iii. can be the step of comparing the ratio of ii. to a threshold (numerical) value, wherein, when the value of the ratio of ii. is higher or equal than (more particularly higher than) said threshold value, said human patient is diagnosed or predicted to be at high risk of having or developing PCP,
- Said threshold value may e.g., have been predetermined by comparing the values, or the distribution of the values, that the ratio of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene to the value of quantification of the RNA transcripts of said second P. jirovecil mitochondrial gene takes in reference human cohorts of P. jirovecii carriers, who have been pre-established as a function of their status of:
- the reference human cohort of P. jirovecii carriers, who have or develop PCP, and the reference human cohort of P. jirovecii carriers, who do not have and do not develop PCP, may each e.g., comprise more than 100 humans.
- a human carrier of P. jirovecii is classified in either one of said two reference cohorts by any means that the skilled person may find appropriate.
- said means may comprise the analysis of the clinical, radiological and biological features (including microscopical detection of absence or presence of P. jirovecii ) of human individuals by two independent experts, e.g., a pneumologist and an infectious disease specialist (cf. examples and Table 1 below), and, for each of said human individuals, the concurrent conclusion of either presence of PCP (proven, probable or possible PCP, more particularly proven PCP), or of absence of PCP.
- the application also relates to an in vitro method for determining or predicting the efficacy of a drug or treatment against PCP in a human patient, who is a Pneumocystis jirovecii carrier and who has been diagnosed to have or to develop PCP, wherein said method comprises
- the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein
- the second of said two P. jirovecii mitochondrial genes is the mtLSU gene or the mtSSU gene, more particularly the mtLSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P.
- jirovecii mitochondrial genes is the mtLSU gene, it is an increase of the value of said ratio at said second point in time compared to said first point in time that is indicative that said treatment or drug is or will be efficient to treat or alleviate PCP in said human patient.
- the absence of increase, more particularly a decrease, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that said treatment or drug is not or will not be efficient to treat or alleviate PCP in said human patient.
- the first of said two P. jirovecii mitochondrial genes is the mtLSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P. jirovecii mitochondrial genes is the P.
- jirovecii gene the sequence of which codes for the Cytb protein, it is a decrease of the value of said ratio at said second point in time compared to said first point in time that is indicative that said treatment or drug is or will be efficient to treat or alleviate PCP in said human patient.
- the absence of decrease, more particularly an increase, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that said treatment or drug is not or will not be efficient to treat or alleviate PCP in said human patient.
- the application also relates to an in vitro method for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP, wherein said method comprises
- the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein (SEQ ID NO: 3), and the second of said two P. jirovecii mitochondrial genes is the mtLSU gene or the mtSSU gene, more particularly the mtLSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P.
- jirovecii mitochondrial genes is the mtLSU gene, it is an increase of the value of said ratio at said second point in time compared to said first point in time that is indicative that PCP regresses or has been treated in said human patient.
- the absence of increase, more particularly a decrease, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that PCP does not regress or does not have been treated in said human patient.
- the first of said two P. jirovecii mitochondrial genes is the mtLSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second first of said two P. jirovecii mitochondrial genes is the P.
- jirovecii gene the sequence of which codes for the Cytb protein, it is a decrease of the value of said ratio at said second point in time compared to said first point in time that is indicative that PCP regresses or has been treated in said human patient.
- the absence of decrease, more particularly an increase, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that PCP does not regress or does not have been treated in said human patient.
- the second of said two P. jirovecii mitochondrial genes can e.g., be a P. jirovecii gene, the sequence of which transcribes into a P. jirovecil ribosomal RNA, such as the mtLSU gene (SEQ ID NO: 1) or the mtSSU gene (SEQ ID NO: 2), more particularly the mtLSU gene.
- the second of said two P. jirovecii mitochondrial genes can e.g., be the mtLSU gene.
- said second P. jirovecii ribosomal RNA is the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.
- said first P. jirovecii ribosomal RNA is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mitochondrial P. jirovecii Small Sub-Unit (mtSSU) gene.
- the respective RNA transcripts of said two different P. jirovecil mitochondrial genes are quantified in the RNA material of the same sample of biological fluid.
- RNA material of said sample of biological fluid can be extracted and/or purified from the sample.
- RNA extraction means and RNA purification means are known to the person of ordinary skill in the art.
- RNA extraction means comprise cell lysis reagent(s) and/or buffer(s).
- RNA purification means comprise silica membrane.
- the RNA material of said sample of biological fluid is purified by silica membrane filtration of said sample of biological fluid.
- the means of the application may further comprise a control of nucleic acid extraction and/or purification, more particularly an internal control of nucleic acid extraction and/or purification. More particularly, the means of the application may further comprise a control of RNA extraction and/or purification, more particularly an internal control of RNA extraction and/or purification.
- the means of the application may further comprise a RNA acting as an internal control of RNA extraction and/or purification, more particularly an artificial or exogenous RNA, more particularly a RNA acting as an Internal Extraction Control RNA (IECR) (cf. the example 2 below), or may further comprise a cell which comprises such a RNA (e.g., by genetic engineering).
- a RNA acting as an internal control of RNA extraction and/or purification more particularly an artificial or exogenous RNA, more particularly a RNA acting as an Internal Extraction Control RNA (IECR) (cf. the example 2 below)
- IECR Internal Extraction Control RNA
- RNA or IECR may e.g., be a RNA sequence (e.g., a RNA sequence of 30-500 nucleotides), which is not a human or fungal nucleic acid sequence, more preferably which has less than 60% (e.g., less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 1%) identity to any human or fungal nucleic acid sequence.
- IECR are commercially available. Examples of IECR include:
- the internal control of RNA extraction and/or purification can be performed by detecting that a human gene is still present after said extraction and/or purification step.
- suitable human genes are known in the art and include constitutive genes, such as the human albumin (ALB) gene or the human TATA Box binding protein (TBP).
- the means of the application may further comprise at least probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene, such as the human albumin (ALB) gene or the human TATA Box binding protein (TBP); cf. example 2 below.
- Said sample of biological fluid may e.g., be a sample of lower respiratory tract fluid, such as a sample of bronchoalveolar lavage fluid, or induced sputum, or a sample of upper respiratory tract fluid, such as a sample of sputum, nasopharyngeal aspirate, oral wash or nasal swab.
- lower respiratory tract fluid such as a sample of bronchoalveolar lavage fluid, or induced sputum
- a sample of upper respiratory tract fluid such as a sample of sputum, nasopharyngeal aspirate, oral wash or nasal swab.
- Said human patient can be HIV-positive or is HIV-negative, more particularly HIV-negative. More particularly, said human patient is HIV-negative and immunocompromised.
- the means of the application are reliable with HIV-negative human patients, whereas the P. jirovecii charge of HIV-negative human patients is lower than that of HIV-positive human patients.
- said human patient is a human patient, more particularly a HIV-negative human patient, who is receiving, has received or will receive an immunosuppressive treatment, more particularly an immunosuppressor agent or drug, more particularly chemotherapy, an antirejection drug or steroids.
- said human patient is a human patient, more particularly a HIV-negative human patient, who is receiving, has received or will receive a graft of organ(s) and/or tissue(s) (e.g., bone marrow, heart, kidney, liver organ(s), and/or tissue(s) thereof).
- Said immunosuppressive treatment, immunosuppressor agent or drug, antirejection drug may e.g., be intended to prevent and/or palliate the rejection of said transplanted organ(s) and tissue(s) and/or graft-versus-host disease.
- said human patient is a human patient, more particularly a HIV-negative patient, who has an autoimmune disease and/or an inflammatory disease.
- said human patient is a human patient, more particularly a HIV-negative human patient, who has a haematological malignancy and/or a solid malignancy.
- said human patient is a human patient, more particularly a HIV-negative human patient, who is a preterm baby (more particularly a preterm baby, who is born at less than 37 weeks gestational age), a newborn or neonate (more particularly of 1-day old to less than 4-week old) or an infant (more particularly of 4-week old to less than 1-year old). More particularly, said human patient is a human patient, more particularly a HIV-negative human patient, who is a preterm baby (more particularly a preterm baby, who is born at less than 37 weeks gestational age), a newborn or neonate (more particularly of 1-day old to less than 4-week old).
- said quantification of RNA transcripts is performed by (cDNA) reverse-transcription and PCR amplification (for each of said two P. jirovecii mitochondrial genes). More particularly, said (cDNA) reverse-transcription and PCR amplification can be performed (as a one-step RT-PCR reaction, i.e.,) in the same tube (for each of said two P. jirovecii mitochondrial genes).
- the (cDNA) reverse-transcription and PCR amplification of the RNA transcripts of said first P. jirovecii mitochondrial gene can be performed in the same tube, and the reverse-transcription and PCR amplification of the RNA transcripts of said second P. jirovecii mitochondrial gene can be performed in the same tube.
- the (cDNA) reverse-transcription and PCR amplification of the RNA transcripts of said first P. jirovecil mitochondrial gene can be performed in a tube different from, or in the same tube as, the tube in which the (cDNA) reverse-transcription and PCR amplification of the RNA transcripts of second first P. jirovecii mitochondrial gene is performed.
- Said PCR advantageously is real-time PCR.
- said PCR is a quantitative PCR, more particularly a quantitative real-time PCR, more particularly a quantitative real-time RT-PCR, more particularly a one-step quantitative real-time RT-PCR.
- Said threshold value can e.g., be in the 1.00-2.00 range, more particularly in the 1.00-1.80 range, more particularly in the 1.20-1.70 range, more particularly in the 1.27-1.66 range, more particularly is of 1.50.
- said ratio is the fold change of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene compared to said second P. jirovecii mitochondrial gene.
- first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein
- second P. jirovecil mitochondrial gene is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene or the mtSSU gene, more particularly the mtLSU gene.
- said threshold value can e.g., be in the 1/2.00-1/1.00 range, more particularly in the 1/1.80-1/1.00 range, more particularly in the 1/1.70-1/1.20 range, more particularly in the 1/1.66-1/1.27 range, more particularly is of 1/1.50.
- Said threshold value can e.g., be in the 2.7-3.3 range, more particularly in the 3.1-3.3 range, for example 3.2.
- the ratio calculation is performed using the equation
- said threshold value can e.g., be in the 1/3.3-1/2.7 range, more particularly in the 1/3.3-1/3.1 range, for example 1/3.2.
- the quantification of the respective RNA transcripts may be achieved by any means that the person of ordinary skill in the art may found appropriate.
- Such means include hybridization- or sequence-based means, as well as any means that enable to quantify a transcriptome, such as e.g., the RNA-Seq method (cf. Wang et al. 2009).
- the application provides a DNA library as well as computer means, which are suitable for implementation of the RNA-Seq method (cf. below).
- the quantification of the respective RNA transcripts may comprise:
- said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein
- said first cDNA target advantageously consists of 100-120 nucleotides (more particularly of 100-110 nucleotides, more particularly of 102-108 nucleotides, more particularly of 104-106 nucleotides, more particularly of 105 nucleotides), and comprises or is
- said first cDNA target advantageously consists of 60-110 nucleotides and comprises or is
- said second cDNA target advantageously consists of 115-125 nucleotides and comprises or is
- said second P. jirovecii mitochondrial gene is the P. jirovecii gene is the mtSSU gene
- said second cDNA target advantageously consists of 60-110 nucleotides and comprises or is
- the quantification of the respective RNA transcripts comprises:
- said first RNA target may advantageously consist of 100-120 nucleotides (more particularly of 100-110 nucleotides, more particularly of 102-108 nucleotides, more particularly of 104-106 nucleotides, more particularly of 105 nucleotides), and comprises or is
- said first RNA target advantageously consists of 60-110 nucleotides and comprises or is
- said second RNA target advantageously consists of 115-125 nucleotides and comprises or is
- said second RNA target advantageously consists of 60-110 nucleotides and comprises or is
- reverse polymerase refers to a RNA-dependent DNA polymerase
- polymerase refers to a “DNA-dependent DNA polymerase”.
- nucleotide encompasses naturally-occurring nucleotides, as well as no-naturally-occurring nucleotides, such as Locked Nucleic Acid (LNATM) nucleotides.
- LNATM nucleotide is understood in accordance with its ordinary meaning in the field, i.e., a nucleotide in which the ribose or deoxyribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom.
- nucleotide encompasses more particularly naturally-occurring nucleotides (nucleotides A, G, T and C for DNA molecules; nucleotides A, G, U and C for RNA molecules).
- said first or second P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein
- said first or second primer pair is a primer pair which anneals to the cDNA reverse transcripts of the RNA transcripts of said first or second P. jirovecii mitochondrial gene (or to the RNA transcripts of said first or second P.
- a (cDNA or DNA) amplicon or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof, which is of 100-120 nucleotide-long (more particularly of 100-110 nucleotide-long, more particularly of 102-108 nucleotide-long, more particularly of 104-106 nucleotide-long, more particularly of 105 nucleotide-long), and which comprises or is
- each primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20 nucleotides).
- said first or second primer pair is the primer pair of SEQ ID NO: 31 and SEQ ID NO: 32.
- said first or second primer pair is the primer pair of SEQ ID NO: 60 and SEQ ID NO: 32.
- Said first or second cDNA or RNA target may be a P. jirovecii mtLSU target.
- said first or second P. jirovecii mitochondrial gene is the mtLSU gene
- said first or second (mtLSU) cDNA target may consist of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and comprises or is
- said first or second (mtLSU) RNA target may consist of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and comprises or is
- said first or second primer pair may e.g., be a (mtLSU) primer pair, which anneals to the cDNA reverse-transcripts of the RNA transcripts of the P. jirovecil mtLSU gene (or to the RNA transcripts of the P.
- jirovecii mtLSU gene as well as to the cDNA reverse-transcripts thereof) to produce a (cDNA or DNA) amplicon (or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof), which is of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and which comprises or is
- each (mtLSU) primer of first or said second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 26 nucleotides).
- said first or second primer pair is the (mtLSU) primer pair of SEQ ID NO: 11 and SEQ ID NO: 12.
- said first or second cDNA or RNA target may e.g., be a P. jirovecii mtSSU target.
- said first or second (mtSSU) cDNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
- said first or second (mtSSU) RNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
- said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P.
- a (cDNA or DNA) amplicon or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
- each (mtSSU) primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20-23 nucleotides).
- said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 16 and SEQ ID NO: 17.
- said first or second (mtSSU) cDNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
- said first or second (mtSSU) RNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
- said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P.
- a (cDNA or DNA) amplicon or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
- each (mtSSU) primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20-23 nucleotides).
- said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 21 and SEQ ID NO: 22.
- said first or second (mtSSU) cDNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
- said first or second (mtSSU) RNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
- said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P.
- a (cDNA or DNA) amplicon or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
- each (mtSSU) primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20-23 nucleotides).
- said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 26 and SEQ ID NO: 27.
- the Tm of said first primer pair does not differ by more than 5° C. (more particularly by more than 4° C., more particularly by more than 3° C., more particularly by more than 2° C., more particularly by more than 1° C.) from the Tm of said second primer pair.
- the Tm of said first primer pair may be identical to the Tm of said second primer pair.
- the Tm of said first primer pair and the Tm of said second primer pair may both be of 53° C. or above. More particularly, said first primer pair and said second primer pair may both have a Tm in the 53-65° C. range (more particularly in the 56-64° C. range, more particularly in the 57-63° C. range, more particularly in the 58-63° C. range, more particularly in the 59-62° C. range, more particularly in the 59-61° C. range). For example, said first primer pair and said second primer pair may both have a Tm of 60° C.
- the Tm of said first primer pair and the Tm of said second primer pair are both in the 58-63° C. range and do not differ by more than 5° C. from each other.
- the PCR amplification (for each of said first and second P. jirovecii mitochondrial genes) comprises:
- the PCR amplification (for each of said first and second P. jirovecil mitochondrial genes) comprises:
- the RT-PCR amplification comprises (for each of said first and second P. jirovecii mitochondrial genes):
- the RT-PCR amplification comprises (for each of said first and second P. jirovecii mitochondrial genes):
- the quantification of the RNA transcripts of said first and/or (more particularly, and) said second P. jirovecii mitochondrial gene can be performed using probes, more particularly
- Each of said first and second probes may independently consist of 17-37 nucleotides.
- the quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene can be performed using at least one first probe, which hybridizes to said first cDNA target (or said first amplicons), without hybridizing to said second cDNA target (or to said second amplicons).
- the quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene can be performed using at least one first probe, which specifically hybridizes to said first cDNA target (or to said first amplicons).
- the quantification of the RNA transcripts of said second P. jirovecil mitochondrial gene can be performed using at least one second probe, which hybridizes to said second cDNA target (or said second amplicons), without hybridizing to said first cDNA target (or to said first amplicons).
- the quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene can be performed using at least one second probe, which specifically hybridizes to said second cDNA target (or to said second amplicons).
- the quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene may e.g., be performed using (at least one) first probe, which hybridizes to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- said first probe may hybridize to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 1 ( P. jirovecii mtLSU gene) and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 ( P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1.
- SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said first probe may also not hybridize to human DNA or RNA.
- said first probe specifically hybridizes to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof.
- the sequence of said first probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the first probe the capacity to hybridize to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 19-30 nucleotides (more particularly of 20-24 nucleotides, more particularly of 22 nucleotides), which hybridizes to the sequence of SEQ ID NO: 3 or the sequence complementary to SEQ ID NO: 3, more particularly to the sequence of SEQ ID NO: 30 or the sequence complementary to SEQ ID NO: 30, without hybridizing to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said hybridization portion of said first probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said first probe may specifically hybridize to the sequence of SEQ ID NO: 3 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or to the complementary sequence thereof.
- the hybridization portion of said first probe is the (22 nucleotide-long) sequence of SEQ ID NO: 33 or the complementary sequence thereof, or a LNA-counterpart thereof, such as the (22 nucleotide-long) sequence of SEQ ID NO: 58 or the complementary sequence thereof (SEQ ID NO: 59; cf. example 3 below).
- the sequence of said first probe may consist of said hybridization portion.
- the sequence of said first probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion.
- Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said first probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm).
- the total length of said first probe advantageously is of 28-32 nucleotides, or of 27-31 nucleotides, or of 26-30 nucleotides, or of 25-29 nucleotides.
- Said first probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- fluorophore e.g., 6-carboxyfluorescein, or tetrachlorofluorescein
- quencher e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black
- Said first probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- LNA Locked Nucleic Acid
- Said first probe may e.g., be a DNA or RNA probe.
- said first probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1).
- a TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- said first probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said first probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- a beacon probe i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said first probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- said first probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- SCORPION® probe i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker.
- the quantification may also be performed using at least two of said first probes (i.e., two different first probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- the Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- said first probe may hybridize to
- said first probe may hybridize to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof, without hybridizing to any of SEQ ID NO: 3 ( P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 ( P. jirovecii mtLSU gene) and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said first probe may also not hybridize to human DNA or RNA.
- said first probe specifically hybridizes to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof.
- the sequence of said first probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA portion, which confers to the first probe the capacity to hybridize to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA sequence of 23-29 nucleotides (more particularly of 25-27 nucleotides), which hybridizes to the sequence of SEQ ID NO: 2 or the sequence complementary to SEQ ID NO: 2, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the sequences complementary to SEQ ID NO: 10, 20, 25, without hybridizing to any of SEQ ID NO: 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said hybridization portion of said first probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said first probe may specifically hybridize to the sequence of SEQ ID NO: 2 or to the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof.
- the hybridization portion of said first probe is the (25 or 27 nucleotide-long) sequence of SEQ ID NO: 18, 23 or 28 or the complementary sequence thereof.
- the sequence of said first probe may consist of said hybridization portion.
- the sequence of said first probe may comprise other DNA sequence(s) in addition to said hybridization portion, e.g., other DNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion.
- Said other DNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion.
- Said other DNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said first probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm).
- the total length of said first probe advantageously is of 31-37 nucleotides, or of 30-36 nucleotides, or of 29-36 nucleotides, or of 28-34 nucleotides.
- Said first probe may comprise at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- fluorophore e.g., 6-carboxyfluorescein, or tetrachlorofluorescein
- quencher e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groo
- Said first probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1).
- a TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- said first probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- a beacon probe i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- the Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- said first probe may hybridize to the P. jirovecii mtLSU gene, which is of SEQ ID NO: 1 or to the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 (a P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 10.
- said first probe may hybridize to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 3 ( P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3 or, to any of SEQ ID NO: 2 ( P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said first probe may also not hybridize to human DNA or RNA.
- said first probe specifically hybridizes to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof.
- the sequence of said first probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the first probe the capacity to hybridize to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 17-21 nucleotides (more particularly of 19 nucleotides), which hybridizes to the sequence of SEQ ID NO; 1 or the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 or the sequence complementary to SEQ ID NO: 10, without hybridizing to any of SEQ ID NO. 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said hybridization portion of said first probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said first probe may specifically hybridize to the sequence of SEQ ID NO; 1 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or to the complementary sequence thereof.
- the hybridization portion of said first probe is the (19 nucleotide-long) sequence of SEQ ID NO: 13 or the complementary sequence thereof.
- the sequence of said first probe may consist of said hybridization portion.
- the sequence of said first probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion.
- Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said first probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm).
- the total length of said first probe advantageously is of 25-29 nucleotides, or of 24-28 nucleotides, or of 23-27 nucleotides, or of 22-36 nucleotides.
- Said first probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- fluorophore e.g., 6-carboxyfluorescein, or tetrachlorofluorescein
- quencher e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black
- Said first probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- LNA Locked Nucleic Acid
- Said first probe may e.g., be a DNA or RNA probe.
- said first probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1).
- a TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- said first probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said first probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- a beacon probe i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said first probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- said first probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- SCORPION® probe i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker.
- the quantification may also be performed using at least two of said first probes (i.e., two different first probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- the Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- the quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene may e.g., be performed using (at least one) second probe, which hybridizes to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- said second probe may hybridize to the P. jirovecii mtLSU gene, which is of SEQ ID NO: 1 or to the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 (a P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 10.
- said second probe may hybridize to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 3 ( P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3 or, to any of SEQ ID NO: 2 ( P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said second probe may also not hybridize to human DNA or RNA.
- said second probe specifically hybridizes to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof.
- the sequence of said second probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the second probe the capacity to hybridize to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 17-21 nucleotides (more particularly of 19 nucleotides), which hybridizes to the sequence of SEQ ID NO; 1 or the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 or the sequence complementary to SEQ ID NO: 10, without hybridizing to any of SEQ ID NO; 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said hybridization portion of said second probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said second probe may specifically hybridize to the sequence of SEQ ID NO: 1 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or to the complementary sequence thereof.
- the hybridization portion of said second probe is the (19 nucleotide-long) sequence of SEQ ID NO: 13 or the complementary sequence thereof.
- the sequence of said second probe may consist of said hybridization portion.
- the sequence of said second probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion.
- Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said second probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm).
- the total length of said second probe advantageously is of 25-29 nucleotides, or of 24-28 nucleotides, or of 23-27 nucleotides, or of 22-36 nucleotides.
- Said second probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- fluorophore e.g., 6-carboxyfluorescein, or tetrachlorofluorescein
- quencher e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black
- Said second probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- LNA Locked Nucleic Acid
- Said second probe may e.g., be a DNA or RNA probe.
- said second probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRAX or BHQ-1).
- a TAQMAN@ probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- said second probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- a beacon probe i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- said second probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- SCORPION® probe i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker.
- the quantification may also be performed using at least two of said second probes (i.e., two different second probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- the Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- said second probe may hybridize to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 1 ( P. jirovecii mtLSU gene) and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 ( P.
- Said second probe may also not hybridize to human DNA or RNA.
- said second probe specifically hybridizes to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof.
- the sequence of said second probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the second probe the capacity to hybridize to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 19-30 nucleotides (more particularly of 20-24 nucleotides, more particularly of 22 nucleotides), which hybridizes to the sequence of SEQ ID NO: 3 or the sequence complementary to SEQ ID NO: 3, more particularly to the sequence of SEQ ID NO: 30 or the sequence complementary to SEQ ID NO: 30, without hybridizing to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1.
- Said hybridization portion of said second probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said second probe may specifically hybridize to the sequence of SEQ ID NO: 3 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or to the complementary sequence thereof.
- the hybridization portion of said second probe is the (22 nucleotide-long) sequence of SEQ ID NO: 33 or the complementary sequence thereof, or a LNA-counterpart thereof, such as the (22 nucleotide-long) sequence of SEQ ID NO: 58 or the complementary sequence thereof (SEQ ID NO: 59; cf. example 3 below).
- the sequence of said second probe may consist of said hybridization portion.
- the sequence of said second probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion.
- Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said second probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm).
- the total length of said second probe advantageously is of 28-32 nucleotides, or of 27-31 nucleotides, or of 26-30 nucleotides, or of 25-29 nucleotides.
- Said second probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- fluorophore e.g., 6-carboxyfluorescein, or tetrachlorofluorescein
- quencher e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black
- Said second probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- LNA Locked Nucleic Acid
- Said second probe may e.g., be a DNA or RNA probe.
- said second probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1).
- a TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- said second probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- a beacon probe i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- said second probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- SCORPION® probe i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker.
- the quantification may also be performed using at least two of said second probes (i.e., two different second probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- the Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- said second probe may hybridize to
- said second probe may hybridize to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof, without hybridizing to any of SEQ ID NO: 3 ( P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said second probe may also not hybridize to human DNA or RNA.
- said second probe specifically hybridizes to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof.
- the sequence of said second probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA portion, which confers to the second probe the capacity to hybridize to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA sequence of 23-29 nucleotides (more particularly of 25-27 nucleotides), which hybridizes to the sequence of SEQ ID NO: 2 or the sequence complementary to SEQ ID NO: 2, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the sequences complementary to SEQ ID NO: 10, 20, 25, without hybridizing to any of SEQ ID NO: 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said hybridization portion of said second probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said second probe may specifically hybridize to the sequence of SEQ ID NO: 2 or to the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof.
- the hybridization portion of said second probe is the (25 or 27 nucleotide-long) sequence of SEQ ID NO: 18, 23 or 28 or the complementary sequence thereof.
- the sequence of said second probe may consist of said hybridization portion.
- the sequence of said second probe may comprise other DNA sequence(s) in addition to said hybridization portion, e.g., other DNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion.
- Said other DNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion.
- Said other DNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said second probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm).
- the total length of said second probe advantageously is of 31-37 nucleotides, or of 30-36 nucleotides, or of 29-36 nucleotides, or of 28-34 nucleotides.
- Said second probe may comprise at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- fluorophore e.g., 6-carboxyfluorescein, or tetrachlorofluorescein
- quencher e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groo
- Said second probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1).
- a TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- said second probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- a beacon probe i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- the Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- said at least one first probe is implemented in real-time PCR. More particularly, said at least one first probe advantageously is implemented in the same tube as said first primer pair in real-time PCR amplification.
- said at least one second probe in implemented in real-time PCR. More particularly, said at least one second probe advantageously is implemented in the same tube as said second primer pair in real-time PCR amplification.
- said at least one first probe and one second probe are implemented in real-time PCR. More particularly, said at least one first probe and said at least one second probe are implemented in the same tube as said first primer pair and second primer pair in real-time PCR amplification.
- the application also relates to each individual product that is implemented or obtainable by a method of the application.
- the application also relates to each of said first primer pair, said second primer pair, said first probe and said second probe, individually as a product.
- the application also relates to each of said first cDNA targets, said second cDNA targets, said first RNA targets, said second RNA targets, said first amplicons and said second amplicons, individually as a product.
- the application also relates to the association or combinations of such products.
- the application relates to the association or combination of at least two or at least three different elements from the following list of four (different) elements: said first primer pair, said second primer pair, said first probe and said second probe; or to the association or combination of the four of them.
- the application relates to the association or combination of said first probe and said second probe.
- the application relates to the association or combination of said first primer pair and said second primer pair.
- the application relates to the association or combination of said first primer pair and said first probe.
- the application relates to the association or combination of said second probe and said second primer pair.
- kits can be associated or combined in a kit, more particularly in a kit for simultaneous, separate or sequential use, or in a composition, more particularly in a liquid composition, such as an amplification composition.
- Said association, combination, kit or composition may further comprise at least one reverse transcriptase (i.e., at least one RNA-dependent DNA polymerase), or at least one reverse transcriptase and at least one DNA-dependent DNA polymerase.
- said kit comprises at least said first primer pair and/or at least said first probe, more particularly at least said primer pair and at least said first probe.
- Said kit may further comprise an internal control for RNA extraction and/or purification, such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- an internal control for RNA extraction and/or purification such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- the application relates to the association or combination of at least two or at least three or at least four or at least five different elements from the following list of six (different) elements: said first cDNA targets, said second cDNA targets, said first RNA targets, said second RNA targets, said first amplicons and said second amplicons; or to the association or combination of the six of them. More particularly, the application relates to the association or combination of said first amplicons and said second amplicons.
- Each of said six elements can be contained in a composition, more particularly in a liquid composition, such as an amplification composition.
- Said association, combination or composition may further comprise at least one reverse transcriptase (i.e., at least one RNA-dependent DNA polymerase), or at least one reverse transcriptase and at least one polymerase (more particularly at least one DNA-dependent DNA polymerase).
- at least one reverse transcriptase i.e., at least one RNA-dependent DNA polymerase
- at least one reverse transcriptase and at least one polymerase more particularly at least one DNA-dependent DNA polymerase
- Said reverse transcriptase (or said reverse transcriptase and DNA-dependent DNA polymerase) can be any reverse transcriptase (or any reverse transcriptase and DNA-dependent DNA polymerase), which the person of average skill in the art may find appropriate.
- reverse transcriptase examples include the SUPERSCRIPT® III Reverse Transcriptase (RT) commercialized by INVITROGENTM (INVITROGENTM by LIFE TECHNOLOGIESTM; 5791 Van Allen way: Carlsbad; Calif. 92008, U.S.A.).
- RT Reverse Transcriptase
- polymerases examples include a Thermus aquaticus polymerase.
- Said product(s), association(s), combination(s), kit(s), composition(s) is(are) suitable for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- PCP PneumoCystis Pneumonia
- the application thus also relates to the (in vitro) use of said product(s), association(s), combination(s), kit(s), composition(s) for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- PCP PneumoCystis Pneumonia
- the application relates to the in vitro use of a reverse transcriptase (i.e., a RNA-dependent DNA polymerase) and of oligonucleotides:
- a reverse transcriptase i.e., a RNA-dependent DNA polymerase
- said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein
- said second P. jirovecii mitochondrial gene is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA (mtLSU gene or mtSSU gene, more particularly mtLSU gene).
- said first P. jirovecii mitochondrial gene is the mtSSU P. jirovecii gene
- said second P. jirovecii mitochondrial gene is the P. jirovecii mtLSU gene.
- Said use may further comprises the use of a polymerase (i.e., of a DNA-dependent DNA polymerase).
- a polymerase i.e., of a DNA-dependent DNA polymerase
- Said use may further comprise the use a RNA extraction and/or purification internal control, such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- a RNA extraction and/or purification internal control such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- kits which comprises said reverse transcriptase and said oligonucleotides.
- Said kit may further comprise a polymerase (i.e., a DNA-dependent DNA polymerase).
- PCP PneumoCystis Pneumonia
- Said kit can be viewed as a kit suitable for diagnosing or predicting PneumoCystis Pneumonia (PCP) in a human patient (more particularly, a human patient, who is a Pneumocystis jirovecil carrier), or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly, a human patient, who is a Pneumocystis jirovecil carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who receives or has received a drug or treatment against PCP.
- Said kit may further comprise written instructions for implementing said reverse transcriptas
- Said kit may be a kit for simultaneous, separate or sequential use, more particularly for simultaneous use, of said reverse transcriptase and said oligonucleotides (or of said reverse transcriptase, said oligonucleotides and said polymerase).
- Said kit may comprise container(s) (e.g., tube(s)), wherein said reverse transcriptase and said oligonucleotides (or said reverse transcriptase, said oligonucleotides and said polymerase) are contained.
- said reverse transcriptase and said polymerase are contained in the same container (e.g., in the same tube).
- Said first primer pair can be contained in a container (e.g., tube), which is different from the container (e.g., tube) in which said second primer pair is contained.
- Said first probe can be contained in a container (e.g., tube), which is different from the container (e.g., tube) in which said second probe is contained.
- Said first primer pair and said first probe may be in the same container (e.g., tube).
- Said second primer pair and said second probe may be in the same container (e.g., tube).
- kits may further comprise means for RNA extraction and/or purification.
- said kit may further comprise cell lysis reagent(s) and/or buffer(s), and/or RNA purification means, such as e.g., a silica membrane.
- Said kit may further comprise an internal control for RNA extraction and/or purification such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- an internal control for RNA extraction and/or purification such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- nucleotide sequence of each primer of said first and second primer pairs may independently consist of 15-30 nucleotides (e.g., of 18-28 or 19-27 or 20-26 nucleotides) (cf. above).
- the nucleotide sequence of each of said first and second probes independently consists of 17-37 nucleotides (e.g., of 20-24 or 28-32 or 17-21 or 25-29 or 23-29 or 31-37 nucleotides) (cf. above).
- said first or second primer pair is a primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of said first or second P. jirovecii mitochondrial gene (or to the RNA transcripts of said first or second P. jirovecii mitochondrial gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 100-120 nucleotide-long (more particularly of 100-110 nucleotide-long, more particularly of 102-108 nucleotide-long, more particularly of 104-106 nucleotide-long, more particularly of 105 nucleotide-long), and which comprises or is
- said first or second primer pair may e.g., be a (mtLSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtLSU gene (or to the RNA transcripts of the P. jirovecii mtLSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and which comprises or is
- said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
- said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecil mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
- said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
- a primer pair which anneals to a (target) cDNA or RNA or DNA
- the forward primer anneal to a first sequence, which is contained in said (target) cDNA or RNA or DNA
- the reverse primer anneals to a second sequence, which is contained in the sequence complementary to said (target) cDNA or RNA or DNA.
- the 5′ end of said first (target) sequence and the 5′ end of said second (target) sequence can be viewed as the start and end positions of the amplicon produced by said primer pair.
- a primer pair which anneals to a (target) cDNA or RNA or DNA, can be viewed as a primer pair, wherein:
- the 5′ end of said first (target) sequence and the 5′ end of said second (target) sequence can be viewed as the start and end positions of the amplicon produced by said primer pair.
- the application also relates to a solid support, such as a nucleic acid microarray, nanoarray, chip or lane, onto which said first primer pair and/or said first probe is/are attached or bound.
- Said solid support may further comprise said second primer pair and/or said second probe attached or bound thereto.
- Said solid support may e.g., be a plastic, glass or silicon microarray, nanoarray, chip or lane.
- the application also relates to the (in vitro) use of a P. jirovecil transcriptome for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- PCP PneumoCystis Pneumonia
- Said use comprises detecting and/or quantifying, more particularly quantifying. (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene.
- said use comprises detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (CYTB gene) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU or mtSSU, more particularly mtLSU).
- said use comprises detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (mtSSU) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU).
- the application also relates to a nucleic acid library, which is or comprises the transcriptome of P. jirovecii , more particularly the RNA transcripts of P. jirovecii .
- This transcriptome or transcripts can be those of a patient's biological sample as discussed above.
- Such a library is useful for detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene.
- such a library is useful for detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (CYTB gene) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU or mtSSU).
- a library is useful for detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (mtSSU) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU).
- the library of the application is notably suitable for high throughput sequencing, e.g., for implementation of the RNA-Seq method described in Wang et al. 2009.
- Said library can be used in accordance with the application, e.g., for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- PCP PneumoCystis Pneumonia
- Said nucleic acid library can e.g., be a DNA library, which comprises or consists of DNA fragments of 40-400 bp, wherein each of said DNA fragments comprise the cDNA reverse transcript of a P. jirovecii RNA fragment of 40-400 nucleotides, wherein said P. jirovecii RNA fragment of 40-400 nucleotides is a fragment of 40-400 nucleotides from the RNA transcript of a P. jirovecii mitochondrial gene.
- said P. jirovecii mitochondrial gene is the mtLSU gene, the mtSSU or the CYTB gene.
- said DNA library comprises or consists of:
- said DNA library comprises or consists of:
- each of said DNA fragments may optionally further comprise:
- the application also relates to a computer program product, for storage in a memory of a processing unit or on a removable memory support for cooperation with a reader of said processing unit, which comprises (code) instructions for carrying out a method of the application (when read or executed by a processor or microprocessor).
- the computer program product of the application may comprise (code) instructions, which (when read or executed by a processor or microprocessor) align RNA or cDNA sequence reads on the mitochondrial DNA sequence of P. jirovecii to detect and/or quantify (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (e.g., cytb or mtSSU) and of said second P. jirovecii mitochondrial gene (e.g., mtLSU or mtSSU).
- code code
- the computer program product of the application may comprise (code) instructions, which (when read or executed by a processor or microprocessor) align RNA or cDNA sequence reads on the mitochondrial DNA sequence of P. jirovecii to detect and/or quantify (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (e.g., cytb
- the application also relates to a computer device, comprising a processing unit in the memory of which is stored the computer program product of the application, and measurement values for the respective values of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene (e.g., cytb or mtSSU) and of said second P. jirovecii mitochondrial gene (e.g., mtLSU or mtSSU).
- a computer device comprising a processing unit in the memory of which is stored the computer program product of the application, and measurement values for the respective values of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene (e.g., cytb or mtSSU) and of said second P. jirovecii mitochondrial gene (e.g., mtLSU or mtSSU).
- the application also relates to a kit for use in the treatment and/or prevention and/or palliation of PCP in a human patient, (more particularly, a human patient, who is a Pneumocystis jirovecii carrier), wherein comprises one or several ingredient(s) for simultaneous, separate or sequential use in said treatment and/or prevention and/or palliation.
- a human patient who is a Pneumocystis jirovecii carrier
- Said one or several active ingredient(s) may e.g., be
- said human patient is a human patient, who has been diagnosed or predicted to be at high risk of having or developing PCP with a method of the application.
- the application also relates to a method for the treatment and/or prevention and/or palliation of PCP in a human patient in need thereof, wherein said human patient is a Pneumocystis jirovecii carrier. Said method comprises:
- Said drug or combination of drugs may comprise
- BAL BronchoAlveolar Lavage Fluids
- the BALF was centrifuged at 2,800 g for 10 minutes, the pellet was re-suspended with 4 mL of phosphate-buffered saline and split in four fractions of 1 mL. The four tubes were then centrifuged at 8,000 g for 5 minutes and the pellets of two tubes were frozen and stored at ⁇ 80° C. The two other pellets were used for classical staining, immunofluorescence procedure and DNA extraction as described in Alanio et al. 2011.
- the 192 corresponding patients were cared for in three hospitals in the north of Paris (Hospital Saint Louis, 1 avenue Claude Vellefaux 75010 Paris France; Hospital Lariboisière, 2 rue Ambroise Parè 75010 Paris France; and Hospital Robert Debrè, 48 Boulevard Serrurier 75019 Paris France).
- the sex ratio was 1.5 and the median age was 50 years with a range of 02 to 82 years.
- P. jirovecil immunofluorescence, DNA or RNA detection
- the whole medical file including clinical, radiological and biological features was retrospectively analyzed by two expert physicians (one pneumologist and one infectious disease specialist).
- PCP PneumoCystis pneumonia
- PCP Pneumocystis pneumonia
- ID presentation therapy prophylaxis diagnosis
- BAL or IS presentation therapy prophylaxis diagnosis
- RNA transcripts of the mitochondrial Small SubUnit also known as RNS
- mtSSU mitochondrial Small SubUnit
- SEQ ID NO: 2 which is: (SEQ ID NO: 2) TAAGATAATTCACAAAAGAAAGAGTTTAATGTTAGCTCCGAATCAACGCTATCTAGAGGCATTACACATGCA AATCGTACGTTTAAAGTGGTGAACAGGTGAGTAAAGATAGAAATCTACCTATTCATAAGGTTAGATACCTTT TAAAAGAACAATTGTTTGTGAATAGATGAGTCTAAGTGGGGGAGGTAGTTGTGAGGTGAAGATCCTCCCAAG CCTAAGAACCCTAGTTATATTTGAAAGAATGAATAACCACATTGGCTCTGAAACAACAGCCAAGATTTTCAT CCAAGAAAGTCCAGCAGTGGGGAATATTGGTCAATGATCGAAAGATTGAACCAGCTATCTAGAAGAATTTGT ATTCTGTTATTAGAGAGGATTATGACGTTATCTAATTAAAGTCTCGACCAATTCTCGTGCCAGCAGTCGCGG TAAGACGTGAGGCTAGCGTTATTCATAATTATTATTAGGTCTAAAGGGTACG
- the reference sequence used to design primers and a probe for the quantification of the RNA transcripts of the Beta TUBuline (BTUB) is referenced in GEN BANK® under the accession number AF170964.1 (SEQ ID NO: 4), which is: (SEQ ID NO: 4) 1 ggcgcctctt tttggagcac cattagcggt gaacacggtc ttgatagcac tggcctgtaa 61 gcaatattgt aatactgcag tgtgtttgca gaggtgatta gaaatgccta taaggcagca 121 aaaggcatt gaaaagactc caaagaagta caaagatgct ctgcaaacaa tctaaaaca 181 tgcagtaata cttttttcca
- the reference sequence used to design primers arid a probe for the quantification of the RNA transcripts of HSP70 is referenced in GEN BANK® under the accession number DQ987621.1 (SEQ ID NO: 5), which is: (SEQ ID NO.
- the reference sequence used to design primers and a probe for the quantification of the RNA transcripts of NAD1 is referenced in GEN BANK® under the accession number JX499143.1, REGION: 29671 . . . 30672 (SEQ ID NO: 7), which is: (SEQ ID NO: 7) 29671 atgttaaatt gtattcaagt gggtattgtt 29701 ttattacctg ttttgttaag tgtagcttttt gtgacattag ctgaacgtaa agttatggga 29761 tcgattcaac gacgtgtggg tcctaatgttt gtgggttatt atggtttgttt acaacctgca 29821 gctgatgctt taaattatt attaaagaa actattatt
- the reference sequence used to design primers and a probe for the quantification of the RNA transcripts of ATP9 is referenced in GEN BANK® under the accession number JX499143.1, REGION: 20225 . . . 20449 (SEQ ID NO: 8), which is: (SEQ ID NO.
- RNA transcripts were tested (quantification of RNA transcripts). All PCR reactions were performed on a LIGHTCYCLER® 480 instrument (ROCHE DIAGNOSTICS; 2, Avenue du Vercors; BP 59; 38242 MEYLAN CEDEX; FRANCE) in a final volume of 10 ⁇ L containing 0.2 ⁇ L of EXPRESS SuperScript® III Mix for One-Step qRT-PCR (INVITROGENTM by LIFE TECHNOLOGIESTM; 5791 Van Allen way; Carlsbad; CA 92008: U.S.A.), 1 ⁇ EXPRESS SuperScript® III SuperMix Universal buffer (INVITROGENTM by LIFE TECHNOLOGIESTM; 5791 Van Allen way; Carlsbad; CA 92008; U.S.A.), with 0.3 ⁇ M of each primer, 0.1 ⁇ M of the probe and 2
- the mtLSU (RNA) target was: SEQ ID NO: 9 CACUGAAUAUCUCGAGGGAGUAUGAAAAUAUUUAUC UCAGAUAUUUAAUCUCAAAAUAACUAUUUCUUAAAA UAAAUAAUCAGACUAUGUGCGAUAAGGUAGAUAGUC GAAAGGGAAACAG.
- the cDN A reverse-transcript of the mtLSU target was (fragment 861-981 from SEQ ID NO: 1): SEQ ID NO: 10 CACTGAATATCTCGAGGGAGTATGAAAATATTTAT CTCAGATATTTAATCTCAAAATAACTATTCTTAAA ATAAATAATCAGACTATGTGCGATAAGGTAGATAG TCGAAAGGGAAACAG.
- Primers and probe used for the detection of the targeted region of the mtLSU RNA were: PjF1: (SEQ ID NO: 11) 5′-CACTGAATATCTCGAGGGAGTATGAA-3′ PjR1: (SEQ ID NO: 12) 5′-CTGTTTCCCTTTCGACTATCTACCTT-3′ and the PjSL probe: (SEQ ID NO: 13) 5′-TCGCACATAGTCTGATTAT-3′ under TAQMAN® format (FAMTM in 5′ and MGB® in 3′).
- RNA target can be: SEQ ID NO: 14 GCAAUGAUGGAAGUCGGAGCUAAUCCCCUAAAAG AUUGUUUAGUCCGGAUAAGUGCCUGGAACUCGGC UCUUUGAAGUUGGA.
- the cDNA reverse-transcript of this mtSSU target can be (fragment 1154-1235 from SEQ ID NO: 2): SEQ ID NO: 15 GCAATGATGGAAGTCGGAGCTAATCCCCTAAAAGAT TGTTTAGTCCGGATAAGTGCCTGGAACTCGGCTCTT TGAAGTTGGA.
- Primers arid probe for the detection of this mtSSU RNA target region can be: Pj1154F: (SEQ ID NO: 16) 5′-GCAATGATGGAAGTCGGAGC-3′.
- PJ1235R (SEQ ID NO: 17) 5′-TCCAACTTCAAAGAGCCGAGT-3′.
- Pj1190P probe (SEQ ID NO: 18) 5′- TGTTTAGTCCGGATAAGTGCCTGGA-3′ under TAQMAN® format (FAMTM in 5′ and BHQ-1® in 3′).
- BHQ-1® Black Hole Quencher®-1.
- RNA target can be: SEQ ID NO: 19 GGAUGCAAUGAUGGAAGUCGGAGCUAAUCCCCUAAA AGAUUGUUUAGUCCGGAUAAGUGCCUGGAACUCGGC UCUUUGAAGUUGGAAUUGCU.
- the cDNA reverse-transcript of this mtSSU target can be (fragment 1150-1241 from SEQ ID NO: 2): SEQ ID NO: 20 GGATGGAATGATGGAAGTCGGAGCTAATCCCCTAAA AGATTGTTTAGTCCGGATAAGTGCCTGGAACTCGGC TCTTTGAAGTTGGAATTGCT.
- Primers and probe for the detection of this mtSSU RNA target region can be: Pj1150F: (SEQ ID NO: 21) 5′-GGATGCAATGATGGAAGTCGGA-3′, Pj1241R: (SEQ ID NO: 22) 5′-AGCAATTCCAACTTCAAAGAGCC-3′, and the Pj1190P probe: (SEQ ID NO: 23) 5′-TGTTTAGTCCGGATAAGTGCCTGGAAC-3′ under TAQMAN® format (FAMTM in 5′ and BHQ-1® in 3′).
- Still another mtSSU (RNA) target can be: SEQ ID NO: 24 UCAUGACCCUUAUGAAGUGGGCUACAGACGUGCUGC AAAAUUUUCUACAAUGGGAUGCAAUGAUGGAAGUCG GAGC.
- the cDNA reverse-transcript of this mtSSU target can be (fragment 1098-1173 from SEQ ID NO: 2): SEQ ID NO: 25 TCATGACCCTTATGAAGTGGGCTACAGACGTGCTGC AAAATTTTCTACAATGGGATGCAATGATGGAAGTCG GAGC.
- Primers and probe for the detection of this mtSSU RNA target region can be: Pj1098F: (SEQ ID NO: 26) 5′-TCATGACCCTTATGAAGTGGGC-3′, Pj1173R: (SEQ ID NO: 27) 5′-GCTCCGACTTCCATCATTGC-3′. and the Pj1125P probe: (SEQ ID NO: 28) 5′-ACGTGCTGCAAAATTTTCTACAATGGG-3′ under TAQMAN® format (FAMTM in 5′ and BHQ® in 3′).
- the CYTB (RNA) target was: SEQ ID NO: 29 CUCCCAGAAUUCUCGUUUGGUCUAUUGGUGUAGU UAUCUUCUUAAUUAUGAUUGUUACUGCUUUCUUG GGAUAUGUUCUGCCUUUUGGUCAAAUGUCAUUGU GGG.
- the cDNA reverse-transcript of the CYTB target was (fragment 242-346 from SEQ ID NO: 3): SEQ ID NO: 30 CTCCCAGAATTCTCGTTTGGTCTATTGGTGTAGTT ATCTTCTTAATTATGATTGTTACTGCTTTCTTGGG ATATGTTCTGCCTTTTGGTCAAATGTCATTGTGGG.
- CYTB_Pj242F (SEQ ID NO: 31) 5′-CTCCCAGAATTCTCGTTTGG-3′
- CYTB_Pj346R (SEQ ID NO: 32) 5′-CCCACAATGACATTTGACCA-3′
- the CYTB_Pj301P probe (SEQ ID NO: 33) 5′-CTTTCTTGGGATATGTTCTGCC-3′ under TAQMAN® format (FAMTM in 5′ and TAMRATM in 3′).
- TAMRATM carboxytetramethylrhodamine fluorescent dye.
- BTUB_PJ766F (SEQ ID NO: 34) 5′-CCATTAACAAGCAAGGGATCAC-3′
- BTUB_Pj861R (SEQ ID NO: 35) 5′-CGATGCTGCCATCATATTCTT-3′
- the BTUB_Pj795P probe (SEQ ID NO: 36) 5′-TCGGTCATTGACAGTTCCTGAA-3′ under TAQMAN® format (FAMTM in 5′ and TAMRATM in 3′).
- HSP70_PJ126F (SEQ ID NO: 37) 5′-GGAGATTTCATCAATGGTCCTT-3′
- HSP70_Pj202R (SEQ ID NO: 38) (5′-CGGCATTGGAAACITIAGTCC-3′
- HSP70_PJ157P probe (SEQ ID NO: 39) 5′-AAGGAGGTGGCAGAAGCGT A-3′ under TAQMAN® format (FAMTM in 5′ and TAMRATM in 3′).
- FAMTM TAQMAN® format
- COX1_Pj228F (SEQ ID NO: 40) 5′-AGGTTTTGGTAATTGGTTGGTTCC-3′
- COX1_PJ324R (SEQ ID NO: 41) 5′-AGAAGGCGGTAACAACCAGAA-3′
- COX1_Pj261P probe SEQ ID NO: 42) 5′-TGGAGCACCAGATATGGCCTTTCCAAGA-3′; under TAQMAN® format (FAMTM in 5′ and BHQ-1TM in 3′).
- BHQ-1TM Black Hole Quencher®-1.
- Primers and probe used for the detection of NAD1 RNA were: NAD1_Pj579F: (SEQ ID NO: 43) 5′-AGCAGAAACGAATTGAGCTCCT-3′
- ATP9_PJ25F (SEQ ID NO: 46) 5′-GGTTCAGGGTTAGCTACAATTGGA-3′
- ATP9_Pj118R (SEQ ID NO: 47) 5′-AAGGATTTCGACTTGTCGCTACT-3′
- ATP9_Pj52P probe (SEQ ID NO: 48) 5′-GCAGGGGCTGGTATCGGTATCGGTTTAG-3′ under TAQMAN® format (FAMTM in 5′ and BHQ-1TM in 3′).
- CYTB/mtLSU ratio E (CYTB) ⁇ Cq(CYTB) /E (mtLSU) ⁇ Cq(mtLSU)
- the real-time PCR efficiency values for CYTB, mtLSU, BTUB and HSP70 are reported in Table 8.
- RNA and DNA PCR were compared to the miLSU DNA PCR performed as a routine test. From the 200 samples, 34 (17%) were both positive and 148 (74%) were both negative with RNA and DNA PCR; cf. Table 2 below.
- RNA detection gave a 10 fold higher detection than DNA with a mean ⁇ Cq (DNA-RNA) at 3.577 (95% confidence interval: 2.681-4.473).
- PCP patients 14 samples (14 patients) were diagnostic samples and 5 samples (4 patients) were not performed as diagnostic samples but to search for other etiology of a persistent or recently acquired pneumonia after PCP diagnosis and more than 15 days of cotrimoxazole treatment (analyzed apart for the others specimens and called follow-up samples).
- Patients with PCP were composed of hematological malignancies (7/14, 50%), HIV patients (8/14, 57%), solid organ transplant (SOT) (1/14, 7%) and other background (2/14, 14%). Immunofluorescence was positive in 8/14 (57%) patients and negative in 6/14 (43%) patients.
- sensitivity and specificity were 0.57 (95% CI, 0.289-0.823) and 1.00 (95% CI, 0.888-1.000), respectively.
- the ROC curve analysis of the quantification results allowed determination of the best quantification cycle (Cq) threshold between 30.49 and 31.78 ( FIGS. 2A and 3B ).
- ROC curve analysis of the CYTB/mtLSU ratios was performed and showed that a threshold between 1.27 and 1.66 allowed the higher likelihood ratio (LR: 12.96) (cf. Table 4 below, cf. FIGS. 2A and 3B ).
- HSP70 gene was tested because its mRNA was one of the most abundant transcripts found in a transcriptome analysis of Pneumocystis carinii during a fulminate infection in a rat model of pneumocystosis.
- the BTUB gene was used as a reference gene and also tested in comparison to mtLSU
- Other mitochondrial genes were also investigated: COX1, NAD1 and ATP9.
- BTUB and HSP70 gene expression were tested in all samples in parallel to CYTB and mtLSU, COX1, NAD1, and ATP9 were tested in 9 positive samples (4 recovered from PCP patients; and 5 recovered from patients without PCP). ATP9 was not enough expressed to be used as a diagnostic marker.
- Example 2 Addition of an Internal Control as Control of RNA Extraction and/or Purification
- An artificial or exogenous RNA can be added to the sample prior to the extraction and/or purification step.
- Such an artificial or exogenous RNA is known as an Internal Extraction Control RNA (IECR).
- IECR can be an artificial cell containing calibrated RNA. Following RNA extraction and in parallel to testing the target genes (CYTB and mtLSU), the presence and the quantity of the control IECR, will be tested upon addition in dedicated mix, and specific primers in a specific well. Signal derived from the Internal Control RNA confirms the success of the extraction step and is also used to determine the presence of inhibitors in the RNA sample. IECR contains a sequence that had no significant known homology to any published sequence and should not interfere with the detection of the sample RNA (human and fungi). A negative control reaction may also be performed.
- IECR examples include:
- control can be performed by detecting that a human gene is still present after said extraction and/or purification step.
- suitable human genes include constitutive genes, such as the human albumin (ALB) gene or the human TATA Box binding protein (TBP).
- Said human gene can be detected using a probe, more particularly a primer pair and a (real-time) probe, which specifically detect said human gene.
- primer pair and (real-time) probe for the human albumin (ALB) gene examples include
- ALB Hs_10F (SEQ ID NO: 49) TCGTTACACCAAGAAAGTACCCC; ALB_Hs_89R (SEQ ID NO: 50) TGCTGCCCACTTTTCCTAGG; ALB_Hs_34P (SEQ ID NO: 51) AGTGTCAACTCCAACTCTTGTAGAGGT.
- primer pair and (real-time) probe for the human TATA Box binding protein (TBP) include
- TBP_Hs_107F (SEQ ID NO: 52) TGGCGTGTGAAGATAACCCA; TBP_Hs_204R (SEQ ID NO: 53) CGCTGGAACTCGTCTCACTA; and TBP_Hs_142P (SEQ ID NO: 54) TGCTGAGAAGAGTGTGGTGGAGATGC; or TBP_Hs_73F (SEQ ID NO: 55) ATCTTTGCAGTGACCCAGCA; TBP_Hs_169R (SEQ ID NO: 56) GAGCATCTCCAGCACACTCT; and TBP_Hs_93R (SEQ ID NO: 57) GCATCACTGTTTCTTGGCGTGTGAAG
- the CYTB (cDNA) probe that was used in Example 1 above was the probe of SEQ ID NO: 33 under TAQMAN® format, using the FAMTM fluorophore in 5′ and the TAMRATM quencher in 3′.
- a Black-Hole Quencher®-1 (BHQ®1) was successfully used. With this alternate quencher, the efficiency of the simplex RT-PCR was of 1.94.
- the simplex RT-PCR efficiency was of 1.92 for mtLSU (primers and probe of SEQ ID NOs: 11-13 as described in Example 1).
- the simplex RT-PCR efficiency was of 1.95 for mtSSU (primers and probe of SEQ ID NOs: 26-28 as described in Example 1).
- Each simplex RT-PCR was performed as described in Example 1, i.e., on a LIGHTCYCLER® 480 instrument (ROCHE DIAGNOSTICS; 2, Avenue du Vercors; BP 59; 38242 MEYLAN CEDEX; FRANCE) in a final volume of 10 ⁇ L containing 0.2 ⁇ L of EXPRESS SuperScript® III Mix for One-Step qRT-PCR (INVITROGENTM by LIFE TECHNOLOGIESTM: 5791 Van Allen way; Carlsbad: CA 92008; U.S.A.), 1 ⁇ EXPRESS SuperScript® III SuperMix Universal buffer (INVITROGENTM by LIFE TECHNOLOGIESTM; 5791 Van Allen way; Carlsbad; CA 92008; U.S.A.), with 0.3 ⁇ M of each primer, 0.1 ⁇ M of the probe and 2 ⁇ L of a 1:2 dilution of RNA.
- the reaction consisted of a reverse transcription step at 50° C. 15 min, followed by DNA poly
- the nucleotide sequence of SEQ ID NO: 33 (CYTB cDNA probe) can be modified to replace at least one nucleotide by its Locked Nucleic Acid (LNATM) version (EXIQONTM Inc. 14 F Gill Street Woburn Mass. 01801 U.S.A.).
- LNATM Locked Nucleic Acid
- At least one of the T. A and G nucleotides of the sequence of SEQ ID NO: 33 can be replaced by a LNATM-T, LNATM-A or LNATM-G, respectively.
- one to five nucleotides of the sequence of SEQ ID NO: 33 can (each) be replaced by their (respective) LNATM version.
- one to five of the T, A and G nucleotides of the sequence of SEQ ID NO: 33 can (each) be replaced by their (respective) LNATM counterpart, i.e., a LNATM-T, LNATM-A or LNATM-G, respectively.
- LNA modifications are intended to increase the specificity of the nucleotide sequence (i.e., in the case of SEQ ID NO: 33 or the complementary sequence thereof, to increase the specificity of the CYTB cDNA probe).
- the CYTB forward primer that was used in Example 1 above was the primer of sequence SEQ ID NO: 31.
- Such degenerated primer is intended to allow the detection and the quantification of CYTB mRNA in a sample from a patient having, in this genome, either a C or A at the position 255 of the nucleotide sequence SEQ ID NO: 3 corresponding to CYTB gene.
- Bronchoalveolar lavage (BAL) fluid samples of 18 patients were analyzed for detection and quantification of the RNA transcripts of mtSSU and mtLSU [twelve non-PCP patients that are P. pneumonia carriers; and six PCP patients, who did not receive any anti-PCP treatment or who have received an anti-PCP treatment for at most 15 days].
- RNA transcripts mtSSU and mtLSU.
- mtLSU RT-PCR was performed as described in Example 1 above (with the mtLSU primers of SEQ ID NOs: 11-12 and the probe of SEQ ID NO: 13).
- mtSSU RT-PCR was performed as described in Example 1 above (with the mtSSU primers of SEQ ID NOs: 26-27 and the probe of SEQ ID NO: 28).
- mtSSU gene gives significantly better cycles results than mtLSU with a median of 27.90 [C195% 24.39-28.55] compared to 30.00 [C195% 26.51-31.36], respectively (p ⁇ 0.001). Please see FIG. 5 .
- the mtSSU/mtLSU RNA ratio allows discrimination between PCP and carriage (the optimal ratio being of 2.7).
- a ratio from 3.1 to 3.3 would lead to 100% sensitivity but with a lower specificity (75% at 3.1 and 66.6% at 3.3). However, if the purpose were to allow PCP diagnosis together with identifying the patients with carriage, a ratio of 3.1 to 3.3 would be optimal to avoid misidentification of PCP patients who needs to be treated for PCP.
- FIG. 7 shows the distribution of the mtSSU/mtLSU RNA ratio values in the PCP patients and in the carrier patients.
- FIG. 8 shows the distribution of quantification values (cycles) of the RNA transcripts of the mtSSU et mtLSU genes in the PCP patients and in the carrier patients.
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 15/564,246, filed Oct. 4, 2017, which is the U.S. Natl. Stage of International Appln. PCT/EP2016/058355, filed Apr. 15, 2016, which claims the benefit of European Appln. 15305562.9 filed Apr. 15, 2015, all of which are herein incorporated by reference in their entirety.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 15, 2021, is named B11232A_ST25.txt and is 24,543 bytes in size.
- The application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP). The means of the application involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecil mitochondrial genes.
- The means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- PneumoCystis Pneumonia (PCP) is an opportunistic infection due to the ascomycetous fungus Pneumocystis jirovecii. This pathogen is specific for humans whereas related species exists for other terrestrial mammals, and growing evidence suggest that P. jirovecii could be considered as a commensal of human respiratory tract. It lives and thrives at the surface of the alveolar cells (type I pneumocytes) and can be found typically as two main forms: (i) the trophic form that undergo asexual multiplication by binary fission and (ii) ascus (cyst) containing eight ascospores that is the result of the sexual mode of replication. The complete life cycle of Pneumocystis carinii has been studied in rats. Experiments in animals suggest that Pneumocystis is transmissible from host to host with immunocompetent individuals as the most important reservoir and asci as the potential agent of transmission. Epidemiological and experimental data suggests that P. jirovecii is also a transmissible organism in humans. HIV-infected individuals with low CD4 counts are at risk of developing PCP. Despite highly effective prophylaxis with cotrimoxazole (association of a Dihydrofolate reductase inhibitor (trimethoprim) and of a sulfonamide antibiotic (sulfamethoxazole)) and highly active anti-retroviral treatments, PCP remains one of the most prevalent infections in patients with AIDS. PCP also occurs in non-HIV immunocompromised patients, including patients with hematological or solid malignancies, transplant recipients, and those receiving immunosuppressive treatments for autoimmune or inflammatory diseases.
- In non-HIV immunocompromised patients, PCP is typically more acute and severe than in HIV patients. PCP diagnosis is also harder since the average fungal charge is lower in non-HIV patients than in HIV patients.
- Overall, PCP carries a mortality rate of 35 to 55% in non-HIV immunocompromised patients, compared to 10 to 20% in HIV-infected patients.
- Diagnosis of PCP usually relies on microscopic demonstration of P. jirovecii in respiratory specimens using various staining methods that includes conventional staining (Calcofluor White. Toluidine Blue O, Gomori methamine, Giemsa staining) and anti-P. jirovecii immunofluorescence assays (IFA) (direct or indirect IFA). It is known for a long time that immunofluorescence is more sensitive than conventional staining. Alternatively, in the 1990's, two methods have been developed: beta-D-glucan (BDG) detection and PCR.
- The lack of sensitivity of microscopic methods due to low burden of P. jirovecii in non-HIV immunocompromised patients has justified the development of diagnostic PCR-based methods in the early 1990's to detect DNA in clinical samples rather than the microorganism itself. Initially. DNA detection aimed also at increasing sensitivity of P. jirovecii detection to avoid invasive procedure such as BronchoAlveolar Lavage (BAL) in patients suspected of PCP with the ambition to use induced sputa (IS) and/or upper respiratory specimens (URS, nasopharyngeal aspirate, oral washes or nasal swab) as diagnostic specimens. These methods were more sensitive and reproducible than microscopic detection (conventional staining and/or immunofluorescence), considered as gold-standard test in respiratory samples such as BronchoAlveolar Lavage Fluid (BALF) or induced sputa at that time.
- Single (sPCR) and nested end point (nPCR) formats used initially for DNA detection were progressively replaced by the quantitative real-time PCR (qPCR) format, where the PCR products is detected and quantified during amplification without opening of the reaction tube. The main advantages of this format are preventing false positives due to environmental contamination with previously amplified products, and to provide rapid quantitative results. Subgroup analysis regarding the PCR format was performed in the meta-analyses and showed higher sensitivity and specificity in qPCR assays compared to the global analysis. In addition, recommendations for diagnostic PCR already exist, highlighting the necessity to use real-time PCR format.
- The difference in performance reported for different PCR assays could be explained by the different DNA targets used for amplification and the primer designs. Indeed, most of the authors have developed their own primers, although generally designed to amplify a multicopy gene, which increase the sensitivity compared to a single copy gene. The P. jirovecii mitochondrial Large Sub-Unit ribosomal RNA (rRNA) gene (mtLSU) is the most commonly used. The multicopy Major Surface Antigen (MSG) gene was also targeted in various reports. Multiple single copy nuclear gene were also used such as 18S ribosomal DNA (rDNA), 5S rDNA, Internal transcribed spacer (ITS), DHPS, KEX, HSP70, Beta-TUBulin (BTUB) and CDC2. Indeed, ribosomal RNA genes cluster is unique in Pneumocystis.
- Comparison of analytical performance could be easily achieved using the quantification results of external quality controls. A comparison of three PCR assays using MSG (multicopy) and DHPS (single copy) target genes demonstrated the transferability of the results.
- However, PCR revealed the possibility to detect Pneumocystis DNA in pulmonary specimens from immunocompromised individuals without clinical signs or symptoms of PCP. This phenomenon was called P. jirovecii colonization or carriage. For this reason, PCR is not completely accepted as a diagnostic criterion for PCP, although the sensitivity of PCR assays is higher than microscopy and PCR was cost-effective in non-invasive specimens.
- One simple method to discriminate active Pneumocystis pneumonia from P. jirovecii carriage in respiratory samples of patients at risk of PCP is to determine quantitative thresholds. Since PCR is much more sensitive than microscopy, to define thresholds for assessing the diagnosis is crucial and cannot be performed without reliable quantification.
- Real-time quantitative PCR refers to real-time PCR that is able to quantify the amount of DNA in the extract using calibration curves based on reference DNA (plasmid), expressed as copy/volume unit. However, quantitative results can be expressed with other units. Alternatively, some authors use the crude qPCR results (as quantification cycle, Cq, Ct, or Cp), or some others translate it into a number of microorganisms based on counts (for example trophic form equivalent). No international standard qPCR assay and no threshold are currently consensual. Large international studies, or at least prospective studies, are highly needed to allow technical validation of this tool. Thereafter, the use of qPCR for clinical interpretation of qPCR results would be possible and validated.
- For samples harboring positive IFA, qPCR and microscopic quantification, as evaluated as the number of cysts (often expressed as +, ++ or +++), gave similar results. When qPCR results are in congruence with IFA, there is little question about the interpretation of the results. However, there is an overlap around the sensitivity limit of IFA, with some samples IFA negative and PCR positive whereas other samples are IFA positive with a lower P. jirovecii DNA content. A consensus of the lowest qPCR results corresponding to the IFA positive samples harboring the lowest fungal load is almost impossible since IFA is dependent of the examiner and the quality of the sample. On the other end of the spectrum, there is little doubt about the interpretation of the qPCR negative results. The negative predictive value of PCR assays has reached a consensus. The only point to be checked is the correct amplification of the internal control to avoid false negative results. Discrepancies appear for the IFA-negative qPCR-positive results. Some authors propose a grey zone. For instance, two cut-off values of 120 and 1900 trophic form equivalent/mL were proposed to discriminate active pneumonia from carriage, with a grey zone between them.
- There is a need for new means for diagnosing, predicting or monitoring PCP, more particularly for means, which discriminate PCP from P. jirovecil carriage. Therefore, we developed a new PCR method for the detection of Pneumocystis RNA.
- Our test is based on the detection and the quantification of the RNA transcripts of two genes of Pneumocystis jirovecii in the BAL fluid of patients.
- The application provides means, which are notably useful for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP).
- The means of the application notably enable to discriminate a PCP patient from a P. jirovecii carrier, who does not have or does not develop PCP, including when the patient is HIV-negative. The PCP status of HIV-negative human patients is especially difficult to determine, because the P. jirovecii charge of these patients is lower than that of HIV-positive human patients. The means of the application may thereby avoid that said P. jirovecii carriers receive an unnecessary PCP treatment.
- The means of the application involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes. The means of the application involve more particularly determining the ratio of the RNA transcripts of one of said two different P. jirovecii mitochondrial genes (hereinafter the first P. jirovecii mitochondrial gene) to the RNA transcripts of the other of said two different P. jirovecii mitochondrial genes (hereinafter the second P. jirovecii mitochondrial gene).
- Each of the two different P. jirovecii mitochondrial genes are independently selected from the group consisting of
-
- the P. jirovecii gene (SEQ ID NO: 3), the sequence of which codes for the Cytb protein, and
- the P. jirovecii genes, the respective sequences of which transcribe into a P. jirovecii ribosomal RNA, such as the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene (SEQ ID NO: 1) and the mitochondrial P. jirovecii Small Sub-Unit (mtSSU) gene (SEQ ID NO: 2).
- At least one of said two different P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene or the mtSSU gene.
- More particularly, at least one of said two different P. jirovecii mitochondrial genes is the mtLSU gene.
- For example, the first P. jirovecii mitochondrial gene of said ratio is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene.
- For example, the second P. jirovecii mitochondrial gene of said ratio is the mtSSU gene or the mtLSU gene (while still being different from the first P. jirovecii mitochondrial gene of said ratio), more particularly the mtLSU gene.
- For example, the first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, and the second P. jirovecil mitochondrial gene is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecil ribosomal RNA, such as the mtLSU gene or the mtSSU gene [ratio Cytb/(mtLSU or mtSSU), more particularly ratio Cytb/mtLSU]. For example, the first P. jirovecii mitochondrial gene is the mtSSU gene, and the second P. jirovecii mitochondrial gene is the mtLSU gene [ratio mtSSU/mtLSU].
- The means of the application are notably suitable
-
- for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or
- for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or
- for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- The means of the application comprises methods, products (e.g., primers and/or probes), association(s) or combination(s) of at least two of these products, as well as kit(s) and composition(s) comprising at least one of said products.
- The means of the application also comprises solid supports such as microarray, nanoarray, chip, onto which at least one of said product is attached, as well as nucleic acid library(ies) which are suitable for the quantification of a P. jirovecii transcriptome, computer program product(s), computer device(s) and kit(s) for use in the treatment and/or prevention and/or palliation of PCP in a human patient.
-
FIG. 1 . Comparison of mLSU quantification thresholds obtained with DNA (Cq mtLSU DNA PCR) or RNA amplification (Cq mtLSU RNA PCR) in BALF of patients. The mean loss of Cq is 3.58 (95% CI: 2.68-4.47), corresponding approximately to about a 10 fold higher expression for RNA. -
FIGS. 2A and 2B : ROC curves of mtLSU RNA qPCR (qPCR) and the CYTB/mtLSU ratio (PCP Xpress) tests for diagnostic (A, n=41) or diagnostic and follow-up (B, n=46) samples. Sens, sensitivity; Spec, Specificity; LR, Likelihood ratio. -
FIG. 3A . Plot of the mtLSU RNA quantification cycle (Cq) for each mtLSU positive samples in the different categories of samples. The range of threshold that allows the higher likelihood ratio is depicted as a dotted line]30.49 to 31.78[. Cleared dots are from patients classified in a category but for which the ratio is in favor of the other group of patient. -
FIG. 3B . Plots of the values of the CYTB/mtLSU ratio for each category of patients in samples in which both CYTB and mtLSU RNAs were amplified. PCP samples harbored mostly a CYTB/mtLSU <1.27, whereas non-PCP samples (carriers) or patients treated for a minimum of 15 days (PCP Rx) harbored mostly a CYTB/mtLSU ratio >1.66. Sixteen samples had CYTB unamplified so that the ratio was no calculated. Those samples were from patients without PCP. The range of threshold that allows the higher likelihood ratio is depicted as a dotted line]1.27 to 1.66[. Cleared dots are from patients classified in a category but for which the ratio is in favor of the other group of patients. -
FIG. 4 : ROC curve analysis for the BTUB, HSP70 and CYTB to mtLSU ratios. The higher likelihood ration was obtained with the CYTB/mtLSU ratio. -
FIG. 5 : mtLSU and mtSSU quantification in BAL fluid samples by PCR. -
FIG. 6 : analysis of the ROC curves obtained with the PCR (cycle) quantification of mtSSU and of mtLSU (in BAL fluid samples), and obtained with the mtSSU/mtLSU ratio. The maximal Likehood Ratio (LR) of the mtSSU/mtLSU ratio is at 10 (for an optimal ratio of 2.7) [whereas the maximal LR of each of mtLSU and mtSSU quantification alone is at 6]. A ratio of 3.1-3.3 would however allow to reach a sensitivity of 100%, and may appear preferable for accurate PCP detection. -
FIG. 7 : distribution of the mtSSU/mtLSU ratio in the BAL fluid samples of PCP patients and of P. jirovecii carrier (but non-PCP) patients. The ratio of 2.7 is showed in dashed line. -
FIGS. 8A and 8B : distribution of the mtSSU (FIG. 8A on the left) and mtLSU (FIG. 8B on the right) quantification cycles in the BAL fluid samples of PCP patients and of P. jirovecii carrier (but non-PCP) patients. - The present application relates to the subject-matter as defined in the claims as filed and as herein described.
- In the application, unless specified otherwise or unless a context dictates otherwise, all the terms have their ordinary meaning in the relevant field(s).
- The application provides means, which involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes.
- An aspect of the application is that the means of the application are based on the analysis of RNA transcripts, and not on the analysis of DNA. A further aspect of the application is that the RNA transcripts of the application are those of (P. jirovecii) mitochondrial genes.
- The means of the application involve more particularly determining the ratio of the RNA transcripts of one of said two different P. jirovecii mitochondrial genes (hereinafter the first P. jirovecii mitochondrial gene) to the RNA transcripts of the other of said two different P. jirovecil mitochondrial genes (hereinafter the second P. jirovecii mitochondrial gene).
- Each of the two different P. jirovecii mitochondrial genes are independently selected from the group consisting of
-
- the P. jirovecil gene (SEQ ID NO: 3), the sequence of which codes for the Cytb protein, and
- the P. jirovecii genes, the respective sequences of which transcribe into a P. jirovecii ribosomal RNA, such as the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene (SEQ ID NO: 1) and the mitochondrial P. jirovecii Small Sub-Unit (mtSSU) gene (SEQ ID NO: 2).
- At least one of said two different P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene or the mtLSU gene.
- According to an aspect of the application, at least one of said two different P. jirovecil mitochondrial genes is the mtLSU gene.
- According to an aspect of the application, the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein (SEQ ID NO: 3).
- The second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene (SEQ ID NO: 1) or the mtSSU gene (SEQ ID NO: 2), more particularly the mtLSU gene.
- According to an aspect of the application, the first of said two P. jirovecii mitochondrial genes is the mtSSU gene.
- The second of said two P. jirovecii mitochondrial genes is the mtLSU gene, or the P. jirovecii gene, the sequence of which codes for the Cytb protein, more particularly the mtLSU gene.
- According to an aspect of the application, the first of said two P. jirovecii mitochondrial genes is the mtLSU gene.
- The second of said two P. jirovecii mitochondrial genes is the mtSSU gene, or the P. jirovecii gene, the sequence of which codes for the Cytb protein, more particularly the mtSSU gene.
- The means of the application are notably suitable
-
- for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or
- for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or
- for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- Advantageously, the means of the invention are sufficiently reliable to determine the PCP status of a human patient, who is HIV-negative, more particularly a HIV-negative and immunocompromised human patient. The PCP status of HIV-negative human patients is especially difficult to determine, because the P. jirovecii charge of these patients is lower than that of HIV-positive human patients.
- The quantification of the RNA transcripts of said two different P. jirovecii mitochondrial genes may be achieved by any means that the skilled person may found appropriate. Nevertheless, the application provides Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) means, which RT-PCR means can be implemented in real-time.
- The application relates to an in vitro method for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly an in vitro method for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, wherein said method comprises
-
- i. in the RNA material of a sample of biological fluid previously obtained from the respiratory tract of said human patient, detecting and/or quantifying the (number of or the concentration of) RNA transcripts of (each of) two different P. jirovecii mitochondrial genes, more particularly quantifying the (number of or the concentration of) RNA transcripts of (each of) two different P. jirovecii mitochondrial genes to obtain a value of quantification of the RNA transcripts of a first P. jirovecii mitochondrial gene and a value of quantification of the RNA transcripts of a second P. jirovecil mitochondrial gene,
- ii. calculating the ratio of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene of i. to the value of quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene of i., and
- iii. comparing the value of the ratio of ii. to a threshold (numerical) value,
wherein said human patient is diagnosed or predicted to be at high risk of having or developing PCP or to be at low risk of having or developing PCP depending on whether the value of the ratio of ii. is equal to or lower than said threshold value, or whether the value of the ratio of ii. is higher than said threshold value.
- When the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein (SEQ ID NO: 3) and the second of said two P. jirovecii mitochondrial genes is the mtLSU or mtSSU gene, more particularly the mtLSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P. jirovecii mitochondrial genes is the mtLSU gene, said step iii. can be the step of comparing the ratio of ii. to a threshold (numerical) value, wherein, when the value of the ratio of ii. is equal to or lower than (more particularly lower than) said threshold value, said human patient is diagnosed or predicted to be at high risk of having or developing PCP,
- wherein, when the value of the ratio of ii. is higher than said threshold value, said human patient is diagnosed or predicted to be at low risk of having or developing PCP.
- Of course, inverting the first and second mitochondrial genes in the ratio results in accordingly inverting the threshold value and the conclusion that results from the comparison of the ratio to the threshold value.
- Therefore, when the first of said two P. jirovecil mitochondrial genes is the mtLSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said step iii. can be the step of comparing the ratio of ii. to a threshold (numerical) value, wherein, when the value of the ratio of ii. is higher or equal than (more particularly higher than) said threshold value, said human patient is diagnosed or predicted to be at high risk of having or developing PCP,
- wherein, when the value of the ratio of ii. is lower than said threshold value, said human patient is diagnosed or predicted to be at low risk of having or developing PCP.
- Said threshold value may e.g., have been predetermined by comparing the values, or the distribution of the values, that the ratio of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene to the value of quantification of the RNA transcripts of said second P. jirovecil mitochondrial gene takes in reference human cohorts of P. jirovecii carriers, who have been pre-established as a function of their status of:
-
- P. jirovecii carriers, who have or develop PCP, or of
- P. jirovecii carriers, who do not have and do not develop PCP,
in order to classify said human patient into that of those reference cohorts to which it has the highest probability of belonging.
- The reference human cohort of P. jirovecii carriers, who have or develop PCP, and the reference human cohort of P. jirovecii carriers, who do not have and do not develop PCP, may each e.g., comprise more than 100 humans. A human carrier of P. jirovecii is classified in either one of said two reference cohorts by any means that the skilled person may find appropriate. For example, said means may comprise the analysis of the clinical, radiological and biological features (including microscopical detection of absence or presence of P. jirovecii) of human individuals by two independent experts, e.g., a pneumologist and an infectious disease specialist (cf. examples and Table 1 below), and, for each of said human individuals, the concurrent conclusion of either presence of PCP (proven, probable or possible PCP, more particularly proven PCP), or of absence of PCP.
- The application also relates to an in vitro method for determining or predicting the efficacy of a drug or treatment against PCP in a human patient, who is a Pneumocystis jirovecii carrier and who has been diagnosed to have or to develop PCP, wherein said method comprises
-
- quantifying (the number of or the concentration of) RNA transcripts in the RNA material of a sample of biological fluid previously obtained from the respiratory tract of said human patient at a first point in time as well as at a second point in time, wherein said second point in time is later than said first point in time, wherein at least one of said first and second points in time is comprised in a time period during which said human patient is receiving said drug or treatment, wherein said RNA transcripts are the (respective) RNA transcripts of two different P. jirovecii mitochondrial genes, to obtain the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene at said first point in time and at said second point in time as well as the value of quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene at said first point in time and at said second point in time, respectively.
- calculating the ratio of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene to the value of quantification of RNA transcripts of said second P. jirovecii mitochondrial gene, to obtain the value of said ratio at said first point in time as well as its value at said second point in time, and
- comparing the value of said ratio at said second point in time to its value at said first point in time, wherein an increase or a decrease of the value of said ratio at said second point in time compared to said first point in time is indicative that said treatment or drug is or will be efficient to treat or alleviate PCP in said human patient.
- When the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, and the second of said two P. jirovecii mitochondrial genes is the mtLSU gene or the mtSSU gene, more particularly the mtLSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P. jirovecii mitochondrial genes is the mtLSU gene, it is an increase of the value of said ratio at said second point in time compared to said first point in time that is indicative that said treatment or drug is or will be efficient to treat or alleviate PCP in said human patient. The absence of increase, more particularly a decrease, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that said treatment or drug is not or will not be efficient to treat or alleviate PCP in said human patient.
- Of course, inverting the first and second mitochondrial genes in the ratio results in accordingly inverting the threshold value and the conclusion that results from the comparison of the ratio to the threshold value.
- Therefore, when the first of said two P. jirovecii mitochondrial genes is the mtLSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, it is a decrease of the value of said ratio at said second point in time compared to said first point in time that is indicative that said treatment or drug is or will be efficient to treat or alleviate PCP in said human patient. The absence of decrease, more particularly an increase, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that said treatment or drug is not or will not be efficient to treat or alleviate PCP in said human patient.
- The application also relates to an in vitro method for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP, wherein said method comprises
-
- quantifying (the number of or the concentration of) RNA transcripts in the RNA material of a sample of biological fluid previously obtained from the respiratory tract of said human patient at a first point in time as well as at a second point in time, wherein said second point in time is later than said first point in time, wherein at least one of said first and second points in time is comprised in a time period during which said human patient is receiving said drug or treatment, wherein said RNA transcripts are the (respective) RNA transcripts of two different P. jirovecii mitochondrial genes, to obtain the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene at said first point in time and at said second point in time as well as the value of quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene at said first point in time and at said second point in time, respectively.
- calculating the ratio of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene to the value of quantification of RNA transcripts of said second P. jirovecii mitochondrial gene, to obtain the value of said ratio at said first point in time as well as its value at said second point in time, and
- comparing the value of said ratio at said second point in time to its value at said first point in time, wherein an increase or a decrease of the value of said ratio at said second point in time compared to said first point in time is indicative that PCP regresses or has been treated in said human patient.
- When the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein (SEQ ID NO: 3), and the second of said two P. jirovecii mitochondrial genes is the mtLSU gene or the mtSSU gene, more particularly the mtLSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second of said two P. jirovecii mitochondrial genes is the mtLSU gene, it is an increase of the value of said ratio at said second point in time compared to said first point in time that is indicative that PCP regresses or has been treated in said human patient. The absence of increase, more particularly a decrease, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that PCP does not regress or does not have been treated in said human patient.
- Of course, inverting the first and second mitochondrial genes in the ratio results in accordingly inverting the threshold value and the conclusion that results from the comparison of the ratio to the threshold value.
- Therefore, when the first of said two P. jirovecii mitochondrial genes is the mtLSU gene and the second of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mtSSU gene, or when the first of said two P. jirovecii mitochondrial genes is the mtSSU gene and the second first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, it is a decrease of the value of said ratio at said second point in time compared to said first point in time that is indicative that PCP regresses or has been treated in said human patient. The absence of decrease, more particularly an increase, of the value of said ratio at said second point in time compared to said first point in time may be or is indicative that PCP does not regress or does not have been treated in said human patient.
- When the first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein, the second of said two P. jirovecil mitochondrial genes can e.g., be a P. jirovecii gene, the sequence of which transcribes into a P. jirovecil ribosomal RNA, such as the mtLSU gene (SEQ ID NO: 1) or the mtSSU gene (SEQ ID NO: 2), more particularly the mtLSU gene.
- When the first of said two P. jirovecii mitochondrial genes is the mtSSU gene, the second of said two P. jirovecii mitochondrial genes can e.g., be the mtLSU gene.
- According to an aspect of the application, said second P. jirovecii ribosomal RNA is the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.
- According to an aspect of the application, said first P. jirovecii ribosomal RNA is the P. jirovecii gene, the sequence of which codes for the Cytb protein, or is the mitochondrial P. jirovecii Small Sub-Unit (mtSSU) gene.
- Advantageously, the respective RNA transcripts of said two different P. jirovecil mitochondrial genes are quantified in the RNA material of the same sample of biological fluid.
- The RNA material of said sample of biological fluid can be extracted and/or purified from the sample. RNA extraction means and RNA purification means are known to the person of ordinary skill in the art. For example, RNA extraction means comprise cell lysis reagent(s) and/or buffer(s). For example, RNA purification means comprise silica membrane.
- Advantageously, the RNA material of said sample of biological fluid is purified by silica membrane filtration of said sample of biological fluid.
- The means of the application may further comprise a control of nucleic acid extraction and/or purification, more particularly an internal control of nucleic acid extraction and/or purification. More particularly, the means of the application may further comprise a control of RNA extraction and/or purification, more particularly an internal control of RNA extraction and/or purification.
- More particularly, the means of the application may further comprise a RNA acting as an internal control of RNA extraction and/or purification, more particularly an artificial or exogenous RNA, more particularly a RNA acting as an Internal Extraction Control RNA (IECR) (cf. the example 2 below), or may further comprise a cell which comprises such a RNA (e.g., by genetic engineering).
- Said RNA or IECR may e.g., be a RNA sequence (e.g., a RNA sequence of 30-500 nucleotides), which is not a human or fungal nucleic acid sequence, more preferably which has less than 60% (e.g., less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 1%) identity to any human or fungal nucleic acid sequence. Examples of IECR are commercially available. Examples of IECR include:
-
- the RNA extraction control commercialized by BIOLINE (BIOLINE USA Inc.; 305 Constitution Dr.; TAUNTON; Mass. 027080; U.S.A.) under catalog number BIO-38040 or BIO-35040,
- the AMBION® ERCC RNA Spike-In Controls, which are commercialized by LIFE TECHNOLOGIES S.A.S. (route de l'orme des merisiers; Immeuble Discovery—Zone Technologique; 91190 SAINT AUBIN, FRANCE), under catalog number 4456740, and
- the RNA Internal Control, which is commercialized by QIAGEN® (QIAGEN® France S.A.S.; 3, avenue du Canada: LP 809; 91974 COURTABOEUF CEDEX; FRANCE) under catalog number 211492.
- Alternatively to the IECR, the internal control of RNA extraction and/or purification can be performed by detecting that a human gene is still present after said extraction and/or purification step. Examples of suitable human genes are known in the art and include constitutive genes, such as the human albumin (ALB) gene or the human TATA Box binding protein (TBP). Hence, the means of the application may further comprise at least probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene, such as the human albumin (ALB) gene or the human TATA Box binding protein (TBP); cf. example 2 below.
- Said sample of biological fluid may e.g., be a sample of lower respiratory tract fluid, such as a sample of bronchoalveolar lavage fluid, or induced sputum, or a sample of upper respiratory tract fluid, such as a sample of sputum, nasopharyngeal aspirate, oral wash or nasal swab.
- Said human patient can be HIV-positive or is HIV-negative, more particularly HIV-negative. More particularly, said human patient is HIV-negative and immunocompromised. Advantageously, the means of the application are reliable with HIV-negative human patients, whereas the P. jirovecii charge of HIV-negative human patients is lower than that of HIV-positive human patients.
- Advantageously, said human patient is a human patient, more particularly a HIV-negative human patient, who is receiving, has received or will receive an immunosuppressive treatment, more particularly an immunosuppressor agent or drug, more particularly chemotherapy, an antirejection drug or steroids. For example, said human patient is a human patient, more particularly a HIV-negative human patient, who is receiving, has received or will receive a graft of organ(s) and/or tissue(s) (e.g., bone marrow, heart, kidney, liver organ(s), and/or tissue(s) thereof). Said immunosuppressive treatment, immunosuppressor agent or drug, antirejection drug may e.g., be intended to prevent and/or palliate the rejection of said transplanted organ(s) and tissue(s) and/or graft-versus-host disease. For example, said human patient is a human patient, more particularly a HIV-negative patient, who has an autoimmune disease and/or an inflammatory disease.
- Advantageously, said human patient is a human patient, more particularly a HIV-negative human patient, who has a haematological malignancy and/or a solid malignancy.
- Advantageously, said human patient is a human patient, more particularly a HIV-negative human patient, who is a preterm baby (more particularly a preterm baby, who is born at less than 37 weeks gestational age), a newborn or neonate (more particularly of 1-day old to less than 4-week old) or an infant (more particularly of 4-week old to less than 1-year old). More particularly, said human patient is a human patient, more particularly a HIV-negative human patient, who is a preterm baby (more particularly a preterm baby, who is born at less than 37 weeks gestational age), a newborn or neonate (more particularly of 1-day old to less than 4-week old).
- Advantageously, said quantification of RNA transcripts is performed by (cDNA) reverse-transcription and PCR amplification (for each of said two P. jirovecii mitochondrial genes). More particularly, said (cDNA) reverse-transcription and PCR amplification can be performed (as a one-step RT-PCR reaction, i.e.,) in the same tube (for each of said two P. jirovecii mitochondrial genes).
- Hence, the (cDNA) reverse-transcription and PCR amplification of the RNA transcripts of said first P. jirovecii mitochondrial gene can be performed in the same tube, and the reverse-transcription and PCR amplification of the RNA transcripts of said second P. jirovecii mitochondrial gene can be performed in the same tube.
- The (cDNA) reverse-transcription and PCR amplification of the RNA transcripts of said first P. jirovecil mitochondrial gene can be performed in a tube different from, or in the same tube as, the tube in which the (cDNA) reverse-transcription and PCR amplification of the RNA transcripts of second first P. jirovecii mitochondrial gene is performed.
- Said PCR advantageously is real-time PCR.
- Advantageously, said PCR is a quantitative PCR, more particularly a quantitative real-time PCR, more particularly a quantitative real-time RT-PCR, more particularly a one-step quantitative real-time RT-PCR.
- Said threshold value can e.g., be in the 1.00-2.00 range, more particularly in the 1.00-1.80 range, more particularly in the 1.20-1.70 range, more particularly in the 1.27-1.66 range, more particularly is of 1.50.
- For example, said ratio calculation is performed using the equation
-
R=E(CYTb)−Cq(CYTb) /E(mtrDNA)−Cq(mtrDNA) - wherein
-
- R is said ratio,
- CYTB is the cDNA reverse-transcript of the RNA transcripts of said P. jirovecii gene, the sequence of which codes for the Cytb protein,
- mtrDNA is the cDNA reverse-transcript of the RNA transcripts of said P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA,
- E is the value of the PCR efficiency of one amplification cycle in the exponential phase for the indicated cDNA, and
- Cq is the value of the PCR quantification cycle for the indicated cDNA.
- Advantageously, said ratio is the fold change of the value of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene compared to said second P. jirovecii mitochondrial gene.
- These features may notably apply when said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, and when said second P. jirovecil mitochondrial gene is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, such as the mtLSU gene or the mtSSU gene, more particularly the mtLSU gene.
- Of course, when said first P. jirovecil mitochondrial gene is the mtLSU gene and said second P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said threshold value can e.g., be in the 1/2.00-1/1.00 range, more particularly in the 1/1.80-1/1.00 range, more particularly in the 1/1.70-1/1.20 range, more particularly in the 1/1.66-1/1.27 range, more particularly is of 1/1.50.
- Said threshold value can e.g., be in the 2.7-3.3 range, more particularly in the 3.1-3.3 range, for example 3.2.
- For example, the ratio calculation is performed using the equation
-
R=E(mtSSU)−Cq(mtSSU) /E(mtLSU)−Cq(mtLSU) - wherein
-
- R is said ratio,
- mtSSU is the cDNA reverse-transcript of the RNA transcripts of said mitochondrial P. jirovecii mtSSU gene,
- mtLSU is the cDNA reverse-transcript of the RNA transcripts of said mitochondrial P. jirovecii mtLSU gene,
- E is the value of the PCR efficiency of one amplification cycle in the exponential phase for the indicated cDNA, and
- Cq is the value of the PCR quantification cycle for the indicated cDNA.
- These features may notably apply when said first P. jirovecil mitochondrial gene is the mtSSU gene, and wherein said second P. jirovecii mitochondrial gene is the mtLSU gene.
- Of course, when said first P. jirovecil mitochondrial gene is the mtLSU gene and said second P. jirovecii mitochondrial gene is the mtSSU gene, said threshold value can e.g., be in the 1/3.3-1/2.7 range, more particularly in the 1/3.3-1/3.1 range, for example 1/3.2.
- In a method of the application, the quantification of the respective RNA transcripts may be achieved by any means that the person of ordinary skill in the art may found appropriate.
- Such means include hybridization- or sequence-based means, as well as any means that enable to quantify a transcriptome, such as e.g., the RNA-Seq method (cf. Wang et al. 2009). The application provides a DNA library as well as computer means, which are suitable for implementation of the RNA-Seq method (cf. below).
- In a method of the application, the quantification of the respective RNA transcripts may comprise:
-
- the cDNA reverse transcription of the RNA transcripts of said first P. jirovecii mitochondrial gene (using a reverse transcriptase) to obtain first cDNA reverse-transcripts, and the PCR amplification of a first cDNA target from said first cDNA reverse-transcripts (using a polymerase and) using a first primer pair to obtain first amplicons (first cDNA or DNA nucleic acids), and
- the cDNA reverse transcription of the RNA transcripts of said second P. jirovecii mitochondrial gene (using a reverse transcriptase and) to obtain second cDNA reverse-transcripts, and the PCR amplification of a second cDNA target from said second cDNA reverse-transcripts (using a polymerase and) using a second primer pair to obtain second amplicons (second cDNA or DNA nucleic acids),
wherein said method further comprises the quantification of (the number of or the concentration of) said first amplicons and of (the number of or the concentration of) said second amplicons,
wherein the value of quantification of (e.g., the number of or the concentration of) said first amplicons is the value of quantification of (e.g., the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene, and the value of quantification of (e.g., the number of or the concentration of) said second amplicons is the value of quantification of (e.g., the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene.
- When said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said first cDNA target advantageously consists of 100-120 nucleotides (more particularly of 100-110 nucleotides, more particularly of 102-108 nucleotides, more particularly of 104-106 nucleotides, more particularly of 105 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 30, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 30 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 30.
- When said first P. jirovecii mitochondrial gene is the mtSSU gene, said first cDNA target advantageously consists of 60-110 nucleotides and comprises or is
-
- the sequence of SEQ ID NO: 15 or of SEQ ID NO: 20 or of SEQ ID NO: 25, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 15 or as SEQ ID NO: 20 or as SEQ ID NO: 25, and which is at least 95% identical to SEQ ID NO: 15 or SEQ ID NO: 20 or SEQ ID NO: 25, respectively.
- When said second P. jirovecii mitochondrial gene is mtLSU gene, said second cDNA target advantageously consists of 115-125 nucleotides and comprises or is
-
- the sequence of SEQ ID NO: 10, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 10 and which is at least 95% identical to SEQ ID NO: 10.
- When said second P. jirovecii mitochondrial gene is the P. jirovecii gene is the mtSSU gene, said second cDNA target advantageously consists of 60-110 nucleotides and comprises or is
-
- the sequence of SEQ ID NO: 15 or of SEQ ID NO: 20 or of SEQ ID NO: 25, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 15 or as SEQ ID NO: 20 or as SEQ ID NO: 25, and which is at least 95% identical to SEQ ID NO: 15 or SEQ ID NO: 20 or SEQ ID NO: 25, respectively.
- In a method of the application, the quantification of the respective RNA transcripts comprises:
-
- the cDNA reverse transcription of a first RNA target contained in the RNA transcripts of said first P. jirovecii mitochondrial gene (using a reverse transcriptase and) using a first primer pair to obtain first cDNA reverse-transcripts, and the PCR amplification of said first cDNA reverse-transcripts (using a polymerase and) using the same first primer pair to obtain first amplicons, and
- the cDNA reverse transcription of a second RNA target from the RNA transcripts of said second P. jirovecii mitochondrial gene (using a reverse transcriptase and) using a second primer pair to obtain second cDNA reverse-transcripts, and the PCR amplification of said second cDNA reverse-transcripts (using a polymerase and) using the same second primer pair to obtain second amplicons.
wherein said method further comprises the quantification of (the number of or the concentration of) said first amplicons and of (the number of or the concentration of) said second amplicons,
wherein the value of quantification of (e.g., the number of or the concentration of) said first amplicons is the value of quantification of (e.g., the number of or the concentration of) the RNA transcripts of said first P. jirovecil mitochondrial gene, and the value of quantification of (e.g., the number of or the concentration of) said second amplicons is the value of quantification of (e.g., the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene.
- When said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said first RNA target may advantageously consist of 100-120 nucleotides (more particularly of 100-110 nucleotides, more particularly of 102-108 nucleotides, more particularly of 104-106 nucleotides, more particularly of 105 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 29, or
- a RNA sequence, which is of the same length as SEQ ID NO: 29 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 29.
- When said first P. jirovecii mitochondrial gene is the mrSSU gene, said first RNA target advantageously consists of 60-110 nucleotides and comprises or is
-
- the sequence of SEQ ID NO: 14 or of SEQ ID NO: 19 or of SEQ ID NO: 24, or
- a RNA sequence, which is of the same length as SEQ ID NO: 14 or as SEQ ID NO: 19 or as SEQ ID NO: 24, and which is at least 95% identical to SEQ ID NO: 14 or SEQ ID NO: 19 or SEQ ID NO: 24, respectively.
- When said second P. jirovecii mitochondrial gene is the mtLSU gene, said second RNA target advantageously consists of 115-125 nucleotides and comprises or is
-
- the sequence of SEQ ID NO: 9, or
- a RNA sequence, which is of the same length as SEQ ID NO: 9 and which is at least 95% identical to SEQ ID NO: 9.
- When said second P. jirovecil mitochondrial gene is the mtSSU gene, said second RNA target advantageously consists of 60-110 nucleotides and comprises or is
-
- the sequence of SEQ ID NO: 14 or of SEQ ID NO: 19 or of SEQ ID NO: 24, or
- a RNA sequence, which is of the same length as SEQ ID NO: 14 or as SEQ ID NO: 19 or as SEQ ID NO: 24, and which is at least 95% identical to SEQ ID NO: 14 or SEQ ID NO: 19 or SEQ ID NO: 24, respectively.
- In the application, and in accordance with the understanding of the person of average skill in the art, the phrase “reverse polymerase” refers to a RNA-dependent DNA polymerase, and the phrase “polymerase” refers to a “DNA-dependent DNA polymerase”.
- The term “nucleotide” encompasses naturally-occurring nucleotides, as well as no-naturally-occurring nucleotides, such as Locked Nucleic Acid (LNA™) nucleotides. A LNA™ nucleotide is understood in accordance with its ordinary meaning in the field, i.e., a nucleotide in which the ribose or deoxyribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom. The term “nucleotide” encompasses more particularly naturally-occurring nucleotides (nucleotides A, G, T and C for DNA molecules; nucleotides A, G, U and C for RNA molecules).
- In other words, when said first or second P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said first or second primer pair is a primer pair which anneals to the cDNA reverse transcripts of the RNA transcripts of said first or second P. jirovecii mitochondrial gene (or to the RNA transcripts of said first or second P. jirovecii mitochondrial gene as well as to the cDNA reverse transcripts thereof) respectively, to produce a (cDNA or DNA) amplicon (or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof), which is of 100-120 nucleotide-long (more particularly of 100-110 nucleotide-long, more particularly of 102-108 nucleotide-long, more particularly of 104-106 nucleotide-long, more particularly of 105 nucleotide-long), and which comprises or is
-
- the sequence of SEQ ID NO: 30, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 30 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 30.
- The nucleotide sequence of each primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20 nucleotides).
- For example, said first or second primer pair is the primer pair of SEQ ID NO: 31 and SEQ ID NO: 32. Alternatively, said first or second primer pair is the primer pair of SEQ ID NO: 60 and SEQ ID NO: 32.
- Said first or second cDNA or RNA target may be a P. jirovecii mtLSU target.
- For example, when said first or second P. jirovecii mitochondrial gene is the mtLSU gene, said first or second (mtLSU) cDNA target may consist of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 10, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 10 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 10.
- For example, said first or second (mtLSU) RNA target may consist of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 9, or
- a RNA sequence, which is of the same length as SEQ ID NO: 9 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 9.
- In other words, said first or second primer pair may e.g., be a (mtLSU) primer pair, which anneals to the cDNA reverse-transcripts of the RNA transcripts of the P. jirovecil mtLSU gene (or to the RNA transcripts of the P. jirovecii mtLSU gene as well as to the cDNA reverse-transcripts thereof) to produce a (cDNA or DNA) amplicon (or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof), which is of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and which comprises or is
-
- the sequence of SEQ ID NO: 10, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 10 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 10.
- The nucleotide sequence of each (mtLSU) primer of first or said second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 26 nucleotides).
- For example, said first or second primer pair is the (mtLSU) primer pair of SEQ ID NO: 11 and SEQ ID NO: 12.
- Alternatively, said first or second cDNA or RNA target may e.g., be a P. jirovecii mtSSU target.
- For example, said first or second (mtSSU) cDNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 15, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 15 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 15.
- For example, said first or second (mtSSU) RNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 14, or
- a RNA sequence, which is of the same length as SEQ ID NO: 14 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 14.
- In other words, said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a (cDNA or DNA) amplicon (or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof), which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 15, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 15 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 15.
- The nucleotide sequence of each (mtSSU) primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20-23 nucleotides).
- For example, said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 16 and SEQ ID NO: 17.
- For example, said first or second (mtSSU) cDNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 20, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 20 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 20.
- For example, said first or second (mtSSU) RNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 19, or
- a RNA sequence, which is of the same length as SEQ ID NO: 19 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 19.
- In other words, said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a (cDNA or DNA) amplicon (or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof), which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 20, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 20 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 20.
- The nucleotide sequence of each (mtSSU) primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20-23 nucleotides).
- For example, said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 21 and SEQ ID NO: 22.
- For example, said first or second (mtSSU) cDNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 25, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 25 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO; 25.
- For example, said first or second (mtSSU) RNA target may consist of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 24, or
- a RNA sequence, which is of the same length as SEQ ID NO: 24 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO; 24.
- In other words, said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a (cDNA or DNA) amplicon (or to produce cDNA reverse-transcripts as well as the (cDNA or DNA) amplicon thereof), which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 25, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 25 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 25.
- The nucleotide sequence of each (mtSSU) primer of said first or second primer pair may independently consist of 15-30 nucleotides (more particularly of 18-28 nucleotides, more particularly of 19-27 nucleotides, more particularly of 20-26 nucleotides, more particularly of 20-23 nucleotides).
- For example, said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 26 and SEQ ID NO: 27.
- Advantageously, the Tm of said first primer pair does not differ by more than 5° C. (more particularly by more than 4° C., more particularly by more than 3° C., more particularly by more than 2° C., more particularly by more than 1° C.) from the Tm of said second primer pair. The Tm of said first primer pair may be identical to the Tm of said second primer pair.
- Alternatively or complementarily, the Tm of said first primer pair and the Tm of said second primer pair may both be of 53° C. or above. More particularly, said first primer pair and said second primer pair may both have a Tm in the 53-65° C. range (more particularly in the 56-64° C. range, more particularly in the 57-63° C. range, more particularly in the 58-63° C. range, more particularly in the 59-62° C. range, more particularly in the 59-61° C. range). For example, said first primer pair and said second primer pair may both have a Tm of 60° C.
- For example, the Tm of said first primer pair and the Tm of said second primer pair are both in the 58-63° C. range and do not differ by more than 5° C. from each other.
- Any PCR or RT-PCR conditions that the skilled person finds appropriate may be implemented.
- For example, the PCR amplification (for each of said first and second P. jirovecii mitochondrial genes) comprises:
-
- polymerase activation at 95° C. for 2-10 min, and
- 45-50 cycles of 95° C. for 15-30 seconds and 60° C. for 30-60 seconds.
- For example, the PCR amplification (for each of said first and second P. jirovecil mitochondrial genes) comprises:
-
- polymerase activation at 95° C. for 2 min, and
- 45 cycles of 95° C. for 15 seconds and 60° C. for 30 seconds.
- For example, the RT-PCR amplification comprises (for each of said first and second P. jirovecii mitochondrial genes):
-
- reverse transcription at 42-61° C., preferably 50° C. for 2-15 min,
- polymerase activation at 95° C. for 2 min, and
- 45 cycles of 95° C. for 15 seconds and 60° C. for 30 seconds.
- For example, the RT-PCR amplification comprises (for each of said first and second P. jirovecii mitochondrial genes):
-
- reverse transcription at 50° C. for 2 min,
- polymerase activation at 95° C. for 2 min, and
- 45 cycles of 95° C. for 15 seconds and 60° C. for 30 seconds.
- The quantification of the RNA transcripts of said first and/or (more particularly, and) said second P. jirovecii mitochondrial gene can be performed using probes, more particularly
-
- using at least one first probe, which hybridizes to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene (CYTB), and/or (more particularly, and) at least one second probe, which hybridizes to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene (mtLSU or mtSSU, more particularly mtLSU), or more particularly
- using at least one first probe, which hybridizes to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene (mtSSU), and/or (more particularly, and) at least one second probe, which hybridizes to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene (mtLSU).
- Each of said first and second probes may independently consist of 17-37 nucleotides.
- More particularly, the quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene can be performed using at least one first probe, which hybridizes to said first cDNA target (or said first amplicons), without hybridizing to said second cDNA target (or to said second amplicons).
- More particularly, the quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene can be performed using at least one first probe, which specifically hybridizes to said first cDNA target (or to said first amplicons).
- More particularly, the quantification of the RNA transcripts of said second P. jirovecil mitochondrial gene can be performed using at least one second probe, which hybridizes to said second cDNA target (or said second amplicons), without hybridizing to said first cDNA target (or to said first amplicons).
- More particularly, the quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene can be performed using at least one second probe, which specifically hybridizes to said second cDNA target (or to said second amplicons).
- The quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene may e.g., be performed using (at least one) first probe, which hybridizes to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- For example, when said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said first probe may hybridize to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 1 (P. jirovecii mtLSU gene) and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 (P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1. SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2. Said first probe may also not hybridize to human DNA or RNA. Advantageously, said first probe specifically hybridizes to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof.
- The sequence of said first probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the first probe the capacity to hybridize to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 19-30 nucleotides (more particularly of 20-24 nucleotides, more particularly of 22 nucleotides), which hybridizes to the sequence of SEQ ID NO: 3 or the sequence complementary to SEQ ID NO: 3, more particularly to the sequence of SEQ ID NO: 30 or the sequence complementary to SEQ ID NO: 30, without hybridizing to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2. Said hybridization portion of said first probe may also not hybridize to human DNA or RNA. Said hybridization portion of said first probe may specifically hybridize to the sequence of SEQ ID NO: 3 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or to the complementary sequence thereof. For example, the hybridization portion of said first probe is the (22 nucleotide-long) sequence of SEQ ID NO: 33 or the complementary sequence thereof, or a LNA-counterpart thereof, such as the (22 nucleotide-long) sequence of SEQ ID NO: 58 or the complementary sequence thereof (SEQ ID NO: 59; cf. example 3 below).
- The sequence of said first probe may consist of said hybridization portion.
- Alternatively, the sequence of said first probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion. This (these) other DNA or RNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion. Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said first probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm). The total length of said first probe advantageously is of 28-32 nucleotides, or of 27-31 nucleotides, or of 26-30 nucleotides, or of 25-29 nucleotides.
- Said first probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- Said first probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- Said first probe may e.g., be a DNA or RNA probe. For example, said first probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1). A TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- Alternatively, said first probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said first probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- Alternatively, said first probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- The quantification may also be performed using at least two of said first probes (i.e., two different first probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- The Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- For example, when said first P. jirovecii mitochondrial gene is the mtSSU gene, said first probe may hybridize to
-
- the P. jirovecil mtSSU gene, which is of SEQ ID NO: 2 or to the sequence complementary to SEQ ID NO: 2, more particularly to the sequence of SEQ ID NO: 15 (a P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 15, and/or
- to the sequence of SEQ ID NO: 20 (another P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 20, and/or
- to the sequence of SEQ ID NO: 25 (still another P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 25.
- More particularly, said first probe may hybridize to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof, without hybridizing to any of SEQ ID NO: 3 (P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 (P. jirovecii mtLSU gene) and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said first probe may also not hybridize to human DNA or RNA.
- Advantageously, said first probe specifically hybridizes to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof.
- The sequence of said first probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA portion, which confers to the first probe the capacity to hybridize to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA sequence of 23-29 nucleotides (more particularly of 25-27 nucleotides), which hybridizes to the sequence of SEQ ID NO: 2 or the sequence complementary to SEQ ID NO: 2, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the sequences complementary to SEQ ID NO: 10, 20, 25, without hybridizing to any of SEQ ID NO: 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said hybridization portion of said first probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said first probe may specifically hybridize to the sequence of SEQ ID NO: 2 or to the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof. For example, the hybridization portion of said first probe is the (25 or 27 nucleotide-long) sequence of SEQ ID NO: 18, 23 or 28 or the complementary sequence thereof.
- The sequence of said first probe may consist of said hybridization portion.
- Alternatively, the sequence of said first probe may comprise other DNA sequence(s) in addition to said hybridization portion, e.g., other DNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion. This (these) other DNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion. Said other DNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said first probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm). The total length of said first probe advantageously is of 31-37 nucleotides, or of 30-36 nucleotides, or of 29-36 nucleotides, or of 28-34 nucleotides.
- Said first probe may comprise at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- Said first probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1). A TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- Alternatively, said first probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- The Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- When said first P. jirovecii mitochondrial gene is the mtLSU gene, said first probe may hybridize to the P. jirovecii mtLSU gene, which is of SEQ ID NO: 1 or to the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 (a P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 10.
- More particularly, said first probe may hybridize to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 3 (P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3 or, to any of SEQ ID NO: 2 (P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said first probe may also not hybridize to human DNA or RNA.
- Advantageously, said first probe specifically hybridizes to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof.
- The sequence of said first probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the first probe the capacity to hybridize to the cDNA reverse-transcript of said first P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 17-21 nucleotides (more particularly of 19 nucleotides), which hybridizes to the sequence of SEQ ID NO; 1 or the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 or the sequence complementary to SEQ ID NO: 10, without hybridizing to any of SEQ ID NO. 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said hybridization portion of said first probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said first probe may specifically hybridize to the sequence of SEQ ID NO; 1 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or to the complementary sequence thereof. For example, the hybridization portion of said first probe is the (19 nucleotide-long) sequence of SEQ ID NO: 13 or the complementary sequence thereof.
- The sequence of said first probe may consist of said hybridization portion.
- Alternatively, the sequence of said first probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion. This (these) other DNA or RNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion. Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said first probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm). The total length of said first probe advantageously is of 25-29 nucleotides, or of 24-28 nucleotides, or of 23-27 nucleotides, or of 22-36 nucleotides.
- Said first probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- Said first probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- Said first probe may e.g., be a DNA or RNA probe.
- For example, said first probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1). A TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- Alternatively, said first probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said first probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- Alternatively, said first probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- The quantification may also be performed using at least two of said first probes (i.e., two different first probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- The Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- The quantification of the RNA transcripts of said second P. jirovecii mitochondrial gene may e.g., be performed using (at least one) second probe, which hybridizes to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- When said second P. jirovecii mitochondrial gene is the mtLSU gene, said second probe may hybridize to the P. jirovecii mtLSU gene, which is of SEQ ID NO: 1 or to the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 (a P. jirovecii mtLSU target) or to the sequence complementary to SEQ ID NO: 10.
- More particularly, said second probe may hybridize to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 3 (P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3 or, to any of SEQ ID NO: 2 (P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said second probe may also not hybridize to human DNA or RNA.
- Advantageously, said second probe specifically hybridizes to the sequence of SEQ ID NO: 1 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or the complementary sequence thereof.
- The sequence of said second probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the second probe the capacity to hybridize to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 17-21 nucleotides (more particularly of 19 nucleotides), which hybridizes to the sequence of SEQ ID NO; 1 or the sequence complementary to SEQ ID NO: 1, more particularly to the sequence of SEQ ID NO: 10 or the sequence complementary to SEQ ID NO: 10, without hybridizing to any of SEQ ID NO; 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2.
- Said hybridization portion of said second probe may also not hybridize to human DNA or RNA. Said hybridization portion of said second probe may specifically hybridize to the sequence of SEQ ID NO: 1 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 10 or to the complementary sequence thereof. For example, the hybridization portion of said second probe is the (19 nucleotide-long) sequence of SEQ ID NO: 13 or the complementary sequence thereof.
- The sequence of said second probe may consist of said hybridization portion.
- Alternatively, the sequence of said second probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion. This (these) other DNA or RNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion. Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said second probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm). The total length of said second probe advantageously is of 25-29 nucleotides, or of 24-28 nucleotides, or of 23-27 nucleotides, or of 22-36 nucleotides.
- Said second probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- Said second probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- Said second probe may e.g., be a DNA or RNA probe.
- For example, said second probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRAX or BHQ-1). A TAQMAN@ probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- Alternatively, said second probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- Alternatively, said second probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- The quantification may also be performed using at least two of said second probes (i.e., two different second probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- The Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- For example, when said second P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, said second probe may hybridize to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof, without hybridizing to any of SEQ ID NO: 1 (P. jirovecii mtLSU gene) and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 (P. jirovecii mtSSU gene) and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1, SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2. Said second probe may also not hybridize to human DNA or RNA. Advantageously, said second probe specifically hybridizes to the sequence of SEQ ID NO: 3 or the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or the complementary sequence thereof.
- The sequence of said second probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA or RNA portion, which confers to the second probe the capacity to hybridize to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA or RNA sequence of 19-30 nucleotides (more particularly of 20-24 nucleotides, more particularly of 22 nucleotides), which hybridizes to the sequence of SEQ ID NO: 3 or the sequence complementary to SEQ ID NO: 3, more particularly to the sequence of SEQ ID NO: 30 or the sequence complementary to SEQ ID NO: 30, without hybridizing to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, or to any of SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2, more particularly to any of SEQ ID NO: 1, the sequence complementary to SEQ ID NO: 1. SEQ ID NO: 2 and the sequence complementary to SEQ ID NO: 2. Said hybridization portion of said second probe may also not hybridize to human DNA or RNA.
- Said hybridization portion of said second probe may specifically hybridize to the sequence of SEQ ID NO: 3 or to the complementary sequence thereof, more particularly to the sequence of SEQ ID NO: 30 or to the complementary sequence thereof. For example, the hybridization portion of said second probe is the (22 nucleotide-long) sequence of SEQ ID NO: 33 or the complementary sequence thereof, or a LNA-counterpart thereof, such as the (22 nucleotide-long) sequence of SEQ ID NO: 58 or the complementary sequence thereof (SEQ ID NO: 59; cf. example 3 below).
- The sequence of said second probe may consist of said hybridization portion.
- Alternatively, the sequence of said second probe may comprise other DNA or RNA sequence(s) in addition to said hybridization portion, e.g., other DNA or RNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion. This (these) other DNA or RNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion. Said other DNA or RNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said second probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm). The total length of said second probe advantageously is of 28-32 nucleotides, or of 27-31 nucleotides, or of 26-30 nucleotides, or of 25-29 nucleotides.
- Said second probe may comprise (e.g., be covalently linked to) at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- Said second probe may e.g., be a Locked Nucleic Acid (LNA) probe.
- Said second probe may e.g., be a DNA or RNA probe. For example, said second probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1). A TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- Alternatively, said second probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- Alternatively, said second probe may be a SCORPION® probe (i.e., a probe, which is linked to a fluorophore at one of its ends and which is linked at the other end to a primer via a PCR blocker).
- The quantification may also be performed using at least two of said second probes (i.e., two different second probes) each comprising at least one fluorophore (e.g., as LIGHTCYCLER® hybridization probes).
- The Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- When said second P. jirovecii mitochondrial gene is the mtSSU gene, said second probe may hybridize to
-
- the P. jirovecii mtSSU gene, which is of SEQ ID NO: 2 or to the sequence complementary to SEQ ID NO: 2, more particularly to the sequence of SEQ ID NO: 15 (a P. jirovecii mtSSU target) or to the sequence complementary to SEQ ID NO: 15, and/or
- to the sequence of SEQ ID NO: 20 (another P. jirovecii mtSSU target) or to the sequence complementary to SEQ ID NO: 20, and/or
- to the sequence of SEQ ID NO: 25 (still another P. jirovecii mtSSU target) or to the sequence complementary to SEQ ID NO: 25.
- More particularly, said second probe may hybridize to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof, without hybridizing to any of SEQ ID NO: 3 (P. jirovecii CYTB gene) and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said second probe may also not hybridize to human DNA or RNA.
- Advantageously, said second probe specifically hybridizes to the sequence of SEQ ID NO: 2 or the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof.
- The sequence of said second probe may e.g., consist of or comprise a hybridization portion, which is or acts as the hybridization portion of the probe, i.e., which is or acts as the DNA portion, which confers to the second probe the capacity to hybridize to the cDNA reverse-transcript of said second P. jirovecii mitochondrial gene.
- Said hybridization portion may e.g., be a DNA sequence of 23-29 nucleotides (more particularly of 25-27 nucleotides), which hybridizes to the sequence of SEQ ID NO: 2 or the sequence complementary to SEQ ID NO: 2, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the sequences complementary to SEQ ID NO: 10, 20, 25, without hybridizing to any of SEQ ID NO: 3 and the sequence complementary to SEQ ID NO: 3, or to any of SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1, more particularly without hybridizing to any of SEQ ID NO: 3, the sequence complementary to SEQ ID NO: 3, SEQ ID NO: 1 and the sequence complementary to SEQ ID NO: 1.
- Said hybridization portion of said second probe may also not hybridize to human DNA or RNA. Said hybridization portion of said second probe may specifically hybridize to the sequence of SEQ ID NO: 2 or to the complementary sequence thereof, more particularly to at least one of the sequences of SEQ ID NO: 15, 20, 25 and the complementary sequences thereof. For example, the hybridization portion of said second probe is the (25 or 27 nucleotide-long) sequence of SEQ ID NO: 18, 23 or 28 or the complementary sequence thereof.
- The sequence of said second probe may consist of said hybridization portion.
- Alternatively, the sequence of said second probe may comprise other DNA sequence(s) in addition to said hybridization portion, e.g., other DNA sequence(s) linked to the 5′ and/or 3′ terminal end(s) of said hybridization portion. This (these) other DNA sequence(s) should not (significantly) reduce the hybridization specificity of said hybridization portion. Said other DNA sequence(s) may e.g., be beacon arm(s), more particularly a 5′ beacon arm and a 3′ beacon arm, which impart a hairpin-configuration to said second probe when unhybridized (e.g., the 3′ beacon arm is complementary to the 5′ beacon arm). The total length of said second probe advantageously is of 31-37 nucleotides, or of 30-36 nucleotides, or of 29-36 nucleotides, or of 28-34 nucleotides.
- Said second probe may comprise at least one fluorophore (e.g., 6-carboxyfluorescein, or tetrachlorofluorescein) and/or at least one quencher (e.g., a carboxytetramethylrhodamine fluorescent dye (e.g., TAMRA®), the Black Hole Quencher®-0, the Black Hole Quencher®-1, the Black Hole Quencher®-2, the Black Hole Quencher®-3, or the Minor Groove Binder® quencher).
- Said second probe may be a TAQMAN® probe, i.e., a probe, wherein a fluorophore is covalently attached to its 5′-end and a quencher is covalently attached to its at the 3′-end (e.g., TAMRA® or BHQ®-1). A TAQMAN® probe is degraded by the 5′-3′ exonuclease activity of the PCR polymerase, thereby releasing the fluorophore from it (and from the proximity of the quencher).
- Alternatively, said second probe may be a beacon probe, i.e., a probe which in addition to said hybridization portion, comprises a beacon arm linked to the 5′ terminal end and a beacon arm linked to the 3′ terminal end (which impart a hairpin-configuration to said second probe when unhybridized), and which carries a fluorophore covalently linked to one of said two beacon arms, and a quencher linked to the other of said two beacon arms.
- The Tm of the probe may be 4-10° C. higher than the Tm of the primer pair.
- Advantageously, said at least one first probe is implemented in real-time PCR. More particularly, said at least one first probe advantageously is implemented in the same tube as said first primer pair in real-time PCR amplification.
- Advantageously, said at least one second probe in implemented in real-time PCR. More particularly, said at least one second probe advantageously is implemented in the same tube as said second primer pair in real-time PCR amplification.
- Advantageously, said at least one first probe and one second probe are implemented in real-time PCR. More particularly, said at least one first probe and said at least one second probe are implemented in the same tube as said first primer pair and second primer pair in real-time PCR amplification.
- The application also relates to each individual product that is implemented or obtainable by a method of the application.
- More particularly, the application also relates to each of said first primer pair, said second primer pair, said first probe and said second probe, individually as a product.
- More particularly, the application also relates to each of said first cDNA targets, said second cDNA targets, said first RNA targets, said second RNA targets, said first amplicons and said second amplicons, individually as a product.
- The application also relates to the association or combinations of such products.
- More particularly, the application relates to the association or combination of at least two or at least three different elements from the following list of four (different) elements: said first primer pair, said second primer pair, said first probe and said second probe; or to the association or combination of the four of them.
- More particularly, the application relates to the association or combination of said first probe and said second probe.
- More particularly, the application relates to the association or combination of said first primer pair and said second primer pair.
- More particularly, the application relates to the association or combination of said first primer pair and said first probe.
- More particularly, the application relates to the association or combination of said second probe and said second primer pair.
- For example, they can be associated or combined in a kit, more particularly in a kit for simultaneous, separate or sequential use, or in a composition, more particularly in a liquid composition, such as an amplification composition. Said association, combination, kit or composition may further comprise at least one reverse transcriptase (i.e., at least one RNA-dependent DNA polymerase), or at least one reverse transcriptase and at least one DNA-dependent DNA polymerase.
- Advantageously, said kit comprises at least said first primer pair and/or at least said first probe, more particularly at least said primer pair and at least said first probe.
- Said kit may further comprise an internal control for RNA extraction and/or purification, such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- More particularly, the application relates to the association or combination of at least two or at least three or at least four or at least five different elements from the following list of six (different) elements: said first cDNA targets, said second cDNA targets, said first RNA targets, said second RNA targets, said first amplicons and said second amplicons; or to the association or combination of the six of them. More particularly, the application relates to the association or combination of said first amplicons and said second amplicons. Each of said six elements can be contained in a composition, more particularly in a liquid composition, such as an amplification composition. Said association, combination or composition may further comprise at least one reverse transcriptase (i.e., at least one RNA-dependent DNA polymerase), or at least one reverse transcriptase and at least one polymerase (more particularly at least one DNA-dependent DNA polymerase).
- Said reverse transcriptase (or said reverse transcriptase and DNA-dependent DNA polymerase) can be any reverse transcriptase (or any reverse transcriptase and DNA-dependent DNA polymerase), which the person of average skill in the art may find appropriate.
- Examples of reverse transcriptase include the SUPERSCRIPT® III Reverse Transcriptase (RT) commercialized by INVITROGEN™ (INVITROGEN™ by LIFE TECHNOLOGIES™; 5791 Van Allen way: Carlsbad; Calif. 92008, U.S.A.).
- Examples of polymerases (i.e., of DNA-dependent DNA polymerases) include a Thermus aquaticus polymerase.
- Said product(s), association(s), combination(s), kit(s), composition(s) is(are) suitable for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- The application thus also relates to the (in vitro) use of said product(s), association(s), combination(s), kit(s), composition(s) for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- More particularly, the application relates to the in vitro use of a reverse transcriptase (i.e., a RNA-dependent DNA polymerase) and of oligonucleotides:
-
- for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or
- for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or
- for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP,
wherein said oligonucleotides comprise primers and/or probes, wherein said primers comprises a first primer pair and a second primer pair, wherein said probes comprise a first probe and a second probe,
wherein said first primer pair and/or said first probe specifically hybridizes to the cDNA reverse transcripts of the RNA transcripts of said first P. jirovecii mitochondrial gene (cf. above),
wherein said second primer pair and/or said second probe specifically hybridizes to the cDNA reverse transcripts of the RNA transcripts of said second P. jirovecii mitochondrial gene (cf. above).
- For example, said first P. jirovecii mitochondrial gene is the P. jirovecii gene, the sequence of which codes for the Cytb protein, and said second P. jirovecii mitochondrial gene is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA (mtLSU gene or mtSSU gene, more particularly mtLSU gene).
- For example, said first P. jirovecii mitochondrial gene is the mtSSU P. jirovecii gene, and said second P. jirovecii mitochondrial gene is the P. jirovecii mtLSU gene.
- Said use may further comprises the use of a polymerase (i.e., of a DNA-dependent DNA polymerase).
- Said use may further comprise the use a RNA extraction and/or purification internal control, such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- The application also relates to a kit, which comprises said reverse transcriptase and said oligonucleotides. Said kit may further comprise a polymerase (i.e., a DNA-dependent DNA polymerase). Said kit can be viewed as a kit suitable for diagnosing or predicting PneumoCystis Pneumonia (PCP) in a human patient (more particularly, a human patient, who is a Pneumocystis jirovecil carrier), or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly, a human patient, who is a Pneumocystis jirovecil carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who receives or has received a drug or treatment against PCP. Said kit may further comprise written instructions for implementing said reverse transcriptase and said oligonucleotides (and optionally said polymerase) in these uses or applications.
- Said kit may be a kit for simultaneous, separate or sequential use, more particularly for simultaneous use, of said reverse transcriptase and said oligonucleotides (or of said reverse transcriptase, said oligonucleotides and said polymerase). Said kit may comprise container(s) (e.g., tube(s)), wherein said reverse transcriptase and said oligonucleotides (or said reverse transcriptase, said oligonucleotides and said polymerase) are contained. Advantageously, said reverse transcriptase and said polymerase are contained in the same container (e.g., in the same tube). Said first primer pair can be contained in a container (e.g., tube), which is different from the container (e.g., tube) in which said second primer pair is contained. Said first probe can be contained in a container (e.g., tube), which is different from the container (e.g., tube) in which said second probe is contained. Said first primer pair and said first probe may be in the same container (e.g., tube). Said second primer pair and said second probe may be in the same container (e.g., tube).
- Said kit may further comprise means for RNA extraction and/or purification. For example, said kit may further comprise cell lysis reagent(s) and/or buffer(s), and/or RNA purification means, such as e.g., a silica membrane.
- Said kit may further comprise an internal control for RNA extraction and/or purification such as an IECR or such as at least one (real-time) probe, more particularly at least one (real-time) probe and at least one primer pair, which specifically detect a human gene (cf. above and example 2 below).
- Each feature or combination of features, which has been described in the context of a method of the application, applies to each product, combination, association, kit or composition as such as well as to their uses, mutatis mutandis.
- For example, the nucleotide sequence of each primer of said first and second primer pairs may independently consist of 15-30 nucleotides (e.g., of 18-28 or 19-27 or 20-26 nucleotides) (cf. above).
- For example, the nucleotide sequence of each of said first and second probes independently consists of 17-37 nucleotides (e.g., of 20-24 or 28-32 or 17-21 or 25-29 or 23-29 or 31-37 nucleotides) (cf. above).
- For example, said first or second primer pair is a primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of said first or second P. jirovecii mitochondrial gene (or to the RNA transcripts of said first or second P. jirovecii mitochondrial gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 100-120 nucleotide-long (more particularly of 100-110 nucleotide-long, more particularly of 102-108 nucleotide-long, more particularly of 104-106 nucleotide-long, more particularly of 105 nucleotide-long), and which comprises or is
-
- the sequence of SEQ ID NO: 30, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 30 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 30. For example, said first or second primer pair is the primer pair of SEQ ID NO: 31 and SEQ ID NO: 32. For example, said first or second primer pair is the primer pair of SEQ ID NO: 60 and SEQ ID NO: 32.
- For example, said first or second primer pair may e.g., be a (mtLSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtLSU gene (or to the RNA transcripts of the P. jirovecii mtLSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 115-125 nucleotides (more particularly of 117-124 nucleotides, more particularly of 119-123 nucleotides, more particularly of 121 nucleotides), and which comprises or is
-
- the sequence of SEQ ID NO: 10, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 10 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 10. For example, said first or second primer pair is the (mtLSU) primer pair of SEQ ID NO: 11 and SEQ ID NO: 12.
- For example, said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 82 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 15, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 15 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 15. For example, said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 16 and SEQ ID NO: 17.
- For example, said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecil mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 92 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 20, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 20 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 20. For example, said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 21 and SEQ ID NO: 22.
- For example, said first or second primer pair may alternatively be a (mtSSU) primer pair, which anneals to the cDNA reverse transcripts of the RNA transcripts of the P. jirovecii mtSSU gene (or to the RNA transcripts of the P. jirovecii mtSSU gene as well as to the cDNA reverse transcripts thereof) to produce a cDNA amplicon, which is of 60-110 nucleotides (more particularly of 76-92 nucleotides, more particularly of 76, 82 or 92 nucleotides, more particularly of 76 nucleotides), and comprises or is
-
- the sequence of SEQ ID NO: 25, or
- a cDNA sequence, which is of the same length as SEQ ID NO: 25 and which is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to SEQ ID NO: 25. For example, said first or second primer pair is the (mtSSU) primer pair of SEQ ID NO: 26 and SEQ ID NO: 27.
- In accordance with the understanding of the person of average skill in the art, a primer pair, which anneals to a (target) cDNA or RNA or DNA, can be viewed as a pair of forward and reverse primers. The forward primer anneal to a first sequence, which is contained in said (target) cDNA or RNA or DNA, and the reverse primer anneals to a second sequence, which is contained in the sequence complementary to said (target) cDNA or RNA or DNA. The 5′ end of said first (target) sequence and the 5′ end of said second (target) sequence can be viewed as the start and end positions of the amplicon produced by said primer pair.
- More particularly, and still in accordance with the understanding of the person of average skill in the art, a primer pair, which anneals to a (target) cDNA or RNA or DNA, can be viewed as a primer pair, wherein:
-
- a first primer of the pair is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to a first sequence, which is contained in said (target) cDNA or RNA or DNA, and which is of the same length as said first primer, and
- the second primer of the same pair is at least 95% (more particularly at least 96%, at least 97%, at least 98% or at least 99%) identical to a second sequence, which is contained in the sequence complementary to said (target) cDNA or RNA or DNA and which is of the same length as said second primer.
- In accordance with the understanding of the person of average skill in the art, the 5′ end of said first (target) sequence and the 5′ end of said second (target) sequence can be viewed as the start and end positions of the amplicon produced by said primer pair.
- The application also relates to a solid support, such as a nucleic acid microarray, nanoarray, chip or lane, onto which said first primer pair and/or said first probe is/are attached or bound. Said solid support may further comprise said second primer pair and/or said second probe attached or bound thereto. Said solid support may e.g., be a plastic, glass or silicon microarray, nanoarray, chip or lane.
- The application also relates to the (in vitro) use of a P. jirovecil transcriptome for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP. Said use comprises detecting and/or quantifying, more particularly quantifying. (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene. For example, said use comprises detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (CYTB gene) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU or mtSSU, more particularly mtLSU). For example, said use comprises detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (mtSSU) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU).
- The application also relates to a nucleic acid library, which is or comprises the transcriptome of P. jirovecii, more particularly the RNA transcripts of P. jirovecii. This transcriptome or transcripts can be those of a patient's biological sample as discussed above. Such a library is useful for detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene. For example, such a library is useful for detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (CYTB gene) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU or mtSSU). For example, such a library is useful for detecting and/or quantifying, more particularly quantifying, (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (mtSSU) and (the number of or the concentration of) the RNA transcripts of said second P. jirovecii mitochondrial gene (mtLSU).
- The library of the application is notably suitable for high throughput sequencing, e.g., for implementation of the RNA-Seq method described in Wang et al. 2009.
- Said library can be used in accordance with the application, e.g., for diagnosing or predicting PneumoCystis Pneumonia (PCP), more particularly for diagnosing or predicting whether a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier) has or develops PCP, or for determining or predicting the efficacy of a drug or treatment against PCP in a human patient (more particularly a human patient, who is a Pneumocystis jirovecii carrier), or for determining whether PCP regresses or has been treated in a human patient who has been diagnosed to have PCP and who is receiving or has received a drug or treatment against PCP.
- Said nucleic acid library can e.g., be a DNA library, which comprises or consists of DNA fragments of 40-400 bp, wherein each of said DNA fragments comprise the cDNA reverse transcript of a P. jirovecii RNA fragment of 40-400 nucleotides, wherein said P. jirovecii RNA fragment of 40-400 nucleotides is a fragment of 40-400 nucleotides from the RNA transcript of a P. jirovecii mitochondrial gene.
- Advantageously, said P. jirovecii mitochondrial gene is the mtLSU gene, the mtSSU or the CYTB gene.
- Advantageously, said DNA library comprises or consists of:
-
- at least one first DNA fragment of 40-400 bp, which comprises the cDNA reverse transcript of a fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii, CYTB gene and
- at least one second DNA fragment of 40-400 bp, which comprises the cDNA reverse transcript of a fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecil mtLSU or mtSSU gene,
wherein said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii CYTB gene is different from said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii mtLSU or mtSSU gene.
- Advantageously:
-
- said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii CYTB gene is specific of the RNA transcript of the P. jirovecii CYTB gene,
- said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii mtLSU gene is specific of the RNA transcript of the P. jirovecii mtLSU gene,
- said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii mtSSU gene is specific of the RNA transcript of the P. jirovecii mtSSU gene.
- Advantageously, said DNA library comprises or consists of:
-
- at least one first DNA fragment of 40-400 bp, which comprises the cDNA reverse transcript of a fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii, mtSSU and
- at least one second DNA fragment of 40-400 bp, which comprises the cDNA reverse transcript of a fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii mtLSU gene,
wherein said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii mtSSU gene is different from said fragment of 40-400 nucleotides from the RNA transcript of the P. jirovecii mtLSU.
- In said DNA libraries, each of said DNA fragments may optionally further comprise:
-
- a first DNA of 30-150 bp, which is not a fragment of P. jirovecii cDNA or DNA, and which is (covalently) linked to the 5′ end said cDNA reverse transcript (e.g., a DNA of 30-150 bp, which is a first sequencing adaptor), and
- a second DNA of 30-150 bp, which is not a fragment of P. jirovecii cDNA or DNA, and which is (covalently) linked to the 3′ end of said cDNA reverse transcript (e.g., a DNA of 30-150 bp, which is a second sequencing adaptor, different from said first sequencing adapter).
- The application also relates to a computer program product, for storage in a memory of a processing unit or on a removable memory support for cooperation with a reader of said processing unit, which comprises (code) instructions for carrying out a method of the application (when read or executed by a processor or microprocessor).
- More particularly, the computer program product of the application may comprise (code) instructions, which (when read or executed by a processor or microprocessor) align RNA or cDNA sequence reads on the mitochondrial DNA sequence of P. jirovecii to detect and/or quantify (the number of or the concentration of) the RNA transcripts of said first P. jirovecii mitochondrial gene (e.g., cytb or mtSSU) and of said second P. jirovecii mitochondrial gene (e.g., mtLSU or mtSSU).
- The application also relates to a computer device, comprising a processing unit in the memory of which is stored the computer program product of the application, and measurement values for the respective values of quantification of the RNA transcripts of said first P. jirovecii mitochondrial gene (e.g., cytb or mtSSU) and of said second P. jirovecii mitochondrial gene (e.g., mtLSU or mtSSU).
- The application also relates to a kit for use in the treatment and/or prevention and/or palliation of PCP in a human patient, (more particularly, a human patient, who is a Pneumocystis jirovecii carrier), wherein comprises one or several ingredient(s) for simultaneous, separate or sequential use in said treatment and/or prevention and/or palliation. Said one or several active ingredient(s) may e.g., be
-
- (the combination or association of) at least one dihydrofolate reductase inhibitor and at least one sulfonamide antibiotic, e.g., (the combination or association of) trimethoprim and sulfamethoxazole (e.g., the cotrimoxazole combination drug), or
- aerosolized pentamidine, or
- primaquine and clindamycin, or
- atovaquone, or
- pyrimethamine, or
- echinocandin(s) (including caspofungin), or
- corticosteroid(s) (including prednisone), or
- anti-inflammatory active ingredient(s), or
- dapsone, or
- dapsone and pyrimethamine and leucovorin.
- More particularly, said human patient is a human patient, who has been diagnosed or predicted to be at high risk of having or developing PCP with a method of the application.
- The application also relates to a method for the treatment and/or prevention and/or palliation of PCP in a human patient in need thereof, wherein said human patient is a Pneumocystis jirovecii carrier. Said method comprises:
-
- diagnosing or predicting whether said human patient is at high risk of having or developing PCP with a method of the application,
- providing a drug or a combination of drugs for the treatment and/or prevention and/or palliation of PCP, and
- administering said drug or a combination of drugs to said human patient.
- Said drug or combination of drugs may comprise
-
- (the combination or association of) at least one dihydrofolate reductase inhibitor and at least one sulfonamide antibiotic, e.g., (the combination or association of) trimethoprim and sulfamethoxazole (e.g., the cotrimoxazole combination drug), or
- aerosolized pentamidine, or
- primaquine and clindamycin, or
- atovaquone, or
- pyrimethamine, or
- echinocandin(s) (including caspofungin), or
- corticosteroid(s) (including prednisone), or
- anti-inflammatory active ingredient(s), or
- dapsone, or
- dapsone and pyrimethamine and leucovorin.
- The term “comprising”, which is synonymous with “including” or “containing”, is open-ended, and does not exclude additional, un-recited element(s), ingredient(s) or method step(s), whereas the term “consisting of” is a closed term, which excludes any additional element, step, or ingredient which is not explicitly recited.
- The term “essentially consisting of” is a partially open term, which does not exclude additional, un-recited element(s), step(s), or ingredient(s), as long as these additional element(s), step(s) or ingredient(s) do not materially affect the basic and novel properties of the invention.
- The term “comprising” (or “comprise(s)”) hence includes the term “consisting of” (“consist(s) of”), as well as the term “essentially consisting of” (“essentially consist(s) of”).
- Accordingly, the term “comprising” (or “comprise(s)”) is, in the application, meant as more particularly encompassing the term “consisting of” (“consist(s) of”), and the term “essentially consisting of” (“essentially consist(s) of”).
- In an attempt to help the reader of the present application, the description has been separated in various paragraphs or sections. These separations should not be considered as disconnecting the substance of a paragraph or section from the substance of another paragraph or section. To the contrary, the application encompasses all the combinations of the various sections, paragraphs and sentences that can be contemplated.
- Each of the relevant disclosures of all references cited herein is specifically incorporated by reference. The following examples are offered by way of illustration, and not by way of limitation.
- Material and Methods
- Samples
- A total of 200 consecutive BronchoAlveolar Lavage (BAL) Fluids (BALF) were collected prospectively between the 1 Jan. 2013 and the 31 Aug. 2013. Fiber optic bronchoscopy was performed after patients stated their non-opposition to the use of BALF for testing new diagnostic procedures. The site of BAL was guided by the topography of the lesions upon lung high-resolution computed tomography, and BAL was performed with four 50-mL aliquots of sterile saline solution following the standardized protocol of Alanio et al. 2011. BALF was sent within the hour after collection to the laboratory. Upon arrival, the BALF was centrifuged at 2,800 g for 10 minutes, the pellet was re-suspended with 4 mL of phosphate-buffered saline and split in four fractions of 1 mL. The four tubes were then centrifuged at 8,000 g for 5 minutes and the pellets of two tubes were frozen and stored at −80° C. The two other pellets were used for classical staining, immunofluorescence procedure and DNA extraction as described in Alanio et al. 2011.
- Classical staining, immunofluorescence and the Cq value of the DNA PCR (Alanio et al. 2011) were recorded for each BALF and also for any non-invasive diagnostic specimen (mostly sputa and induced sputa) performed before the BALF.
- Seven samples were repeated and were considered as new infectious episodes except if PCP diagnosis based on immunofluorescence was positive before.
- Patients
- The 192 corresponding patients were cared for in three hospitals in the north of Paris (Hospital Saint Louis, 1 avenue Claude Vellefaux 75010 Paris France; Hospital Lariboisière, 2 rue Ambroise Parè 75010 Paris France; and Hospital Robert Debrè, 48 Boulevard Serrurier 75019 Paris France). The sex ratio was 1.5 and the median age was 50 years with a range of 02 to 82 years. In the patients with evidence of P. jirovecil (immunofluorescence, DNA or RNA detection), the whole medical file including clinical, radiological and biological features was retrospectively analyzed by two expert physicians (one pneumologist and one infectious disease specialist). For specific analyses, the date of introduction and duration of cotrimoxazole therapy at the time of the BAL was recorded. Outcome at the last follow-up visit was recorded from the electronic medical file. Underlying diseases were divided into four categories (HIV positivity, hematological malignancies, solid organ transplantation, others).
- Probability of PCP Classification
- PneumoCystis pneumonia (PCP) diagnosis as the etiology of an acute pneumonia episode were classified as proven, probable, possible and no PCP. Criteria used for proven, probable, possible classification are summarized in Table 1 below. Other clinical situations were classified as no PCP.
-
TABLE 1 Criteria used to classify patients regarding Pneumocystis pneumonia (PCP) probability in a context of acute pneumonia episode Compatible Compatible clinical and Favorable No Background radiological outcome under No alternative Positive IF PCP (ID) presentation therapy prophylaxis diagnosis (BAL or IS)* Proven X X X X X Probable X X X X X Possible X X X X *based on BALF and sputa specimens. - RNA Extraction
- The day of the experiment, the pellet of one tube was thawed and RNA was extracted using the RNeasy® plus mini kit (catalog number 74136) from QIAGEN® France S.A.S. (3 avenue du Canada: LP 809; 91974 COURTABOEUF CEDEX; FRANCE). Briefly: 350 μL of lysing buffer RLT+1% betamercaptoethanol were added to the pellet and vortexed. 350 μL of
ethanol 70% were added and mixed gently. The final volume was deposited in the column and additional steps were performed following the manufacturer's recommendations. We obtained at theend 50 μL of RNA extracted. -
Gene sequences The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of the mitochondrial Large SubUnit (mtLSU, also known as RNL) is referenced in GENBANK® under the accession number JX499143.1 REGION: 12373 . . . 15076 (SEQ ID NO: 1), which is: (SEQ ID NO: 1) AAAGGGGTTATTAAGGATAACTAGCTAATATATTTAAGGAGGTGTCGAATCCAAAATCATTATTCTAAAGAT GTAATAATGTAAATCCGAGAGGGAAACCTCAATACTAATTACGAAGTGAAATGAAACATCTTAGTAACTTTA GGAAAAGAAATCAACCGAGATTTTATGAGTAGTGGTGAGCGAAAGTAAATTAGCCAAGTATTTATATAATAG ATTAAATATAATTAATTACAAAAATTAATTGTAGTCTTCGAATGAAAGATCAATCTCCTCTTTTAAAAGTTG GAATGCTTTAGCCAAGGATGGTGAAAGCCCAGAGTCCCAGGAATATAAATACAAAATAAGTAGAACGAGAGA TAACTTGTTTGAATACAGATAATATTTATGTAGTAATGTATGGAAGAATTCAACTTTATACTAATTACACAT AAGATTATTAGGGGAACTATCCTCTAAGGCTAAATATAATATATTAAGCGATAGTGAAGAGTACCGTGAGGG AAAGTTGAAAAGAATATAAGTGAAACAGATCTTGAATTAATAACCTTATAAGCAGTCGGAGGTCCAAAGACT GACGACGTACCTTTTGGATAATGGGTCAGCAAGTTAATATGCAATGCAAGTCGCAAGACCTAATGAAGATGA TTCTGAACAGGGATATAAAGTATTGTGTATTAGACCCGAAATCTAGTGATCTTACTATGATCAGACAACTTC AGGTCGAACTGGTGTACGTCGCAAAGTACTCAGAAGAATTGTGGTAAGTAGTGAAATACAAATCGGACTAGG ATATAGCTGGTTTTCTGCGAAAATTGTTTTGGCAAATTGTTTATTCCTCTAAAAAATAGTAGGTATAGCACT GAATATCTCGAGGGAGTATGAAAATATTTATCTCAGATATTTAATCTCAAAATAACTATTTCTTAAAATAAA TAATCAGACTATGTGCGATAAGGTAGATAGTCGAAAGGGAAACAGCCCAGAACAGTAATTAAAGCTCCCCAA TTAATATTAAGTGAAATAAAAGTTGTTGGATATCTAAAACAGTTAAGAAGTGGGCTTGGAAAGAGCCATCTT TTAAAGAACACGTAAAAGTGCAATGATCTATGATCTCCAGCGCTGAAAATATCCGGATCTAAATATTATGCT GAAAGACTGTTTATTTTTCTTTTAATTAACTGTAATTTAATTAAAAAAAATAAGGTAGCAGAACATTTAGTA AATGTGTGAAGAATAGTATTTTATTATTCGGACATAACTAAAGAGAGAATGCTGACATGAGTAACGTTAAAA TAGGTGAAAATCCTATTCGCCGAAAATGGAAGGTTTTTATAGTTCCGCTTAACTACTATAAATCAGATCGGT CTCTAACAGTAATTCGAATGAATAATGGATGAGAAACATATATAAAAATCGTAAGATTCAGGAAAAATTATA TGTAATAACCGTACTAAAACCGACACAGGTCCATGAATATTAATGTATAGAGGCGAATGAGAGAATTATTGC GAAGGAACTCGGCAAATGAATTTCGTAATTTCGAGATAAGAAATACCAATGGTGTCAATAATGAGGTTGTAC AACTGTTTACTTAAAACACAGTACTTTGCAAAGATTAAAAATCATTGTATAAAGTATGAAATCTGCCCAATG CTAAATGATAAAATCTATGGCTTCAATGGCTGTGGGTATAATGTTTAGTGAATGGCGGCCTTAACTATAAGG GTCCTAAGGTAGCGAATTTCCTTGGCCGTTAAATGCGGTCCCGCACGAATGATTTAATGATACAACAACTGT CTCCGGAATAAACTCAGTGAAATTGGATTAGCCGTGAAGATACGGTTTGTATATAGATAGACGGGAAGACCC TATGCAGCTTAACTGTTGTTCTTTATTGTTTTTTTAAATTCTCTTCTGTAGTGCTAAAAGGTAGTCGATGAG ATGTCAGTGAAAAACCTTTGTGGAAATTTAAAATAACTAACTTACTTAATTAAGAACAGTGAAGATTAGACA GTTTCTGTGGGGCGCAGATCTCAAAAATTGTATCTGAGATGCCCAAAGGCATGGTGAAATTGGATGGTAACC AATGAATGTACATTTGTATATCTAGTGGTCTTTAATTACTAGATGATGTTTTATTTAATAAAGTGTAATGGC ATAACTCATGCTTAACAGTAAGACTAAGAAGTCAAACTGACATGTAAGTGGGGCATAATGACCCTCGTTTAC ATTATGGATTGGAACGAGAGTAACGAATAAAAGCTACGCTAGGGATAACAGGGTTATTTCGTGTGAGAGATC GTATTGACCACGAAGTTTGCCACCTCGATGTCGACTCAACCTATCCTCCAGGAGTAGAATATTGGAAGGGTT CGGCTGTTGGCCGATTAAAAGGTTACGTGAGTTGGGTTAAAAACGTTGTGAAACAGTTTGGTTCCTATCTTC TATATATTTTAAAAGTTAATGGAGAATTTACTCTTTGTACGCAAGGATCAGATGTATTTTAACCTCTGGTTT GTCTGTTGTTTGTCGCATCGCAGATACGCTATGTTGATACGGAATAAATATTGAAAGCATATTAAATATGAA GTCCTACTCCATAAACTTTCTTGCGTTGTAGACTACGACGTAGATAGGCTTTATCTGTAAGAATAGTAATGT TTTAAGGTATAAAGTACTAATTTTTTTTTGACTGAATTAT. The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of the mitochondrial Small SubUnit (mtSSU, also known as RNS), is referenced in GENBANK® under the accession number JX499143.1, REGION: 31755 . . . 33192 (SEQ ID NO: 2), which is: (SEQ ID NO: 2) TAAGATAATTCACAAAAGAAAGAGTTTAATGTTAGCTCCGAATCAACGCTATCTAGAGGCATTACACATGCA AATCGTACGTTTAAAGTGGTGAACAGGTGAGTAAAGATAGAAATCTACCTATTCATAAGGTTAGATACCTTT TAAAAGAACAATTGTTTGTGAATAGATGAGTCTAAGTGGGGGAGGTAGTTGTGAGGTGAAGATCCTCCCAAG CCTAAGAACCCTAGTTATATTTGAAAGAATGAATAACCACATTGGCTCTGAAACAACAGCCAAGATTTTCAT CCAAGAAAGTCCAGCAGTGGGGAATATTGGTCAATGATCGAAAGATTGAACCAGCTATCTAGAAGAATTTGT ATTCTGTTATTAGAGAGGATTATGACGTTATCTAATTAAAGTCTCGACCAATTCTCGTGCCAGCAGTCGCGG TAAGACGAGTGAGGCTAGCGTTATTCATAATTATTAGGTCTAAAGGGTACGTAGATGGTTAACTTATCTGTT ATTTATGTGTGAAGGAATTAGTATTCTAATTCGTTTTATTAGTATTCTAATTTTTTTAATAGAACATAAAAG AATTGGATAAATTGATTAACTAGAGTCGAATAGAAGAATAAAGAATTTTAAGAGTAGAGATGAAATTCAACG ATACTTAAAGGACTGCCAATGGCGAAAGCATTATTCTAGGTAACGACTGACATTGAGGTACGTAGGCATAAG TAGCGAAAAGGATTAGATACCCTTGTAGTTTATGCTGTAAACGATGAATGCTAGAGGTCAGAATTTATTTAT TTTTGGTCTTTAAGTGAAGATTTTAAGCATTCCACCTGAGAAGTACTGTCGCAAGACTGAAACTCAAAACAT TAGACGGTCACAGAGATCAGCAGTGAAGCATGTTGTTTAATTCGATAACCCACGATAAATCTTAGCACTTCT TGCATATTTTCCTATTCGGAATTTACAGGTGTTGCATGGCTGTCTTTAGTTCGTGTTGTGAAATGTTAGGTT TATTCCGATAACGAACGTAAACCTTGTCCTTAATTATTTTAAGGAAATGTCTATCGATATTATAGATGAATG AGGATGAAGACAAGTCCTCATGACCCTTATGAAGTGGGCTACAGACGTGCTGCAAAATTTTCTACAATGGGA TGCAATGATGGAAGTCGGAGCTAATCCCCTAAAAGATTGTTTAGTCCGGATAAGTGCCTGGAACTCGGCTCT TTGAAGTTGGAATTGCTAGTAATCGTCTATCATCATGAGACGGTGAATCTTTTATCTGTGATGTACTAACTA CTCGTCAAGCGCGGAAATTTTTTAAGAAATTCAAGTTCTTACGTCCATTTCTTGGAGATCTGTGCTAAGTCG AAATAAGGTAGCTGTAGGGGAACCCTGTAGCTGAATAATTTGTGTTGTTTAAATCCCCCCCATCCTTGTG. The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of CYTochrome B (CYTB) is referenced in GENBANK® under the accession number AF074871.1 (SEQ ID NO: 3), which is: (SEQ ID NO: 3) TATTTATGGAATTATGGTTCATTATCAGGACTGTGTTTAATTATACAGATTATTACGGGTGTGACTTTAGCT ATGGATTATATACCTTCGATTGATTTAGCTTTCTTGAGTGTTGAACATATTATGTGAGATGTAAATTATGGT TGGTTGATTCGTTATATTCATAGTAATACGGCTTCTTTTTTCTTTCTGTTTGTTTATATTCATATTGCTTGA GGTATCTATTATGGATCTTATCGAACTCCCAGAATTCTCGTTTGGTCTATTGGTGTAGTTATCTTCTTAATT ATGATTGTTACTGCTTTCTTGGGATATGTTCTGCCTTTTGGTCAAATGTCATTGTGGGGAGCGACTGTTATT ACTAATTTGATGTCTGCTATACCTTGGATTGGTAATGATATTGTGAATTTTATTTGGGGTGGGTTCTCTGTT AATCATGCTACTCTGAATTGATTCTTCTCTTTACATTATTTATTGCCTTTTGTTTTATTGGCTTTAGTTGTT GCTCATTTAATCTCTTTACATGTTCATGGAAGTAGTAATCCTCTGGGTGTTACTGGTAATTCAGATCGTCTG CCTTTCCATCCCTATTTCTCATTTAAAGATTTAGTTACTGTTTTTTTATTTTTATTAGCTTTATGTTTCTTT GTGTTTTATGCTCCTAATGTCTTGGGACATAGTGATAATTATATTATGGCTAATCCTATGGCTACTCCTCCA AGTATTGTTCCTGAATGGTATCTTTTACCTTTCTATGCAATCTTGTGATCTATTTCGAATAAATTATTTGGA GTTGTGGCTATGTTAGCTGCTATTCTTATTCTTTTTGTTTTACCTCTTGTGGATTTATCTTGAATTTGAGGT TCTGCTTTTAGACCTCTTAGTAAATTCTTTTTTTGGATCTTTGTCACTAATTTCTTCTTGTTAATGTTTGTG GGTTGACAACATGTTGAAGAACCTTTTGTGACGCTTGGACAATATGCTACATTCTTCTATTTCTTCTATTTC TTAGTTGTTATTCGTCTGGTGGGTATTATT. The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of the Beta TUBuline (BTUB) is referenced in GEN BANK® under the accession number AF170964.1 (SEQ ID NO: 4), which is: (SEQ ID NO: 4) 1 ggcgcctctt tttggagcac cattagcggt gaacacggtc ttgatagcac tggcctgtaa 61 gcaatattgt aatactgcag tgtgtttgca gaggtgatta gaaatgccta taaggcagca 121 aaaaggcatt gaaaagactc caaagaagta caaagatgct ctgcaaacaa tctaaaaaca 181 tgcagtaata ctgcatgttt gcagtacttt ttttccaaaa cttatatttt tcagctatca 241 tggaacctct gatctccaac tcgaacggat gaatgtttat ttcaacgagg tttctacgga 301 aaaatgttta tagaatgtca gacatttatt ttaataggca tctggcggga aatacgtgcc 361 tcgtgcagta ctggttgatt tagagcccgg tacaatggat gcagtacgtt ctgggccatt 421 tgggaacctg tttcgaccag ataattttat ttttggtcaa tcaggtgcag gaaataactg 481 ggcaaaaggg cattatacag agggagcgga attggtagat actgtgttag atgtagttcg 541 tcgggaagcc gaagcatgtg attgcttgca aggattccag attacacatt cattaggtgg 601 tggaacgggt gcaggcatgg gaactttgct aatttcgaaa attcgagagg aatatccgga 661 tcggatgatg gcaacgtttt cagtggttcc ctcaccaaaa gtttccgata cagttgtaga 721 gccatataat gcaacattat cagtgcatgt gtgtttttaa gccattttta gaatgtatat 781 taatgaggag gggtagcaat tagttgaaaa ttccgatgaa acattctgta tcgacaatga 841 agcattatat gatattcgta tgcgtacatt aaaattgccg gatccaggat atggtgattt 901 gaatcatctt gtctcggcag taatgagtgg tattacaact tgtcttcgat ttcctggaca 961 actcaactcg gatttgcgta aattggccgt taatatggtg ccgtttcctc gtttgcactt 1021 tttcatggtt gggtttgctc cattaacaag cagtaagatg ctttaaacgt attctgaaat 1081 ggctgattgt tattctgtct agagggatca cattcatttc ggtcattgac agttcctgaa 1141 ttgactcagc aaatgtttga tgcaaagaat atgatggcag catcggatcc gagacatggt 1201 cgctatttaa ctgttgcagc gattttccgc ggtactgttt ccatgaagga ggttgaagat 1261 caaatgcata atgttcagca gaagaactct tcatattttg ttgaatggat tccaaacaat 1321 gtgcaaaccg cgctatgttc tattccacca cgtggtctca aaatgtcatc aacgtttatt 1381 ggcaattcaa catctattca ggaactattt aaacgtgtag gcgaccaatt tgctgca. The reference sequence used to design primers arid a probe for the quantification of the RNA transcripts of HSP70 is referenced in GEN BANK® under the accession number DQ987621.1 (SEQ ID NO: 5), which is: (SEQ ID NO. 5) 1 gacggaaact cggggatcca gaagcgcaat cagatatgaa acattggcct tttaaagtta 61 taqacaaagg tcagaagcct tatattcagg ttgaatataa aggggatatt aaaacattta 121 cgccggagga gatttcatca atggtcctta caaaaatgaa ggaggtggca gaagcgtatc 181 ttgggactaa agtttccaat gccgttatca cggtcccagc atatttcaat gactcacagc 241 gacaggctac gaaagacgca ggattgattg caggattgaa tgttttacgt attatcaatg 301 aacctacagc agcagccatt gcatatggtc tagataagaa gacatcaaat gaaaagaatg 361 tgcttatttt tgatcttgga ggaggaactt ttgacgtatc gttattaact atcgaagagg 421 gaatttttga agtcaaagca accgcaggcg atacccattt gggaggagaa gattttgaca 481 atcgtcttgt aaaccacttc attgctgaac gcaaacacaa gaaagatctt tcagggaatg 541 cacgatctct tcgtcggctt cgaacagcat gtgagcgtgc taaacggact ctttcatcat 601 caacacagac gagtatagaa attgattcct tatttgaagg aattgattta tatacttcta 661 ttactcgtgc tcgatttgaa gaactttgtc aaggtctttt taggggaaca atggaaccag 721 ttgagaaagt tcttcgtgat tctaaaattg ataaatcaag tgttcatgaa attgtattgg 781 ttggtggttc tacgcgtatt ccgcgtattc agaaattggt ttgtgatttt tttaatggaa 841 aagagccaaa tagaacgatc aatccagatg aggctgttgc ctatggtgcg gcagttcaag 901 ttgctattct ttcaggagac acatcggaac aaactcaaga catactcttg cttgatgtgg 961 cgcctctctc aatgggt. The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of COX1 is referenced in GENBANK® under the accession number JX499143.K REGION: 16256 . . . 17836 (SEQ ID NO: 6), which is: (SEQ ID NO: 6) 16256 atgac 16261 atgatggttg ttttcaacaa atgctaagga tatcggagtc ttgtacttga tctttgcact 16321 tttttctgga atgttgggta cagcatattc agtattattg agaatggaat taacttcccc 16381 aggtgttcag tatttacagg gtgataatca attgtataat gtaattttaa cgagtcatgc 16441 gttgttaatg atattcttta tggttatgcc cggaatggta ggaggttttg gtaattggtt 16501 ggttccagta atgattggag caccagatat ggcctttcca agattaaata atatctcctt 16561 ctggttgtta ccgccttctc tgattctgtt aattgcttct tctcttctag aaggtggaag 16621 tggtacaggt tggacttttt atccaccttt gtccagttta caaagtcatt cctcaggtgc 16681 tgtcgatttg tctatcttta gtctacattc agcaggtatt agttctatgt tgggagctat 16741 taattttatt actactgttc ttaatacttg agctcccggt atgactatgc ataaaattcc 16801 attgtttgca tggtctatct ttgttactgc tatactgttg ttattgtcct tgccagtctt 16861 agcaggaggt attactatgc tcttgacgga ttgaaatttt aatacttcct tctatgatgt 16921 cgcaggagga ggggatccta tcctttatca acatctcttc tggttcttcg gacatccaga 16981 agtttatatt ctgattattc caggatttgg tatcattagt catattattt ccactttctc 17041 tggaaaacca gtattcggtt atttaggtat ggtttatgct atgttgtcaa ttggtgtctt 17101 aggatttatt gtctggagtc atcatatgta ttcagtgggt ttagatgttg atacatgagc 17161 ttattttact gctgctacta tgattattgg tgtacctact ggtattaaaa tcttctcttg 17221 gattgctact atgtatggtg gtgtgattcg atttaataca cctatgctct ttgctatcgg 17281 attccttttc ctttttactg tgggaggatt aacgggtatt gtcttgtcta atgcttcttt 17341 agatgtggct ttacatgata cttattatgt tgtagctcat ttccattatg ttttatccat 17401 gggtgcagtc tttgctctct tagcagcttg gtatttctgg tctccaaaaa ttttaggatt 17461 gttctttgat gaaaaattag ggcatttgca tttctggact ctttttattg gagtgaattt 17521 aacttttatg cctatgcatt tcttgggatt acagggtatg cccagatgaa ttcctgatta 17581 tcctgatgct tttgctcagt ggaatcatat ctcaagttta ggtagtttga tttctgttgt 17641 tgctactgtt gtttttattt attctatttt tgatcaattg atctctaaat gattggtacc 17701 gatgaatcct tggtattctc ctgatttctt tgttagtcat acgaatttag aggattccaa 17761 agcttgttcc ttagaatggg cattgatttc accaccagct ttccatgctt atactagttt 17821 acctaaacaa gcttaa. The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of NAD1 is referenced in GEN BANK® under the accession number JX499143.1, REGION: 29671 . . . 30672 (SEQ ID NO: 7), which is: (SEQ ID NO: 7) 29671 atgttaaatt gtattcaagt gggtattgtt 29701 ttattacctg ttttgttaag tgtagctttt gtgacattag ctgaacgtaa agttatggga 29761 tcgattcaac gacgtgtggg tcctaatgtt gtgggttatt atggtttgtt acaacctgca 29821 gctgatgctt taaaattatt attaaaagaa actattattc ctatccattc gaataaagtg 29881 ttgttcttct taggaccttc tattgcatta gtctttgctt taatgggttg gggtattatt 29941 ccatggaatt caggtataac actttgggat tttgatttag gtattttatt tagtttagct 30001 atttcttctt taggtgtgta tggtatttta attgggggtt gggcttctaa ttccaaatat 30061 gctttattag gttccttgtg aagtactgct caattaatta gttatgaatt agttttaact 30121 tcgattgttt ttgttgttgt tcttttatct ggttctttta attttactca cattattgaa 30181 gaacaaaaag ctatttggtt tgttttgcct ttatttcctc tgttcatttt gttctttact 30241 ggtgctttag cagaaacgaa ttgagctcct tttgatttgc cagaagctga atccgaatta 30301 gttgctgggt ttatgactga gtattctgct gcgatctttg ttttcttctt cctagctgaa 30361 tatgctaata ttattcttat ctctactcta gctgctattt tcttcttagg aggttattta 30421 ttacctttcg agttgcattt cttgcctaat ggtttagatg ttctcgttca gggattactt 30481 tctggtttga ttttaggttt gaaagttgct gggattattt tcctctttgt ttgggtttga 30541 tctagcttcc ctagaatttg atatgatcaa ttgttagttc tatgttggac tgttctgtta 30601 cctttgcttt ttgctcggat ttttctggtt ttagctattc ttttttcttt taattctttt 30661 attcatttct ag. The reference sequence used to design primers and a probe for the quantification of the RNA transcripts of ATP9 is referenced in GEN BANK® under the accession number JX499143.1, REGION: 20225 . . . 20449 (SEQ ID NO: 8), which is: (SEQ ID NO. 8) 20225 atgtta caagcagcta aagttattgg ttcagggtta gctacaattg gattagcagg 20281 ggctggtatc ggtatcggtt tagttttcgg taatttacca gtagcgacaa gtcgaaatcc 20341 ttcattgaaa ggacaactct tctcttatgc tatcttggga tttgctctag cagaagctac 20401 tggtcttttc tgtttgatga tggctttcct tctgctatat gcagcttaa. - qRT-PCR Amplification
- For each sample, the expression of the mtLSU, the CYTB, the BTUB, the HSP70, the COX1, the NAD1 and the ATP9 genes were tested (quantification of RNA transcripts). All PCR reactions were performed on a LIGHTCYCLER® 480 instrument (ROCHE DIAGNOSTICS; 2, Avenue du Vercors; BP 59; 38242 MEYLAN CEDEX; FRANCE) in a final volume of 10 μL containing 0.2 μL of EXPRESS SuperScript® III Mix for One-Step qRT-PCR (INVITROGEN™ by LIFE TECHNOLOGIES™; 5791 Van Allen way; Carlsbad; CA 92008: U.S.A.), 1× EXPRESS SuperScript® III SuperMix Universal buffer (INVITROGEN™ by LIFE TECHNOLOGIES™; 5791 Van Allen way; Carlsbad; CA 92008; U.S.A.), with 0.3 μM of each primer, 0.1 μM of the probe and 2 μL of a 1:2 dilution of RNA. The reaction consisted of a reverse transcription step at 50° C. 15 min, followed by DNA polymerase activation at 95° C. 2 min and 45 cycles of 95° C. 15 s and 60° C. 30 s.
-
The mtLSU (RNA) target was: SEQ ID NO: 9 CACUGAAUAUCUCGAGGGAGUAUGAAAAUAUUUAUC UCAGAUAUUUAAUCUCAAAAUAACUAUUUCUUAAAA UAAAUAAUCAGACUAUGUGCGAUAAGGUAGAUAGUC GAAAGGGAAACAG. The cDN A reverse-transcript of the mtLSU target was (fragment 861-981 from SEQ ID NO: 1): SEQ ID NO: 10 CACTGAATATCTCGAGGGAGTATGAAAATATTTAT CTCAGATATTTAATCTCAAAATAACTATTCTTAAA ATAAATAATCAGACTATGTGCGATAAGGTAGATAG TCGAAAGGGAAACAG. Primers and probe used for the detection of the targeted region of the mtLSU RNA were: PjF1: (SEQ ID NO: 11) 5′-CACTGAATATCTCGAGGGAGTATGAA-3′ PjR1: (SEQ ID NO: 12) 5′-CTGTTTCCCTTTCGACTATCTACCTT-3′ and the PjSL probe: (SEQ ID NO: 13) 5′-TCGCACATAGTCTGATTAT-3′ under TAQMAN® format (FAM™ in 5′ and MGB® in 3′). FAM™ = 6-carboxy-fluorescein dye MGB® = Minor Groove Binder® quencher A mtSSU (RNA) target can be: SEQ ID NO: 14 GCAAUGAUGGAAGUCGGAGCUAAUCCCCUAAAAG AUUGUUUAGUCCGGAUAAGUGCCUGGAACUCGGC UCUUUGAAGUUGGA. The cDNA reverse-transcript of this mtSSU target can be (fragment 1154-1235 from SEQ ID NO: 2): SEQ ID NO: 15 GCAATGATGGAAGTCGGAGCTAATCCCCTAAAAGAT TGTTTAGTCCGGATAAGTGCCTGGAACTCGGCTCTT TGAAGTTGGA. Primers arid probe for the detection of this mtSSU RNA target region can be: Pj1154F: (SEQ ID NO: 16) 5′-GCAATGATGGAAGTCGGAGC-3′. PJ1235R: (SEQ ID NO: 17) 5′-TCCAACTTCAAAGAGCCGAGT-3′. and the Pj1190P probe: (SEQ ID NO: 18) 5′- TGTTTAGTCCGGATAAGTGCCTGGA-3′ under TAQMAN® format (FAM™ in 5′ and BHQ-1® in 3′). BHQ-1® = Black Hole Quencher®-1. Another mtSSU (RNA) target can be: SEQ ID NO: 19 GGAUGCAAUGAUGGAAGUCGGAGCUAAUCCCCUAAA AGAUUGUUUAGUCCGGAUAAGUGCCUGGAACUCGGC UCUUUGAAGUUGGAAUUGCU. The cDNA reverse-transcript of this mtSSU target can be (fragment 1150-1241 from SEQ ID NO: 2): SEQ ID NO: 20 GGATGGAATGATGGAAGTCGGAGCTAATCCCCTAAA AGATTGTTTAGTCCGGATAAGTGCCTGGAACTCGGC TCTTTGAAGTTGGAATTGCT. Primers and probe for the detection of this mtSSU RNA target region can be: Pj1150F: (SEQ ID NO: 21) 5′-GGATGCAATGATGGAAGTCGGA-3′, Pj1241R: (SEQ ID NO: 22) 5′-AGCAATTCCAACTTCAAAGAGCC-3′, and the Pj1190P probe: (SEQ ID NO: 23) 5′-TGTTTAGTCCGGATAAGTGCCTGGAAC-3′ under TAQMAN® format (FAM™ in 5′ and BHQ-1® in 3′). Still another mtSSU (RNA) target can be: SEQ ID NO: 24 UCAUGACCCUUAUGAAGUGGGCUACAGACGUGCUGC AAAAUUUUCUACAAUGGGAUGCAAUGAUGGAAGUCG GAGC. The cDNA reverse-transcript of this mtSSU target can be (fragment 1098-1173 from SEQ ID NO: 2): SEQ ID NO: 25 TCATGACCCTTATGAAGTGGGCTACAGACGTGCTGC AAAATTTTCTACAATGGGATGCAATGATGGAAGTCG GAGC. Primers and probe for the detection of this mtSSU RNA target region can be: Pj1098F: (SEQ ID NO: 26) 5′-TCATGACCCTTATGAAGTGGGC-3′, Pj1173R: (SEQ ID NO: 27) 5′-GCTCCGACTTCCATCATTGC-3′. and the Pj1125P probe: (SEQ ID NO: 28) 5′-ACGTGCTGCAAAATTTTCTACAATGGG-3′ under TAQMAN® format (FAM™ in 5′ and BHQ® in 3′). The CYTB (RNA) target was: SEQ ID NO: 29 CUCCCAGAAUUCUCGUUUGGUCUAUUGGUGUAGU UAUCUUCUUAAUUAUGAUUGUUACUGCUUUCUUG GGAUAUGUUCUGCCUUUUGGUCAAAUGUCAUUGU GGG. The cDNA reverse-transcript of the CYTB target was (fragment 242-346 from SEQ ID NO: 3): SEQ ID NO: 30 CTCCCAGAATTCTCGTTTGGTCTATTGGTGTAGTT ATCTTCTTAATTATGATTGTTACTGCTTTCTTGGG ATATGTTCTGCCTTTTGGTCAAATGTCATTGTGGG. Primers and probe used for the detection of the targeted region of the CYTB RNA were: CYTB_Pj242F: (SEQ ID NO: 31) 5′-CTCCCAGAATTCTCGTTTGG-3′ CYTB_Pj346R: (SEQ ID NO: 32) 5′-CCCACAATGACATTTGACCA-3′ and the CYTB_Pj301P probe: (SEQ ID NO: 33) 5′-CTTTCTTGGGATATGTTCTGCC-3′ under TAQMAN® format (FAM™ in 5′ and TAMRA™ in 3′). TAMRA™ = carboxytetramethylrhodamine fluorescent dye. Primers and probe used for the detection of STUB RNA were: BTUB_PJ766F: (SEQ ID NO: 34) 5′-CCATTAACAAGCAAGGGATCAC-3′ BTUB_Pj861R: (SEQ ID NO: 35) 5′-CGATGCTGCCATCATATTCTT-3′ and the BTUB_Pj795P probe: (SEQ ID NO: 36) 5′-TCGGTCATTGACAGTTCCTGAA-3′ under TAQMAN® format (FAM™ in 5′ and TAMRA™ in 3′). Primers and probe used for the detection of HSP70 RNA were: HSP70_PJ126F: (SEQ ID NO: 37) 5′-GGAGATTTCATCAATGGTCCTT-3′ HSP70_Pj202R (SEQ ID NO: 38) (5′-CGGCATTGGAAACITIAGTCC-3′ and the HSP70_PJ157P probe: (SEQ ID NO: 39) 5′-AAGGAGGTGGCAGAAGCGT A-3′ under TAQMAN® format (FAM™ in 5′ and TAMRA™ in 3′). An aliquot of a sample with a defined quantification was used in each PCR to be run as an internal control and to measure reproducibility. For mtLSU, CYTB, BTUB and MSP70, the Cq values ± SD were 24.1 ± 0.3, 23.6 ± 0.3, 32.5 ± 0.3, 29.0 ± 0.2, respectively. Primers and probe used for the detection of COX1 RNA were: COX1_Pj228F: (SEQ ID NO: 40) 5′-AGGTTTTGGTAATTGGTTGGTTCC-3′ COX1_PJ324R: (SEQ ID NO: 41) 5′-AGAAGGCGGTAACAACCAGAA-3′ and the COX1_Pj261P probe: SEQ ID NO: 42) 5′-TGGAGCACCAGATATGGCCTTTCCAAGA-3′; under TAQMAN® format (FAM™ in 5′ and BHQ-1™ in 3′). BHQ-1™ = Black Hole Quencher®-1. Primers and probe used for the detection of NAD1 RNA were: NAD1_Pj579F: (SEQ ID NO: 43) 5′-AGCAGAAACGAATTGAGCTCCT-3′ NAD1_Pj664R: (SEQ ID NO: 44) 5′-TCGCAGCAGAATACTCAGTCAT-3′ and the NAD1_PJ608P probe: (SEQ ID NO: 45) 5′-TGCCAGAAGCTGAATCCGAATTAGTTGC-3′ under TAQMAN® format (FAM™ in 5′ and BHQ-1™ in 3′). Primers and probe used for the detection of ATP9 RNA were: ATP9_PJ25F: (SEQ ID NO: 46) 5′-GGTTCAGGGTTAGCTACAATTGGA-3′ ATP9_Pj118R: (SEQ ID NO: 47) 5′-AAGGATTTCGACTTGTCGCTACT-3′ and the ATP9_Pj52P probe: (SEQ ID NO: 48) 5′-GCAGGGGCTGGTATCGGTATCGGTTTAG-3′ under TAQMAN® format (FAM™ in 5′ and BHQ-1™ in 3′). - Gene Expression Determination
- For determination of the gene expression level of the different samples, all quantification data (Cq) were normalized compared to the BTUB expression. Experimental calibration curves allowed determination of the PCR efficiency (e) that was required to determine gene expression for each PCR. At the end, the expression of CYTB was compared to that of mtLSU gene without taking into account BTUB expression with modification of the formula of Pfaffl 2001 as:
-
CYTB/mtLSU ratio=E(CYTB)−Cq(CYTB) /E(mtLSU)−Cq(mtLSU) - The real-time PCR efficiency (E) of one cycle in the exponential phase was calculated according the formula E=10[−1/slope] as described in Pfaffl 2001. The real-time PCR efficiency values for CYTB, mtLSU, BTUB and HSP70 are reported in Table 8.
- Data Analysis
- Correlation with clinical data was performed only with one sample per patient. Statistical analyses were performed with PRISM® v5.0 (GraphPAD Software Inc.; 7825 Fay Avenue; Suite 230: LA JOLLA, Calif. 92037, U.S.A.).
- Results
- Detection of RNA in BALF
- From all 200 samples, mtLSU RNA PCR was compared to the miLSU DNA PCR performed as a routine test. From the 200 samples, 34 (17%) were both positive and 148 (74%) were both negative with RNA and DNA PCR; cf. Table 2 below.
-
TABLE 2 Distribution of the number of samples regarding DNA and RNA mtLSU PCR Positive RNA Negative RNA Number of samples mtLSU PCR mtLSU PCR Total Positive DNA mtLSU PCR 34 5 39 Negative DNA mtLSU PCR 13 148 161 Total 47 153 200 - In 5 (2.5%) samples, mtLSU DNA but not RNA was detected, whereas in 13 samples, mtLSU RNA was detected but not DNA (cf. Table 2 above). RNA detection (n=47) is more sensitive than DNA detection (n=39) in BALF.
- In addition, the fungal load was significantly higher with RNA than with DNA detection (
FIG. 1 , paired t-test: p<0.0001). RNA detection gave a 10 fold higher detection than DNA with a mean ΔCq (DNA-RNA) at 3.577 (95% confidence interval: 2.681-4.473). - In the 47 samples positive for mtLSU rRNA, CYTB, BTUB and HSP70 mRNA were detected in 31 (66%), 32 (68%) and 32 (68%) samples, respectively.
- Clinical Probability of PCP Classification
- From the 200 BALF prospectively collected from 192 patients, 2 samples (2 patients) harboring a positive DNA PCR were excluded because of lack of clinical data.
- At the end, a total of 49 patients (50 samples) with either RNA or DNA detection were investigated for classification. Eighteen patients were considered as PCP (proven PCP in 14 patients, probable PCP in 1 patient and possible PCP in 3 patients) and 31 patients as no PCP.
- No difference in the repartition of the different groups of disease was observed in patients with and without PCP (chi-2, p=0.063, cf. Table 3 below).
-
TABLE 3 Distribution of the PCP and no PCP patients according to different groups of diseases Background PCP no PCP p Hematological malignancies 7 13 0.063 HIV positive 8 4 SOT 1 2 others 2 5 No ID 0 7 Total 18 31 - In the PCP patients, 14 samples (14 patients) were diagnostic samples and 5 samples (4 patients) were not performed as diagnostic samples but to search for other etiology of a persistent or recently acquired pneumonia after PCP diagnosis and more than 15 days of cotrimoxazole treatment (analyzed apart for the others specimens and called follow-up samples). Patients with PCP were composed of hematological malignancies (7/14, 50%), HIV patients (8/14, 57%), solid organ transplant (SOT) (1/14, 7%) and other background (2/14, 14%). Immunofluorescence was positive in 8/14 (57%) patients and negative in 6/14 (43%) patients. Based on immunofluorescence results, sensitivity and specificity were 0.57 (95% CI, 0.289-0.823) and 1.00 (95% CI, 0.888-1.000), respectively. The ROC curve analysis of the quantification results (mtLSU RNA PCR) allowed determination of the best quantification cycle (Cq) threshold between 30.49 and 31.78 (
FIGS. 2A and 3B ). Based on the quantification results, optimal sensitivity and specificity were 0.812 (95% CI, 0.543-0.959) and 0.960 (95% CI, 0.796-0.999) for diagnostic samples (n=41,FIG. 2A and Table 7) and 0.650 (94% CI 0.408-0.846) and 0.961 (95% CI, 0.804-0.999) for diagnostic and follow-up samples (n=46,FIG. 2B and Table 7). - Variable CYTB/mtLSU Ratio in Different Categories of Patients
- No PCP patient was recorded in the 16 samples with positive mtLSU RNA and negative CYTB RNA PCR and in the 152 samples with negative mtLSU and CYTB RNA PCR (cf. Table 6 below).
-
TABLE 6 Repartition of the samples in the different categories of samples regarding the expression of CYTB and mtLSU Clinical classification PCP w Rx Categories of samples PCP 15 days no PCP CYTB/mtLSU > 1.66 1 5 9 CYTB/mtLSU < 1.27 13 0 2 No CYTB 0 0 16 No CYTB/ No mtLSU 0 0 152 - The ROC curve analysis of the CYTB/mtLSU ratios was performed and showed that a threshold between 1.27 and 1.66 allowed the higher likelihood ratio (LR: 12.96) (cf. Table 4 below, cf.
FIGS. 2A and 3B ). -
TABLE 4 ROC curve data of the PCP Xpress test based on diagnostic samples (n = 41) Cutoff CYTB/mtLSU Likelihood ratio Sensitivity % 95% CI Specificity % 95% CI ratio −156.9 100.0 87.23 to 100.0 7.143 0.1807 to 33.87 1.08 −3.985 100.0 87.23 to 100.0 14.29 1.779 to 42.81 1.17 −2.864 96.30 81.03 to 99.91 14.29 1.779 to 42.81 1.12 −2.386 96.30 81.03 to 99.91 21.43 4.658 to 50.80 1.23 −2.191 96.30 81.03 to 99.91 28.57 8.389 to 58.10 1.35 −1.992 96.30 81.03 to 99.91 35.71 12.76 to 64.86 1.50 −1.926 96.30 81.03 to 99.91 42.86 17.66 to 71.14 1.69 −1.903 96.30 81.03 to 99.91 50.00 23.04 to 76.96 1.93 −1.763 92.59 75.71 to 99.09 50.00 23.04 to 76.96 1.85 −1.546 92.59 75.71 to 99.09 57.14 28.86 to 82.34 2.16 −1.398 92.59 75.71 to 99.09 64.29 35.14 to 87.24 2.59 −1.279 92.59 75.71 to 99.09 71.43 41.90 to 91.61 3.24 −1.222 92.59 75.71 to 99.09 78.57 49.20 to 95.34 4.32 0.02900 92.59 75.71 to 99.09 85.71 57.19 to 98.22 6.48 1.472 92.59 75.71 to 99.09 92.86 66.13 to 99.82 12.96 1.909 88.89 70.84 to 97.65 92.86 66.13 to 99.82 12.44 2.544 85.19 66.27 to 95.81 92.86 66.13 to 99.82 11.93 3.959 81.48 61.92 to 93.70 92.86 66.13 to 99.82 11.41 5.402 77.78 57.74 to 91.38 92.86 66.13 to 99.82 10.89 6.060 74.07 53.71 to 88.89 92.86 66.13 to 99.82 10.37 8.202 70.37 49.82 to 86.25 92.86 66.13 to 99.82 9.85 10.11 66.67 46.04 to 83.48 92.86 66.13 to 99.82 9.33 10.96 62.96 42.37 to 80.60 92.86 66.13 to 99.82 8.81 14.93 59.2.6 38.80 to 77.61 92.86 66.13 to 99.82 8.30 59.02 59.26 38.80 to 77.61 100.0 76.84 to 100.0 - After addition of the 5 follow-up samples, a ratio between the same range allowed the higher likelihood ratio (LR: 13.13) (cf. Table 5 below, cf.
FIGS. 2B and 3B ). -
TABLE 5 ROC curve data of the PCP Xpress test based on diagnostic (n = 41) and follow up (n = 5) samples Cutoff CYTB/mtLSU Likelihood ratio Sensitivity % 95% CI % 95% CI ratio 0.1085 100.0 89.11 to 100.0 7.143 0.1807 to 33.87 1.08 0.2585 100.0 89.11 to 100.0 14.29 1.779 to 42.81 1.17 0.3570 100.0 89.11 to 100.0 21.43 4.658 to 50.80 1.27 0.4190 96.88 83.78 to 99.92 21.43 4.658 to 50.80 1.23 0.4585 96.88 83.78 to 99.92 28.57 8.389 to 58.10 1.36 0.5025 96.88 83.78 to 99.92 35.71 12.76 to 64.86 1.51 0.5195 96.88 83.78 to 99.92 42.86 17.66 to 71.14 1.70 0.5260 96.88 83.78 to 99.92 50.00 23.04 to 76.96 1.94 0.5705 96.88 83.78 to 99.92 57.14 28.86 to 82.34 2.26 0.6490 96.88 83.78 to 99.92 64.29 35.14 to 87.24 2.71 0.7170 96.88 83.78 to 99.92 71.43 41.90 to 91.61 3.39 0.7835 93.75 79.19 to 99.23 71.43 41.90 to 91.61 3.28 0.8185 93.75 79.19 to 99.23 78.57 49.20 to 95.34 4.38 1.050 93.75 79.19 to 99.23 85.71 57.19 to 98.22 6.56 1.473 93.75 79.19 to 99.23 92.86 66.13 to 99.82 13.13 1.745 90.63 74.98 to 98.02 92.86 66.13 to 99.82 12.69 1.989 87.50 71.00 to 96.49 92.86 66.13 to 99.82 12.25 2.545 84.38 67.21 to 94.72 92.86 66.13 to 99.82 11.81 3.025 81.25 63.56 to 92.79 92.86 66.13 to 99.82 11.38 3.412 78.13 60.03 to 90.72 92.86 66.13 to 99.82 10.94 4.347 75.00 56.59 to 88.54 92.86 66.13 to 99.82 10.50 5.402 71.88 53.25 to 86.25 92.86 66.13 to 99.82 10.06 6.060 68.75 49.99 to 83.88 92.86 66.13 to 99.82 9.63 7.766 65.63 46.81 to 81.43 92.86 66.13 to 99.82 9.19 9.669 62.50 43.69 to 78.90 92.86 66.13 to 99.82 8.75 10.11 59.38 40.64 to 76.30 92.86 66.13 to 99.82 8.31 10.79 56.25 37.66 to 73.64 92.86 66.13 to 99.82 7.88 11.64 53.13 34.74 to 70.91 92.86 66.13 to 99.82 7.44 14.93 50.00 31.89 to 68.11 92.86 66.13 to 99.82 7.00 59.02 50.00 31.89 to 68.11 100.0 76.84 to 100.0 - Without treatment, all IF positive samples had a ratio <1.27. After 15 days of cotrimoxazole in patients that had an IF-positive sample, CYTB and mtLSU could be amplified and the ratio was >1.66. In IF negative samples, ratio <1.27 and >1.66 were observed corresponding to patient with PCP but with negative IF or to colonized patients.
- After clinical classification, samples from PCP patients had mostly a ratio <1.27 (13/14, 92.9%) whereas those from patients treated with cotrimoxazole >15 days (5/5, 100%) and those from patients without PCP had mostly a ratio >1.66 (9/11, 81.9%) (cf. Table 6 above, cf.
FIG. 3B ). - Performance of the PCP Xpress Test
- The diagnostic performances of our test were then calculated based on different categories of samples. Taking into account the samples for which a ratio is determinable (positive CYTB and mtLSU RNA PCR, n=25), with a CYTB/mtLSU ratio threshold at 1.5 (threshold between ]1.27 to 1.66[), sensitivity, specificity, Positive predictive value (PPV) and negative predictive value (NPV) and the likelihood ratio (LR) were 0.867, 0.900, 0.929, 0.818, 8.667 (cf. Table 7 below).
-
TABLE 7 Sensitivity, specificity, positive predictive and negative predictive values, likelihood ratio of the PCP Xpress and RNA mtLSU qPCR test in diagnostic and diagnostic and follow-up samples Samples Diagnostic and Diagnostic and Follow up Diagnostic and Diagnostic and follow up CYTB and mtLSU positive CYTB and mtLSU positive mtLSU positive and mtLSU positive (n = 25) (n = 30) (n = 41) (n = 46) Test used PCP Xpress RNA qPCR PCP Xpress RNA qPCR PCP Xpress RNA qPCR PCP Xpress RNA qPCR Sensitivity 0.8667 0.8667 0.8667 0.6842 0.8667 0.8125 0.8667 0.6500 [95% CI] [0.5954 to [0.5954 to [0.5954 to [0.4345 to [0.5954 to [0.5435 to [0.5954 to [0.4078 to 0.9834] 0.9834] 0.9834] 0.8742] 0.9834] 0.9595] 0.9834] 0.8461] Specificity 0.9000 0.9000 0.9333 0.9091 0.9615 0.9600 0.9677 0.9615 [95% CI] [0.5550 to [0.5550 to [0.6805 to [0.5872 to [0.8036 to [0.7965 to [0.8330 to [0.8036 to 0.9975] 0.9975] 0.9983] 0.9977] 0.9990] 0.9990] 0.9992] 0.9990] Positive 0.9286 0.9286 0.9286 0.9286 0.9286 0.9286 0.9286 0.9286 Predictive [0.6613 to [0.661.3 to [0.6613 to [0.6613 to [0.6613 to [0.6613 to [0.6613 to [0.6613 to Value [95% CI] 0.9982] 0.9982] 0.9982] 0.9982] 0.9982] 0.9982] 0.9982] 0.9982] Negative 0.8182 0.8182 0.8750 0.6250 0.9259 0.8889 0.9375 0.7813 Predictive [0.4822 to [0.4822 to [0.6165 to [0.3543 to [0.7571 to [0.7084 to [0.7919 to [0.6003 to Value [95% CI] 0.9772] 0.9772] 0.9845] 0.8480] 0.9909] 0.9765] 0.9923] 0.9072] Likelihood 8.667 8.667 13.00 7.526 22.53 20.31 26.87 16.90 Ratio Samples All diagnostic samples (n = 193) All (n = 198) Test used PCP Xpress RNA qPCR PCP Xpress RNA qPCR Sensitivity 0.8667 0.8125 0.8667 0.6500 [95% CI] [0.5954 to 0.9834] [0.5435 to 0.9595] [0.5954 to 0.9834] [0.4078 to 0.8461] Specificity 0.9944 0.9944 0.9945 0.9944 [95% CI] [0.9691 to 0.9999] [0.9689 to 0.9999] [0.9699 to 0.9999] [0.9691 to 0.9999] Positive 0.9286 0.9286 0.9286 0.9286 Predictive [0.6613 to 0.9982] [0.6613 to 0.9982] [0.6613 to 0.9982] [0.6613 to 0.9982] Value [95% CI] Negative 0.9288 0.9832 0.9891 0.9620 Predictive [0.9602 to 0.9986] [0.9518 to 0.9965] [0.9613 to 0.9987] [0.9232 to 0.9846] Value [95% CI] Likelihood 154.3 143.8 158.6 115.7 Ratio PCP Xpress: CYTB/mtLSU threshold between ]1.27 and 1.66[ qPCR RNA mtLSU: Cq threshold at ]30.49 and 31.78[ - If the 16 samples with a negative CYTB expression were added with a CYTB/mtLSU ratio threshold at 1.5 (threshold between]1.27 to 1.66[), sensitivity, specificity. PPV and NPV and LR were 0.867, 0.961, 0.929, 0.926, 22.53 (cf. Table 7 above). If all diagnostic samples were considered, with a threshold of CYTB/mtLSU ratio at 1.5 (threshold between]1.27 to 1.66[), sensitivity, specificity, PPV and NPV and LR were 0.867, 0.994, 0.929, 0.989, 154.3 (cf. Table 7 above). If follow-up samples were included, in each category of samples, the likelihood ratio was higher than with diagnostic samples alone (cf. Table 7 above). Overall, likelihood ratios were higher (LR=158.6) with PCP Xpress than with mtLSU RNA quantification (cf. Table 7 above).
- Testing Gene Expression for Other Gene (HSP70, BTUB, COX1, NAD1, ATP9) Compared to mtLSU
- HSP70 gene was tested because its mRNA was one of the most abundant transcripts found in a transcriptome analysis of Pneumocystis carinii during a fulminate infection in a rat model of pneumocystosis. The BTUB gene was used as a reference gene and also tested in comparison to mtLSU Other mitochondrial genes were also investigated: COX1, NAD1 and ATP9.
- The BTUB and HSP70 gene expression were tested in all samples in parallel to CYTB and mtLSU, COX1, NAD1, and ATP9 were tested in 9 positive samples (4 recovered from PCP patients; and 5 recovered from patients without PCP). ATP9 was not enough expressed to be used as a diagnostic marker.
- For each gene, the ratio compared to mtLSU was calculated as described above.
- The HSP70 and BTUB ratio in our study gave maximum likelihood ratios of 5.83 and 9.69, respectively. These values were lower than for CYTB (cf.
FIG. 4 ). No other ratio (CYTB vs. BTUB, mtLSU vs. BTUB, HSP70 vs. BTUB, HSP70 vs. CYTB) gave accurate discrimination between PCP and non-PCP samples. In addition, it was not possible to see any differences in the COX1 and NAD1 ratios in PCP and non-PCP samples (cf. Table 8 below). -
TABLE 8 Gene expression and ratio to mtLSU obtained for 9 samples (4 from PCP and 5 from non PCP patients) for the BTUB, HSP70, NAD1, COX1 and CYTB genes BTUB | HSP70| NAD1| COX1| CYTB| BTUB mtLSU HSP70 mtLSU NAD1 mtLSU COX1 mtLSU CYTB mtLSU mtLSU Cq ratio Cq ratio Cq ratio Cq ratio Cq ratio Cq Clinical PCR efficacy classification 1.975 1.94 2* 2* 1.973 1.924 Sample 17 PCP 23.145 0.01 21.69 0.03 17.555 0.26 17.56 0.26 16.885 0.52 16.545 Sample 21 PCP 30.03 0.02 28.825 0.07 26.73 0.13 26.73 0.13 25.17 0.53 25.16 Sample 30PCP 28.82 0.01 23.155 0.57 24.68 0.10 24.68 0.10 23.505 0.30 22.585 Sample 51 PCP 32.59 0.02 29.565 0.28 30.33 0.07 30.33 0.07 28.225 0.43 28.01 Sample 6 No PCP 38.73 0.09 38.28 0.23 36.54 0.24 36.54 0.24 32.81 4.98 36.525 Sample 9 No PCP no na 37.51 0.08 34.66 0.17 34.66 0.17 32.035 1.66 34.045 Sample 16 No PCP 37.44 0.02 34.925 0.21 33.81 0.16 33.81 0.16 32.185 0.75 32.98 Sample 27 No PCP 34.57 0.01 32.755 0.09 31.625 0.07 31.63 0.07 29.725 0.41 29.51 Sample 57 No PCP 35.74 0.50 no na 36.4 0.20 36.4 0.20 31.13 11.82 36.1 *PCR efficacy was not calculated for NAD1 and COX1 gene, and was therefore fixed at 2. no = not detected na = not applicable - An artificial or exogenous RNA can be added to the sample prior to the extraction and/or purification step. Such an artificial or exogenous RNA is known as an Internal Extraction Control RNA (IECR).
- IECR can be an artificial cell containing calibrated RNA. Following RNA extraction and in parallel to testing the target genes (CYTB and mtLSU), the presence and the quantity of the control IECR, will be tested upon addition in dedicated mix, and specific primers in a specific well. Signal derived from the Internal Control RNA confirms the success of the extraction step and is also used to determine the presence of inhibitors in the RNA sample. IECR contains a sequence that had no significant known homology to any published sequence and should not interfere with the detection of the sample RNA (human and fungi). A negative control reaction may also be performed.
- Examples of IECR include:
-
- the RNA extraction control commercialized by BIOLINE (BIOLINE USA Inc.; 305 Constitution Dr.; TAUNTON; MA 027080; U.S.A.) under catalog number BIO-38040 or BIO-35040,
- the AMBION® ERCC RNA Spike-In Controls, which are commercialized by LIFE TECHNOLOGIES S.A.S. (route de l'orme des merisiers; Immeuble Discovery—Zone Technologique; 91190 SAINT AUBIN, FRANCE), under catalog number 4456740, and
- the RNA Internal Control, which is commercialized by QIAGEN® (QIAGEN® France S.A.S.; 3, avenue du Canada; LP 809; 91974 COURTABOEUF CEDEX; FRANCE) under catalog number 211492.
- Alternatively to the introduction of an artificial or exogenous RNA prior to the extraction and/or purification step, the control can be performed by detecting that a human gene is still present after said extraction and/or purification step. Examples of suitable human genes are known in the art and include constitutive genes, such as the human albumin (ALB) gene or the human TATA Box binding protein (TBP).
- Said human gene can be detected using a probe, more particularly a primer pair and a (real-time) probe, which specifically detect said human gene.
- Examples of primer pair and (real-time) probe for the human albumin (ALB) gene include
-
ALB Hs_10F (SEQ ID NO: 49) TCGTTACACCAAGAAAGTACCCC; ALB_Hs_89R (SEQ ID NO: 50) TGCTGCCCACTTTTCCTAGG; ALB_Hs_34P (SEQ ID NO: 51) AGTGTCAACTCCAACTCTTGTAGAGGT. - Examples of primer pair and (real-time) probe for the human TATA Box binding protein (TBP) include
-
TBP_Hs_107F (SEQ ID NO: 52) TGGCGTGTGAAGATAACCCA; TBP_Hs_204R (SEQ ID NO: 53) CGCTGGAACTCGTCTCACTA; and TBP_Hs_142P (SEQ ID NO: 54) TGCTGAGAAGAGTGTGGTGGAGATGC; or TBP_Hs_73F (SEQ ID NO: 55) ATCTTTGCAGTGACCCAGCA; TBP_Hs_169R (SEQ ID NO: 56) GAGCATCTCCAGCACACTCT; and TBP_Hs_93R (SEQ ID NO: 57) GCATCACTGTTTCTTGGCGTGTGAAG - The CYTB (cDNA) probe that was used in Example 1 above was the probe of SEQ ID NO: 33 under TAQMAN® format, using the FAM™ fluorophore in 5′ and the TAMRA™ quencher in 3′.
- Alternatively to the TAMRA® quencher, a Black-Hole Quencher®-1 (BHQ®1) was successfully used. With this alternate quencher, the efficiency of the simplex RT-PCR was of 1.94.
- The simplex RT-PCR efficiency was of 1.92 for mtLSU (primers and probe of SEQ ID NOs: 11-13 as described in Example 1).
- The simplex RT-PCR efficiency was of 1.95 for mtSSU (primers and probe of SEQ ID NOs: 26-28 as described in Example 1).
- Each simplex RT-PCR was performed as described in Example 1, i.e., on a LIGHTCYCLER® 480 instrument (ROCHE DIAGNOSTICS; 2, Avenue du Vercors; BP 59; 38242 MEYLAN CEDEX; FRANCE) in a final volume of 10 μL containing 0.2 μL of EXPRESS SuperScript® III Mix for One-Step qRT-PCR (INVITROGEN™ by LIFE TECHNOLOGIES™: 5791 Van Allen way; Carlsbad: CA 92008; U.S.A.), 1× EXPRESS SuperScript® III SuperMix Universal buffer (INVITROGEN™ by LIFE TECHNOLOGIES™; 5791 Van Allen way; Carlsbad; CA 92008; U.S.A.), with 0.3 μM of each primer, 0.1 μM of the probe and 2 μL of a 1:2 dilution of RNA. The reaction consisted of a reverse transcription step at 50° C. 15 min, followed by DNA polymerase activation at 95° C. 2 min and 45 cycles of 95° C. 15 s and 60° C. 30 s.
- The nucleotide sequence of SEQ ID NO: 33 (CYTB cDNA probe) can be modified to replace at least one nucleotide by its Locked Nucleic Acid (LNA™) version (EXIQON™ Inc. 14 F Gill Street Woburn Mass. 01801 U.S.A.).
- For example, at least one of the T. A and G nucleotides of the sequence of SEQ ID NO: 33 can be replaced by a LNA™-T, LNA™-A or LNA™-G, respectively.
- For example, one to five nucleotides of the sequence of SEQ ID NO: 33 can (each) be replaced by their (respective) LNA™ version.
- For example, one to five of the T, A and G nucleotides of the sequence of SEQ ID NO: 33 can (each) be replaced by their (respective) LNA™ counterpart, i.e., a LNA™-T, LNA™-A or LNA™-G, respectively.
- For example, the nucleotide sequence of SEQ ID NO: 33 (CTT-TCT-TGG-GAT-ATG-TTC-TGC-C) can be modified into CT8-TCT-8GG-G5T-ATG-8TC-T7C-C, wherein 8=LNA™-T, 5=LNA™-A and 7=LNA™-G (SEQ ID NO: 58) [the sequence complementary to SEQ ID NO: 58 being G-G6A-GA5-CAT-A8C-CC5-AGA-5AG (SEQ ID NO: 59), wherein 8=LNA™-T, 5=LNA™-A, 7=LNA™-G and 6=LNA™-C].
- Such LNA modifications are intended to increase the specificity of the nucleotide sequence (i.e., in the case of SEQ ID NO: 33 or the complementary sequence thereof, to increase the specificity of the CYTB cDNA probe).
- The CYTB forward primer that was used in Example 1 above was the primer of sequence SEQ ID NO: 31. Alternatively, the nucleotide sequence of SEQ ID NO: 31 (CYTB_Pj242F: 5′-CTC-CCA-GAA-TTC-TCG-TTT-GG-3′) can be modified into CTC-CCA-GAA-TTC-TMG-TTT-GG, wherein M=C or A (SEQ ID NO: 60) according to the IUPAC nucleotide code.
- Such degenerated primer is intended to allow the detection and the quantification of CYTB mRNA in a sample from a patient having, in this genome, either a C or A at the position 255 of the nucleotide sequence SEQ ID NO: 3 corresponding to CYTB gene.
- Bronchoalveolar lavage (BAL) fluid samples of 18 patients were analyzed for detection and quantification of the RNA transcripts of mtSSU and mtLSU [twelve non-PCP patients that are P. pneumonia carriers; and six PCP patients, who did not receive any anti-PCP treatment or who have received an anti-PCP treatment for at most 15 days].
- All samples were positive for both RNA transcripts (mtSSU and mtLSU).
- mtLSU RT-PCR was performed as described in Example 1 above (with the mtLSU primers of SEQ ID NOs: 11-12 and the probe of SEQ ID NO: 13).
- mtSSU RT-PCR was performed as described in Example 1 above (with the mtSSU primers of SEQ ID NOs: 26-27 and the probe of SEQ ID NO: 28).
- Quantification of mtSSU and of mtLSU:
- mtSSU gene gives significantly better cycles results than mtLSU with a median of 27.90 [C195% 24.39-28.55] compared to 30.00 [C195% 26.51-31.36], respectively (p<0.001). Please see
FIG. 5 . - mtSSU/mtLSU Ratio:
- The mtSSU/mtLSU RNA ratio allows discrimination between PCP and carriage (the optimal ratio being of 2.7).
- A ratio from 3.1 to 3.3 would lead to 100% sensitivity but with a lower specificity (75% at 3.1 and 66.6% at 3.3). However, if the purpose were to allow PCP diagnosis together with identifying the patients with carriage, a ratio of 3.1 to 3.3 would be optimal to avoid misidentification of PCP patients who needs to be treated for PCP.
- The comparison of the ROC curves obtained with mtLSU or mtSSU quantification (Cycles) alone gave for both a maximal likelihood ratio at 6 for both. The mtSSU/mtLSU ratio gave the best result (likehood ratio at 10 for ratio of 2.7). Please see
FIG. 6 . -
FIG. 7 shows the distribution of the mtSSU/mtLSU RNA ratio values in the PCP patients and in the carrier patients. -
FIG. 8 shows the distribution of quantification values (cycles) of the RNA transcripts of the mtSSU et mtLSU genes in the PCP patients and in the carrier patients. -
- Alanio et al. 2011. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17: 1531-7.
- Pfaffl 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
- Wang et al. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009 January; 10(1): 57-63.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/552,130 US20220119886A1 (en) | 2015-04-15 | 2021-12-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305562.9 | 2015-04-15 | ||
EP15305562 | 2015-04-15 | ||
PCT/EP2016/058355 WO2016166287A1 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
US201715564246A | 2017-10-04 | 2017-10-04 | |
US17/552,130 US20220119886A1 (en) | 2015-04-15 | 2021-12-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,246 Continuation US11236390B2 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring Pneumocystis pneumonia |
PCT/EP2016/058355 Continuation WO2016166287A1 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220119886A1 true US20220119886A1 (en) | 2022-04-21 |
Family
ID=52946502
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,246 Active 2037-08-16 US11236390B2 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring Pneumocystis pneumonia |
US17/552,130 Pending US20220119886A1 (en) | 2015-04-15 | 2021-12-15 | Means for diagnosing, predicting or monitoring pneumocystis pneumonia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,246 Active 2037-08-16 US11236390B2 (en) | 2015-04-15 | 2016-04-15 | Means for diagnosing, predicting or monitoring Pneumocystis pneumonia |
Country Status (7)
Country | Link |
---|---|
US (2) | US11236390B2 (en) |
EP (1) | EP3283643B8 (en) |
JP (1) | JP7072385B2 (en) |
CN (1) | CN107636172B (en) |
CA (1) | CA2982508A1 (en) |
DK (1) | DK3283643T3 (en) |
WO (1) | WO2016166287A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090637A1 (en) * | 2001-05-08 | 2002-11-14 | Shima Seiki Mfg., Ltd. | Knit wear with collar knit by flat knitting machine and method of knitting it |
CN107354221A (en) * | 2017-08-28 | 2017-11-17 | 合肥千麦医学检验所有限公司 | The PCR detection kit of Ye Shi lung pityrosporion ovales |
KR102026553B1 (en) * | 2018-01-08 | 2019-09-27 | 조선대학교산학협력단 | Diagnosis method of Tsutsugamushi disease using multicopy genes |
CN109251992A (en) * | 2018-09-13 | 2019-01-22 | 昆明医科大学第附属医院 | A kind of LAMP primer composition object and method detecting Ye Shi lung pityrosporion ovale |
CN109346174A (en) * | 2018-10-24 | 2019-02-15 | 南昌大学第二附属医院 | Non-human immunodeficiency virus infected patient PCP risk evaluating system |
CN109666755A (en) * | 2018-12-25 | 2019-04-23 | 北京卓诚惠生生物科技股份有限公司 | For detecting the nucleic acid reagent, kit, system and method for invasive fungi |
CN110408717A (en) * | 2019-07-23 | 2019-11-05 | 四川省农业科学院生物技术核技术研究所 | The specific amplification primer of Ganoderma mitochondria rns gene and its application |
CN111424101A (en) * | 2020-03-30 | 2020-07-17 | 广州市第八人民医院 | Kit and method for quantitatively detecting yersinia sporogenes |
CN111455094B (en) * | 2020-06-17 | 2020-09-08 | 圣湘生物科技股份有限公司 | Composition, kit, application and method for detecting deep infection fungi |
CN113088579B (en) * | 2021-03-16 | 2022-03-22 | 广州医科大学附属第一医院 | Kit and method for qualitatively detecting yersinia sporogenes |
ES2933149A1 (en) * | 2021-07-28 | 2023-02-01 | Fundacion Para El Fomento De La Investig Sanitaria Y Biomedica De La Comunitat Valenciana Fisabio | In vitro METHOD FOR THE DIAGNOSIS OF AN INFECTION BY Pneumocystis jirovecii (Machine-translation by Google Translate, not legally binding) |
CN115820921A (en) * | 2022-12-19 | 2023-03-21 | 领航基因科技(杭州)有限公司 | Primer probe combination for detecting three kinds of lung invasive fungi and digital PCR kit thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110189676A1 (en) | 2008-10-03 | 2011-08-04 | Hall Thomas A | Compositions for use in identification of fungi |
WO2014071946A1 (en) | 2012-11-07 | 2014-05-15 | Statens Serum Institut | Diagnostic pcr primers enabling exhaustive detection of non-human eukaryotic ssu rdna in human clinical samples |
-
2016
- 2016-04-15 US US15/564,246 patent/US11236390B2/en active Active
- 2016-04-15 DK DK16717131.3T patent/DK3283643T3/en active
- 2016-04-15 CA CA2982508A patent/CA2982508A1/en not_active Abandoned
- 2016-04-15 WO PCT/EP2016/058355 patent/WO2016166287A1/en active Application Filing
- 2016-04-15 JP JP2017553984A patent/JP7072385B2/en active Active
- 2016-04-15 CN CN201680021613.0A patent/CN107636172B/en not_active Expired - Fee Related
- 2016-04-15 EP EP16717131.3A patent/EP3283643B8/en active Active
-
2021
- 2021-12-15 US US17/552,130 patent/US20220119886A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107636172A (en) | 2018-01-26 |
US11236390B2 (en) | 2022-02-01 |
EP3283643A1 (en) | 2018-02-21 |
JP7072385B2 (en) | 2022-05-20 |
EP3283643B8 (en) | 2020-06-10 |
DK3283643T3 (en) | 2020-05-18 |
CN107636172B (en) | 2021-11-16 |
CA2982508A1 (en) | 2016-10-20 |
US20180127825A1 (en) | 2018-05-10 |
EP3283643B1 (en) | 2020-04-15 |
WO2016166287A1 (en) | 2016-10-20 |
JP2018511339A (en) | 2018-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220119886A1 (en) | Means for diagnosing, predicting or monitoring pneumocystis pneumonia | |
Stark et al. | Comparison of microscopy, two xenic culture techniques, conventional and real-time PCR for the detection of Dientamoeba fragilis in clinical stool samples | |
US9758828B2 (en) | Methods to detect, treat and prevent acute cellular rejection in kidney allografts | |
Maurin et al. | Quantitative real-time PCR tests for diagnostic and prognostic purposes in cases of legionellosis | |
Munne et al. | Detection of SARS-CoV-2 infection by RT-PCR test: factors influencing interpretation of results | |
Montesinos et al. | Comparison of 2 real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients | |
Schirm et al. | Trichomonas vaginalis detection using real-time TaqMan PCR | |
US20220251655A1 (en) | Mitochondrial dna deletions associated with endometriosis | |
Shipitsyna et al. | Evaluation of polymerase chain reaction assays for the diagnosis of Trichomonas vaginalis infection in Russia | |
Badiee et al. | Detection of Aspergillus species in bone marrow transplant patients | |
Apt et al. | Trypanosoma cruzi burden, genotypes, and clinical evaluation of Chilean patients with chronic Chagas cardiopathy | |
Kariyawasam et al. | Leishmania RNA virus 1 (LRV-1) in Leishmania (Viannia) braziliensis isolates from Peru: a description of demographic and clinical correlates | |
Debourgogne et al. | Characteristics of Pneumocystis pneumonia in Nancy from January 2007 to April 2011 and focus on an outbreak in nephrology | |
WO2010032797A1 (en) | Breast cancer metastasis determination method and blood serum evaluation method | |
CN112522391B (en) | Application of hsa_circ_0008961 as gout diagnosis marker | |
CN111455094B (en) | Composition, kit, application and method for detecting deep infection fungi | |
Maubon et al. | Development, optimization, and validation of a multiplex real-time PCR assay on the BD MAX platform for routine diagnosis of Acanthamoeba keratitis | |
JP2021175381A (en) | Method for detecting infant atopic dermatitis | |
Özkan-Ahmetoğlu et al. | Investigation of intestinal parasites by conventional and molecular methods in children with gastrointestinal system complaints | |
CN114525331B (en) | Detection product for rapidly identifying severe pneumonia | |
Juvet et al. | Saliva sample for testing SARS-CoV-2 infection–a rapid review | |
WO2022059745A1 (en) | Method for detecting infantile atopic dermatitis | |
Sadaka et al. | Prevalence of Chlamydophila pneumoniae in patients with pneumonia in the main university hospital in Alexandria | |
Pandey et al. | Utility of an in-house real-time PCR in whole blood samples as a minimally invasive method for early and accurate diagnosis of invasive mould infections. | |
CN107130015B (en) | Fluorescent quantitative PCR kit for detecting aspergillus fumigatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITE DE PARIS, FRANCE Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:UNIVERSITE PARIS DESCARTES;UNIVERSITE PARIS DIDEROT - PARIS 7;UNIVERSITE DE PARIS;REEL/FRAME:060541/0336 Effective date: 20200101 Owner name: UNIVERSITE PARIS CITE, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:UNIVERSITE DE PARIS;REEL/FRAME:060390/0122 Effective date: 20220304 |
|
AS | Assignment |
Owner name: UNIVERSITE PARIS CITE, FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME;ASSIGNOR:UNIVERSITE DE PARIS;REEL/FRAME:062387/0489 Effective date: 20220304 Owner name: UNIVERSITE DE PARIS, FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060541 FRAME: 0336. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME;ASSIGNORS:UNIVERSITE PARIS DESCARTES;UNIVERSITE PARIS DIDEROT - PARIS 7;REEL/FRAME:062387/0346 Effective date: 20200101 Owner name: UNIVERSITE PARIS CITE, FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBERS PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME;ASSIGNOR:UNIVERSITE DE PARIS;REEL/FRAME:062387/0489 Effective date: 20220304 Owner name: UNIVERSITE DE PARIS, FRANCE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBERS PREVIOUSLY RECORDED AT REEL: 060541 FRAME: 0336. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME;ASSIGNORS:UNIVERSITE PARIS DESCARTES;UNIVERSITE PARIS DIDEROT - PARIS 7;REEL/FRAME:062387/0346 Effective date: 20200101 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |